Opioid receptor modulators

Abstract

Provided herein are opioid receptor modulators and pharmaceutical compositions comprising such compounds.

Description

[Technical Field]

[0001] cross reference This application claims priority to U.S. Provisional Patent Application No. 63 / 171,008, filed April 5, 2021, and U.S. Provisional Patent Application No. 63 / 318,486, filed March 10, 2022, each of which is incorporated by reference herein in its entirety.

[0002] STATEMENT REGARDING FEDERALLY SPONSORED RESEARCH This invention was made with United States government support under Contract Nos. 1UG3DA049598-01 and 1R43DA047723-01 awarded by the National Institutes of Health (NIH). [Background technology]

[0003] Opioid receptors are a group of inhibitory G protein-coupled receptors that have opioids as ligands and have long been used to treat pain. Opioids typically act at these receptors as agonists, antagonists, or partial agonists. There are three classical opioid receptors, originally named mu (μ) (named after morphine, the most commonly recognized exogenous ligand), delta (δ) (named after the vas deferens from which they were first isolated), and kappa (κ) (named after ketocyclazocine, the first ligand to act at this receptor). These opioid receptors are widely distributed throughout the central nervous system and, to a lesser extent, the periphery. Opioids, whether naturally occurring or synthetic, also exhibit significant problematic side effects, including constipation, addiction, and respiratory depression, and attempts to eliminate these attributes have met with limited success. Accordingly, there remains a need in the art for agents that can modulate opioid receptors and that limit the side effects typically associated with such agents. Summary of the Invention

[0004] The present disclosure provides, for example, opioid receptor modulators, processes for their preparation, their use as medicaments for the treatment of neuropsychiatric disorders, depression, obsessive-compulsive disorder, alcoholism, gambling addiction, pain, opioid overdose, opioid use disorders and addictions, and pharmaceutical compositions comprising the disclosed compounds as at least one active ingredient. The present disclosure further provides the use of the compounds described herein as and / or in the manufacture of medicaments for the treatment of neuropsychiatric disorders, depression, obsessive-compulsive disorder, alcoholism, gambling addiction, pain, opioid overdose, opioid use disorders and addictions.

[0005] In one embodiment, there is a compound of formula (I), or a pharmaceutically acceptable salt or solvate thereof:

[0006] [ka] During the ceremony, R 1 is C 6-10 Aryl and C 1-9 heteroaryl, wherein C 6-10 Aryl and C 1-9 Heteroaryl can be one, two, three, four, or five R 7 is optionally replaced by R 2 is C 6-10 Aryl and C 1-9 heteroaryl, wherein C 6-10 Aryl and C 1-9 Heteroaryl can be one, two, three, four, or five R 8 is optionally replaced by R 3 Ha-XR 3a , C2-C8 alkyl, C2-C8 haloalkyl, or C2-C8 alkenyl; X is a bond or C 1-6 is alkylene, R 3a is one, two, three, four, or five R 9 C optionally replaced with3-8 is cycloalkyl, R 4 is hydrogen, C1-C6 alkyl, or C1-C6 haloalkyl; R 5 and R 6 are each independently selected from hydrogen, C-C alkyl, and C-C haloalkyl; or R 5 and R 6 are combined to form an azetidinyl, pyrrolidinyl, piperidinyl, or piperazinyl ring; R 7 are each independently halogen, -CN, or C 1-6 Alkyl, C 1-6 Haloalkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 3-6 Cycloalkyl, C 2-9 Heterocycloalkyl, C 6-10 Aryl, C 1-9 Heteroaryl, -OR 10 , -SR 10 , -C(O)OR 10 , -OC(O)N(R 10 )(R 11 ), -N(R 12 )C(O)N(R 10 )(R 11 ), -N(R 12 )C(O)R 13 , -N(R 12 )C(O)OR 13 , -N(R 12 )S(O)2R 13 , -C(O)R 13 , -OC(O)R 13 , -C(O)N(R 10 )(R 11 ), -C(O)C(O)N(R 10 )(R 11 ), -S(O)R 13 , -S(O)2R 13 , and -S(O)N(R 10 )(R 11 ), where C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6Alkynyl, C 3-6 Cycloalkyl, C 2-9 Heterocycloalkyl, C 6-10 Aryl, and C 1-9 Heteroaryl is substituted with halogen, -CN, C 1-6 Alkyl, C 1-6 Haloalkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 3-6 Cycloalkyl, C 2-9 Heterocycloalkyl, C 6-10 Aryl, C 1-9 Heteroaryl, -OR 14 , -SR 14 , -C(O)OR 14 , -OC(O)N(R 14 )(R 15 ), -N(R 16 )C(O)N(R 14 )(R 15 ), -N(R 16 )C(O)R 17 , -N(R 16 )C(O)OR 17 , -N(R 16 )S(O)2R 17 , -C(O)R 17 , -OC(O)R 17 , -C(O)N(R 14 )(R 15 ), -C(O)C(O)N(R 14 )(R 15 ), -S(O)R 17 , -S(O)2R 17 , and -S(O)N(R 14 )(R 15 Optionally substituted with one, two, or three groups selected from two R 7 are combined to form a heterocycloalkyl ring optionally substituted with oxo, or R 7 and R 6 are combined to form a heterocycloalkyl ring; Each R 8 and each R 9 are each independently halogen, -CN, or C 1-6 Alkyl, C 1-6Haloalkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 3-6 Cycloalkyl, C 2-9 Heterocycloalkyl, C 6-10 Aryl, C 1-9 Heteroaryl, -OR 10 , -SR 10 , -C(O)OR 10 , -OC(O)N(R 10 )(R 11 ), -N(R 12 )C(O)N(R 10 )(R 11 ), -N(R 12 )C(O)R 13 , -N(R 12 )C(O)OR 13 , -N(R 12 )S(O)2R 13 , -C(O)R 13 , -OC(O)R 13 , -C(O)N(R 10 )(R 11 ), -C(O)C(O)N(R 10 )(R 11 ), -S(O)R 13 , -S(O)2R 13 , and -S(O)N(R 10 )(R 11 ), where C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 3-6 Cycloalkyl, C 2-9 Heterocycloalkyl, C 6-10 Aryl, and C 1-9 Heteroaryl is substituted with halogen, -CN, C 1-6 Alkyl, C 1-6 Haloalkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 3-6 Cycloalkyl, C 2-9 Heterocycloalkyl, C 6-10 Aryl, C 1-9 Heteroaryl, -OR 14 , -SR 14 , -C(O)OR 14, -OC(O)N(R 14 )(R 15 ), -N(R 16 )C(O)N(R 14 )(R 15 ), -N(R 16 )C(O)R 17 , -N(R 16 )C(O)OR 17 , -N(R 16 )S(O)2R 17 , -C(O)R 17 , -OC(O)R 17 , -C(O)N(R 14 )(R 15 ), -C(O)C(O)N(R 14 )(R 15 ), -S(O)R 17 , -S(O)2R 17 , and -S(O)N(R 14 )(R 15 Optionally substituted with one, two, or three groups selected from R 10 are each independently hydrogen, C 1-6 Alkyl, C 1-6 Haloalkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 3-6 Cycloalkyl, C 2-9 Heterocycloalkyl, C 6-10 Aryl, and C 1-9 heteroaryl, wherein C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 3-6 Cycloalkyl, C 2-9 Heterocycloalkyl, C 6-10 Aryl, and C 1-9 Heteroaryl is substituted with halogen, C 1-6 Alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, C 3-6 Cycloalkyl, C 2-9 Heterocycloalkyl, C 6-10 Aryl, and C 1-9optionally substituted with one, two, or three groups selected from heteroaryl; R 11 are each independently hydrogen, C 1-6 Alkyl, and C 1-6 haloalkyl; R 12 are each independently hydrogen, C 1-6 Alkyl, and C 1-6 haloalkyl; R 13 are each independently, C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 3-6 Cycloalkyl, C 2-9 Heterocycloalkyl, C 6-10 Aryl, and C 1-9 heteroaryl, wherein C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 3-6 Cycloalkyl, C 2-9 Heterocycloalkyl, C 6-10 Aryl, and C 1-9 Heteroaryl is substituted with halogen, C 1-6 Alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, C 3-6 Cycloalkyl, C 2-9 Heterocycloalkyl, C 6-10 Aryl, and C 1-9 optionally substituted with one, two, or three groups selected from heteroaryl; R 14 are each independently hydrogen, C 1-6 Alkyl, C 1-6 Haloalkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 3-6 Cycloalkyl, C 2-9 Heterocycloalkyl, C 6-10 Aryl, and C 1-9 heteroaryl, wherein C 1-6 Alkyl, C2-6 Alkenyl, C 2-6 Alkynyl, C 3-6 Cycloalkyl, C 2-9 Heterocycloalkyl, C 6-10 Aryl, and C 1-9 Heteroaryl is substituted with halogen, C 1-6 Alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, C 3-6 Cycloalkyl, C 2-9 Heterocycloalkyl, C 6-10 Aryl, and C 1-9 optionally substituted with one, two, or three groups selected from heteroaryl; R 15 are each independently hydrogen, C 1-6 Alkyl, and C 1-6 haloalkyl; R 16 are each independently hydrogen, C 1-6 Alkyl, and C 1-6 haloalkyl, and R 17 are each independently, C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 3-6 Cycloalkyl, C 2-9 Heterocycloalkyl, C 6-10 Aryl, and C 1-9 heteroaryl, wherein C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 3-6 Cycloalkyl, C 2-9 Heterocycloalkyl, C 6-10 Aryl, and C 1-9 Heteroaryl is substituted with halogen, C 1-6 Alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, C 3-6 Cycloalkyl, C 2-9 Heterocycloalkyl, C 6-10 Aryl, and C 1-9It is optionally substituted with one, two, or three groups selected from heteroaryl.

[0007] In some embodiments, there is a compound of Formula (I) having the structure of Formula (Ia) or a pharmaceutically acceptable salt thereof:

[0008] [ka] wherein n is 0, 1, 2, 3, or 4.

[0009] In some embodiments, there is a compound of Formula (I) having the structure of Formula (Ib) or a pharmaceutically acceptable salt thereof:

[0010] [ka] wherein n is 0, 1, 2, 3, or 4.

[0011] In some embodiments, there is a compound of Formula (I) having the structure of Formula (Ic) or a pharmaceutically acceptable salt thereof:

[0012] [ka] wherein n is 0, 1, 2, 3, or 4.

[0013] In some embodiments, there is a compound of Formula (I) having the structure of Formula (Id) or a pharmaceutically acceptable salt thereof:

[0014] [ka] wherein n is 0, 1, 2, or 3.

[0015] In some embodiments, there is a compound of Formula (I) having the structure of Formula (Ie) or a pharmaceutically acceptable salt thereof:

[0016] [ka] wherein n is 0, 1, 2, or 3.

[0017] In some embodiments, there is a compound of formula (I) having the structure of formula (If) or a pharmaceutically acceptable salt thereof:

[0018] [ka] wherein n is 0, 1, 2, or 3.

[0019] In some embodiments, there is a compound of Formula (I) having the structure of Formula (Ig) or a pharmaceutically acceptable salt thereof:

[0020] [ka] wherein n is 0, 1, 2, or 3.

[0021] In some embodiments, there is a compound of Formula (I) having the structure of Formula (Ih) or a pharmaceutically acceptable salt thereof:

[0022] [ka] wherein n is 0, 1, 2, or 3.

[0023] In another embodiment, there is a compound of Formula (I), (Ia), (Ib), (Ic), (Id), (Ie), (If), (Ig), or (Ih), or a pharmaceutically acceptable salt or solvate thereof, wherein R 10 are independently hydrogen and C 1-6 In another embodiment is a compound of Formula (I), (Ia), (Ib), (Ic), (Id), (Ie), (If), (Ig), or (Ih), or a pharmaceutically acceptable salt thereof, wherein R 11is hydrogen. In another embodiment are compounds of Formula (I), (Ia), (Ib), (Ic), (Id), (Ie), (If), (Ig), or (Ih), or a pharmaceutically acceptable salt or solvate thereof, wherein n is 2. In another embodiment are compounds of Formula (I), (Ia), (Ib), (Ic), (Id), (Ie), (If), (Ig), or (Ih), or a pharmaceutically acceptable salt or solvate thereof, wherein n is 1. In another embodiment are compounds of Formula (I), (Ia), (Ib), (Ic), (Id), (Ie), (If), (Ig), or (Ih), or a pharmaceutically acceptable salt or solvate thereof, wherein n is 0. In another embodiment, there is a compound of Formula (I), (Ia), (Ib), (Ic), (Id), (Ie), (If), (Ig), or (Ih), or a pharmaceutically acceptable salt or solvate thereof, wherein R 7 are each independently a halogen, C 1-6 Alkyl, C 1-6 Haloalkyl, -OR 10 , and -C(O)N(R 10 )(R 11 In another embodiment, a compound of Formula (I), (Ia), (Ib), (Ic), (Id), (Ie), (If), (Ig), or (Ih), or a pharmaceutically acceptable salt or solvate thereof, wherein R 10 are each independently hydrogen and C 1-6 In another embodiment is a compound of Formula (I), (Ia), (Ib), (Ic), (Id), (Ie), (If), (Ig), or (Ih), or a pharmaceutically acceptable salt or solvate thereof, wherein R 7 are each independently a halogen and C 1-6 In another embodiment is a compound of Formula (I), (Ia), (Ib), (Ic), (Id), (Ie), (If), (Ig), or (Ih), or a pharmaceutically acceptable salt or solvate thereof, wherein R 3 Ha-XR 3aIn another embodiment are compounds of Formula (I), (Ia), (Ib), (Ic), (Id), (Ie), (If), (Ig), or (Ih), or a pharmaceutically acceptable salt or solvate thereof, wherein X is a bond. In another embodiment are compounds of Formula (I), (Ia), (Ib), (Ic), (Id), (Ie), (If), (Ig), or (Ih), or a pharmaceutically acceptable salt or solvate thereof, wherein X is C 1-6 In another embodiment, there is a compound of Formula (I), (Ia), (Ib), (Ic), (Id), (Ie), (If), (Ig), or (Ih), or a pharmaceutically acceptable salt or solvate thereof, wherein X is -CH2-. In another embodiment, there is a compound of Formula (I), (Ia), (Ib), (Ic), (Id), (Ie), (If), (Ig), or (Ih), or a pharmaceutically acceptable salt or solvate thereof, wherein R 3a One, two, or three R 9 C optionally replaced with 3-8 In another embodiment is a compound of Formula (I), (Ia), (Ib), (Ic), (Id), (Ie), (If), (Ig), or (Ih), or a pharmaceutically acceptable salt or solvate thereof, wherein R 3a One, two, or three R 9 C replaced with 3-8 In another embodiment is a compound of Formula (I), (Ia), (Ib), (Ic), (Id), (Ie), (If), (Ig), or (Ih), or a pharmaceutically acceptable salt or solvate thereof, wherein R 3a One, two, or three R 9 C replaced with 3-8 In another embodiment is a compound of Formula (I), (Ia), (Ib), (Ic), (Id), (Ie), (If), (Ig), or (Ih), or a pharmaceutically acceptable salt or solvate thereof, wherein R 9 are each independently halogen, -CN, or C 1-6 Alkyl, and C 1-6In another embodiment, there is a compound of Formula (I), (Ia), (Ib), (Ic), (Id), (Ie), (If), (Ig), or (Ih), or a pharmaceutically acceptable salt or solvate thereof, wherein R 3a is one R 9 In another embodiment is a compound of Formula (I), (Ia), (Ib), (Ic), (Id), (Ie), (If), (Ig), or (Ih), or a pharmaceutically acceptable salt or solvate thereof, wherein R 3a is C 1-6 In another embodiment is a compound of Formula (I), (Ia), (Ib), (Ic), (Id), (Ie), (If), (Ig), or (Ih), or a pharmaceutically acceptable salt or solvate thereof, wherein R 3a is cyclopropyl substituted with -CF. In another embodiment is a compound of Formula (I), (Ia), (Ib), (Ic), (Id), (Ie), (If), (Ig), or (Ih), or a pharmaceutically acceptable salt or solvate thereof, wherein R 3a is unsubstituted C 3-8 In another embodiment is a compound of Formula (I), (Ia), (Ib), (Ic), (Id), (Ie), (If), (Ig), or (Ih), or a pharmaceutically acceptable salt or solvate thereof, wherein R 3a is unsubstituted cyclopropyl. In another embodiment is a compound of Formula (I), (Ia), (Ib), (Ic), (Id), (Ie), (If), (Ig), or (Ih), or a pharmaceutically acceptable salt or solvate thereof, wherein R 3 is C2-C8 alkyl. In another embodiment is a compound of Formula (I), (Ia), (Ib), (Ic), (Id), (Ie), (If), (Ig), or (Ih), or a pharmaceutically acceptable salt or solvate thereof, wherein R 3is -CH(CH3)2, -C(CH3)3, -CH2CH(CH3)2, or -CH2CH2CH2CH3. In another embodiment is a compound of Formula (I), (Ia), (Ib), (Ic), (Id), (Ie), (If), (Ig), or (Ih), or a pharmaceutically acceptable salt or solvate thereof, wherein R 3 is C2-C8 alkenyl. In another embodiment is a compound of Formula (I), (Ia), (Ib), (Ic), (Id), (Ie), (If), (Ig), or (Ih), or a pharmaceutically acceptable salt or solvate thereof, wherein R 3 is —CH2CH2CH═CH. In another embodiment is a compound of Formula (I), (Ia), (Ib), (Ic), (Id), (Ie), (If), (Ig), or (Ih), or a pharmaceutically acceptable salt or solvate thereof, wherein R 3 is C2-C8 haloalkyl. In another embodiment is a compound of Formula (I), (Ia), (Ib), (Ic), (Id), (Ie), (If), (Ig), or (Ih), or a pharmaceutically acceptable salt or solvate thereof, wherein R 2 is one, two, three, four, or five R 8 C optionally replaced with 6-10 In another embodiment is a compound of Formula (I), (Ia), (Ib), (Ic), (Id), (Ie), (If), (Ig), or (Ih), or a pharmaceutically acceptable salt or solvate thereof, wherein R 2 is one, two, three, four, or five R 8 In another embodiment is a compound of Formula (I), (Ia), (Ib), (Ic), (Id), (Ie), (If), (Ig), or (Ih), or a pharmaceutically acceptable salt or solvate thereof, wherein R 2 One, two, or three R 8 In another embodiment is a compound of Formula (I), (Ia), (Ib), (Ic), (Id), (Ie), (If), (Ig), or (Ih), or a pharmaceutically acceptable salt or solvate thereof, wherein R 2is one, two, three, four, or five R 8 C optionally replaced with 1-9 In another embodiment is a compound of Formula (I), (Ia), (Ib), (Ic), (Id), (Ie), (If), (Ig), or (Ih), or a pharmaceutically acceptable salt or solvate thereof, wherein R 2 One, two, or three R 8 C replaced with 1-9 In another embodiment is a compound of Formula (I), (Ia), (Ib), (Ic), (Id), (Ie), (If), (Ig), or (Ih), or a pharmaceutically acceptable salt or solvate thereof, wherein R 2 is pyridinyl, pyrimidinyl, or thiazolyl, and pyridinyl, pyrimidinyl, and thiazolyl are substituted with one, two, or three R 8 In another embodiment is a compound of Formula (I), (Ia), (Ib), (Ic), (Id), (Ie), (If), (Ig), or (Ih), or a pharmaceutically acceptable salt or solvate thereof, wherein R 8 are each independently a halogen, C 1-6 Alkyl, C 1-6 Haloalkyl, and -OR 10 In another embodiment, a compound of Formula (I), (Ia), (Ib), (Ic), (Id), (Ie), (If), (Ig), or (Ih), or a pharmaceutically acceptable salt or solvate thereof, wherein R 10 are C 1-6 In another embodiment is a compound of Formula (I), (Ia), (Ib), (Ic), (Id), (Ie), (If), (Ig), or (Ih), or a pharmaceutically acceptable salt or solvate thereof, wherein R 2 is unsubstituted phenyl. In another embodiment is a compound of Formula (I), (Ia), (Ib), (Ic), (Id), (Ie), (If), (Ig), or (Ih), or a pharmaceutically acceptable salt or solvate thereof, wherein R 2 is unsubstituted C 1-9In another embodiment is a compound of Formula (I), (Ia), (Ib), (Ic), (Id), (Ie), (If), (Ig), or (Ih), or a pharmaceutically acceptable salt or solvate thereof, wherein R 2 is unsubstituted pyridinyl, unsubstituted pyrimidinyl, or unsubstituted thiazolyl. In another embodiment is a compound of Formula (I), (Ia), (Ib), (Ic), (Id), (Ie), (If), (Ig), or (Ih), or a pharmaceutically acceptable salt or solvate thereof, wherein R 5 and R 6 are each independently selected from hydrogen, C1-C6 alkyl, and C1-C6 haloalkyl. In another embodiment, there is a compound of Formula (I), (Ia), (Ib), (Ic), (Id), (Ie), (If), (Ig), or (Ih), or a pharmaceutically acceptable salt or solvate thereof, wherein R 5 is selected from hydrogen and C1-C6 alkyl. In another embodiment is a compound of Formula (I), (Ia), (Ib), (Ic), (Id), (Ie), (If), (Ig), or (Ih), or a pharmaceutically acceptable salt or solvate thereof, wherein R 6 is selected from hydrogen and C1-C6 alkyl. In another embodiment is a compound of Formula (I), (Ia), (Ib), (Ic), (Id), (Ie), (If), (Ig), or (Ih), or a pharmaceutically acceptable salt or solvate thereof, wherein R 5 and R 6 is C1-C6 alkyl. In another embodiment is a compound of Formula (I), (Ia), (Ib), (Ic), (Id), (Ie), (If), (Ig), or (Ih), or a pharmaceutically acceptable salt or solvate thereof, wherein R 5 and R 6 are combined to form an azetidinyl, pyrrolidinyl, piperidinyl, or piperazinyl ring. In another embodiment are compounds of Formula (I), (Ia), (Ib), (Ic), (Id), (Ie), (If), (Ig), or (Ih), or a pharmaceutically acceptable salt or solvate thereof, wherein R 4is hydrogen.

[0024] In another embodiment, there is a pharmaceutical composition comprising a compound of formula (I) described herein, or a pharmaceutically acceptable salt, solvate thereof, and at least one pharmaceutically acceptable excipient.

[0025] In another embodiment, there is a method of treating a disease or condition selected from neuropsychiatric disorders, depression, obsessive-compulsive disorder, alcoholism, gambling addiction, pain, opioid overdose, opioid use disorder and addiction in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of a compound of formula (I), as described herein, or a pharmaceutically acceptable salt thereof. DETAILED DESCRIPTION OF THE INVENTION

[0026] The compounds disclosed herein modulate one, two, or three of the mu opioid receptor (MOR), kappa opioid receptor (KOR), and / or delta opioid receptor (DOR). As used herein, a "modulator" of a MOR and / or KOR and / or DOR compound, when administered to a subject, results in the desired modulation of the target receptor. For example, the compound may function as a full or partial receptor antagonist or agonist by directly or indirectly interacting with the target receptor.

[0027] As used in this specification and the appended claims, the singular forms "a," "an," and "the" include plural referents unless the context clearly dictates otherwise. Thus, for example, a reference to an "agent" includes a plurality of such agents, and a reference to a "cell" includes a reference to one or more cells (or to a plurality of cells), and equivalents thereof. When ranges are used herein regarding physical properties, such as molecular weight, or chemical properties, such as chemical formulas, all combinations and subcombinations of ranges, and specific embodiments within the ranges, are intended to be encompassed. The term "about," when referring to a numerical value or numerical range, indicates that the referenced numerical value or numerical range is approximate within experimental variability (or within statistical experimental error), and therefore, the numerical value or numerical range may vary from 1% to 15% of the stated numerical value or numerical range. The term "comprising" (and the related words "comprise" or "comprises," "having," or "including") is not intended to exclude that in other specific embodiments, an embodiment of, for example, any composition, method, or process described herein, may "consist of" or "consist essentially of" the recited features.

[0028] definition As used in this specification and the appended claims, unless specified to the contrary, the following terms have the meanings specified below.

[0029] As used herein, C1-C x is C1-C2, C1-C3...C1-C x Contains C1-C x refers to the number of carbon atoms that make up the moiety it designates (excluding any substituents).

[0030] "Amino" refers to the -NH2 radical.

[0031] "Cyano" refers to the -CN radical.

[0032] "Nitro" refers to the -NO2 radical.

[0033] "Oxa" refers to the -O- radical.

[0034] "Oxo" refers to the =O radical.

[0035] "Thioxo" refers to the =S radical.

[0036] "Imino" refers to the =NH radical.

[0037] "Oximo" refers to the =N-OH radical.

[0038] "Alkyl" or "alkylene" refers to a straight or branched hydrocarbon chain radical, consisting solely of carbon and hydrogen atoms, containing no unsaturation, and having from 1 to 18 carbon atoms (e.g., C1-C 18 In certain embodiments, alkyl comprises 3 to 18 carbon atoms (e.g., C3-C 18 In certain embodiments, alkyl comprises 1 to 15 carbon atoms (e.g., C1-C 15 In certain embodiments, alkyl comprises 1 to 12 carbon atoms (e.g., C-C 12In certain embodiments, alkyl contains 1 to 8 carbon atoms (e.g., C1-C8 alkyl). In certain embodiments, alkyl contains 1 to 6 carbon atoms (e.g., C1-C6 alkyl). In other embodiments, alkyl contains 1 to 5 carbon atoms (e.g., C1-C5 alkyl). In other embodiments, alkyl contains 1 to 4 carbon atoms (e.g., C1-C4 alkyl). In other embodiments, alkyl contains 1 to 3 carbon atoms (e.g., C1-C3 alkyl). In other embodiments, alkyl contains 1 to 2 carbon atoms (e.g., C1-C2 alkyl). In other embodiments, alkyl contains 1 carbon atom (e.g., C1 alkyl). In other embodiments, alkyl contains 5 to 15 carbon atoms (e.g., C5-C6 alkyl). 15 In other embodiments, an alkyl group contains 5 to 8 carbon atoms (e.g., C5-C8 alkyl). In other embodiments, an alkyl group contains 2 to 5 carbon atoms (e.g., C2-C5 alkyl). In other embodiments, an alkyl group contains 3 to 5 carbon atoms (e.g., C3-C5 alkyl). In other embodiments, an alkyl group is selected from methyl, ethyl, 1-propyl (n-propyl), 1-methylethyl (isopropyl), 1-butyl (n-butyl), 1-methylpropyl (sec-butyl), 2-methylpropyl (isobutyl), 1,1-dimethylethyl (tert-butyl), and 1-pentyl (n-pentyl). An alkyl is attached to the remainder of the molecule by a single bond. Unless otherwise specified in the specification, an alkyl group may contain the following substituents: halo, cyano, nitro, oxo, thioxo, imino, oximo, trimethylsilanyl, -OR a , -SR a , -OC(O)-R f , -N(R a )2, -C(O)R a , -C(O)OR a , -C(O)N(R a )2, -N(R a )C(O)OR f , -OC(O)-NR a R f , -N(R a )C(O)R f, -N(R a )S(O) t R f (t is 1 or 2), -S(O) t OR a (t is 1 or 2), -S(O) t R f (t is 1 or 2), and -S(O) t N(R a )2 (t is 1 or 2) (where R a are each independently hydrogen, alkyl, haloalkyl, cycloalkyl, aryl, aralkyl, heterocycloalkyl, heteroaryl, or heteroarylalkyl, and R f are each independently alkyl, haloalkyl, cycloalkyl, aryl, aralkyl, heterocycloalkyl, heteroaryl, or heteroarylalkyl).

[0039] "Alkoxy" refers to a radical attached through an oxygen atom of the formula --O-alkyl, where alkyl is an alkyl chain as defined above.

[0040] "Alkenyl" refers to a straight or branched hydrocarbon chain radical group consisting solely of carbon and hydrogen atoms, containing at least one carbon-carbon double bond, and having from 2 to 18 carbon atoms. In certain embodiments, an alkenyl contains from 3 to 18 carbon atoms. In certain embodiments, an alkenyl contains from 3 to 12 carbon atoms. In certain embodiments, an alkenyl contains from 6 to 12 carbon atoms. In certain embodiments, an alkenyl contains from 6 to 10 carbon atoms. In certain embodiments, an alkenyl contains from 8 to 10 carbon atoms. In certain embodiments, an alkenyl contains from 2 to 8 carbon atoms. In other embodiments, an alkenyl contains from 2 to 4 carbon atoms. An alkenyl is attached to the remainder of the molecule by a single bond, and examples include ethenyl (i.e., vinyl), prop-1-enyl (i.e., allyl), but-1-enyl, pent-1-enyl, and pent-1,4-dienyl. Unless stated otherwise in the specification, alkenyl groups may include any of the following substituents: halo, cyano, nitro, oxo, thioxo, imino, oximo, trimethylsilanyl, -OR a , -SR a , -OC(O)-R f , -N(R a )2, -C(O)R a , -C(O)OR a , -C(O)N(R a )2, -N(R a )C(O)OR f , -OC(O)-NR a R f , -N(R a )C(O)R f , -N(R a )S(O) t R f (t is 1 or 2), -S(O) t OR a (t is 1 or 2), -S(O) t R f (t is 1 or 2), and -S(O) t N(R a )2 (t is 1 or 2) (where R aare each independently hydrogen, alkyl, haloalkyl, cycloalkyl, aryl, aralkyl, heterocycloalkyl, heteroaryl, or heteroarylalkyl, and R f are each independently alkyl, haloalkyl, cycloalkyl, aryl, aralkyl, heterocycloalkyl, heteroaryl, or heteroarylalkyl).

[0041] "Alkynyl" refers to a straight or branched hydrocarbon chain radical group consisting solely of carbon and hydrogen atoms, containing at least one carbon-carbon triple bond, and having 2 to 18 carbon atoms. In certain embodiments, an alkynyl contains 3 to 18 carbon atoms. In certain embodiments, an alkynyl contains 3 to 12 carbon atoms. In certain embodiments, an alkynyl contains 6 to 12 carbon atoms. In certain embodiments, an alkynyl contains 6 to 10 carbon atoms. In certain embodiments, an alkynyl contains 8 to 10 carbon atoms. In certain embodiments, an alkynyl contains 2 to 8 carbon atoms. In other embodiments, an alkynyl contains 2 to 4 carbon atoms. An alkynyl is attached to the remainder of the molecule by a single bond and is, for example, ethynyl, propynyl, butynyl, pentynyl, hexynyl, and the like. Unless otherwise specified in the specification, an alkynyl group may be selected from the following substituents: halo, cyano, nitro, oxo, thioxo, imino, oximo, trimethylsilanyl, -OR, -O- ... a , -SR a , -OC(O)-R f , -N(R a )2, -C(O)R a , -C(O)OR a , -C(O)N(R a )2, -N(R a )C(O)OR f , -OC(O)-NR a R f , -N(R a )C(O)R f , -N(R a )S(O) t R f (t is 1 or 2), -S(O)t OR a (t is 1 or 2), -S(O) t R f (t is 1 or 2), and -S(O) t N(R a )2 (t is 1 or 2) (where R a are each independently hydrogen, alkyl, haloalkyl, cycloalkyl, aryl, aralkyl, heterocycloalkyl, heteroaryl, or heteroarylalkyl, and R f are each independently alkyl, haloalkyl, cycloalkyl, aryl, aralkyl, heterocycloalkyl, heteroaryl, or heteroarylalkyl).

[0042] "Aryl" refers to a radical derived from an aromatic monocyclic or polycyclic hydrocarbon ring system by removing a hydrogen atom from a ring carbon atom. The aromatic monocyclic or polycyclic hydrocarbon ring system contains only hydrogen and carbon atoms from 6 to 18 carbon atoms, where at least one ring in the ring system is fully unsaturated, i.e., contains a cyclic delocalized (4n+2) π-electron system according to Hückel theory. Ring systems from which aryl groups are derived include, but are not limited to, groups such as benzene, fluorene, indane, indene, tetralin, and naphthalene. Unless otherwise specified in the specification, the term "aryl" or the prefix "ar-" (as in "aralkyl") refers to any of the following: alkyl, alkenyl, alkynyl, halo, haloalkyl, cyano, nitro, aryl, aralkyl, aralkenyl, aralkynyl, cycloalkyl, heterocycloalkyl, heteroaryl, heteroarylalkyl, -R b -OR a , -R b -OC(O)-R a , -R b -OC(O)-OR a , -R b -OC(O)-N(R a )2, -R b -N(R a )2, -R b -C(O)Ra , -R b -C(O)OR a , -R b -C(O)N(R a )2, -R b -OR c -C(O)N(R a )2, -R b -N(R a )C(O)OR a , -R b -N(R a )C(O)R a , -R b -N(R a )S(O) t R a (t is 1 or 2), -R b -S(O) t OR a (t is 1 or 2), -R b -S(O) t R a (t is 1 or 2), and -R b -S(O) t N(R a )2 (t is 1 or 2), (where R a are each independently hydrogen, alkyl, haloalkyl, cycloalkyl, cycloalkylalkyl, aryl, aralkyl, heterocycloalkyl, heteroaryl, or heteroarylalkyl; R b are each independently a direct bond, or a linear or branched alkylene or alkenylene chain; R c is meant to include aryl radicals optionally substituted with one or more substituents selected from: a straight or branched alkylene or alkenylene chain.

[0043] "Aryloxy" refers to a radical attached through an oxygen atom of the formula -O-aryl, where aryl is as defined above.

[0044] "Aralkyl" is a group of the formula -R c -aryl radical, where R cis an alkylene chain as defined above, e.g., methylene, ethylene, etc. The alkylene chain part of the aralkyl radical is optionally substituted as described above for an alkylene chain. The aryl part of the aralkyl radical is optionally substituted as described above for an aryl group.

[0045] "Aralkyloxy" refers to a radical attached through an oxygen atom of the formula -O-aralkyl, where aralkyl is as defined above.

[0046] "Aralkenyl" refers to a group of the formula -R d -refers to the aryl radical, R d is an alkenylene chain as defined above. The aryl part of the aralkenyl radical is optionally substituted as defined above for an aryl group. The alkenylene chain part of the aralkenyl radical is optionally substituted as defined above for an alkenylene group.

[0047] "Aralkynyl" refers to a group of the formula -R e -refers to the aryl radical, R e is an alkynylene chain as defined above. The aryl part of the aralkynyl radical is optionally substituted as defined above for an aryl group. The alkynylene chain part of the aralkynyl radical is optionally substituted as defined above for an alkynylene chain.

[0048] "Cycloalkyl" refers to a stable non-aromatic monocyclic or polycyclic hydrocarbon radical, consisting solely of carbon and hydrogen atoms, including fused or bridged ring systems, having from 3 to 15 carbon atoms. In certain embodiments, a cycloalkyl contains from 3 to 10 carbon atoms. In other embodiments, a cycloalkyl contains from 5 to 7 carbon atoms. A cycloalkyl is attached to the remainder of the molecule by a single bond. A cycloalkyl is saturated (i.e., contains only one C-C bond) or partially unsaturated (i.e., contains one or more double or triple bonds). Examples of monocyclic cycloalkyls include, for example, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, and cyclooctyl. In certain embodiments, a cycloalkyl contains from 3 to 8 carbon atoms (e.g., C3-C8 cycloalkyl). In other embodiments, a cycloalkyl contains from 3 to 7 carbon atoms (e.g., C3-C7 cycloalkyl). In other embodiments, a cycloalkyl contains from 3 to 6 carbon atoms (e.g., C3-C6 cycloalkyl). In other embodiments, cycloalkyl contains 3 to 5 carbon atoms (e.g., C3-C5 cycloalkyl). In other embodiments, cycloalkyl contains 3 to 4 carbon atoms (e.g., C3-C4 cycloalkyl). Partially unsaturated cycloalkyls are also referred to as "cycloalkenyls." Examples of monocyclic cycloalkenyls include, for example, cyclopentenyl, cyclohexenyl, cycloheptenyl, and cyclooctenyl. Polycyclic cycloalkyl radicals include, for example, adamantyl, norbornyl (i.e., bicyclo[2.2.1]heptanyl), norbornenyl, decalinyl, 7,7-dimethylbicyclo[2.2.1]heptanyl, and the like. Unless otherwise defined herein, the term "cycloalkyl" includes any of the following: alkyl, alkenyl, alkynyl, halo, haloalkyl, oxo, thioxo, cyano, nitro, aryl, aralkyl, aralkenyl, aralkynyl, cycloalkyl, heterocycloalkyl, heteroaryl, heteroarylalkyl, -R b -OR a , -R b-OC(O)-R a , -R b -OC(O)-OR a , -R b -OC(O)-N(R a )2, -R b -N(R a )2, -R b -C(O)R a , -R b -C(O)OR a , -R b -C(O)N(R a )2, -R b -OR c -C(O)N(R a )2, -R b -N(R a )C(O)OR a , -R b -N(R a )C(O)R a , -R b -N(R a )S(O) t R a (t is 1 or 2), -R b -S(O) t OR a (t is 1 or 2), -R b -S(O) t R a (t is 1 or 2), and -R b -S(O) t N(R a )2 (t is 1 or 2), (where R a are each independently hydrogen, alkyl, haloalkyl, cycloalkyl, cycloalkylalkyl, aryl, aralkyl, heterocycloalkyl, heteroaryl, or heteroarylalkyl; R b are each independently a direct bond, or a linear or branched alkylene or alkenylene chain; R c is meant to include cycloalkyl radicals substituted with one or more substituents selected from: (which is a straight or branched alkylene or alkenylene chain).

[0049] "Halo" or "halogen" refers to a bromo, chloro, fluoro, or iodo substituent.

[0050] "Haloalkyl" refers to an alkyl radical, as defined above, that is substituted by one or more halo radicals, as defined above.

[0051] "Haloalkoxy" refers to an alkoxy radical, as defined above, that is substituted by one or more halo radicals, as defined above.

[0052] "Fluoroalkyl" refers to an alkyl radical, as defined above, that is substituted by one or more fluoro radicals, as defined above, e.g., trifluoromethyl, difluoromethyl, fluoromethyl, 2,2,2-trifluoroethyl, 1-fluoromethyl-2-fluoroethyl, etc. The alkyl portion of the fluoroalkyl radical is optionally substituted as defined above for an alkyl group.

[0053] "Heterocycloalkyl" refers to a stable 3- to 18-membered non-aromatic ring radical containing 2 to 12 carbon atoms and 1 to 6 heteroatoms selected from nitrogen, oxygen, and sulfur. Unless otherwise specified in the specification, a heterocycloalkyl radical is a monocyclic, bicyclic, tricyclic, or tetracyclic ring system, including fused, spiro, or bridged ring systems. The heteroatoms in a heterocycloalkyl radical are optionally oxidized. One or more nitrogen atoms, if present, are optionally quaternized. The heterocycloalkyl radical is partially or fully saturated. In some embodiments, a heterocycloalkyl is attached to the rest of the molecule by any atom of the ring. Examples of such heterocycloalkyls include, but are not limited to, dioxolanyl, thienyl[1,3]dithianyl, decahydroisoquinolyl, imidazolinyl, imidazolidinyl, isothiazolidinyl, isoxazolidinyl, morpholinyl, octahydroindolyl, octahydroisoindolyl, 2-oxopiperazinyl, 2-oxopiperidinyl, 2-oxopyrrolidinyl, oxazolidinyl, piperidinyl, piperazinyl, 4-piperidonyl, pyrrolidinyl, pyrazolidinyl, quinuclidinyl, thiazolidinyl, tetrahydrofuryl, trithianyl, tetrahydropyranyl, thiomorpholinyl, thiamorpholinyl, 1-oxo-thiomorpholinyl, and 1,1-dioxo-thiomorpholinyl. Unless otherwise defined herein, the term "heterocycloalkyl" includes any of the following: alkyl, alkenyl, alkynyl, halo, haloalkyl, oxo, thioxo, cyano, nitro, aryl, aralkyl, aralkenyl, aralkynyl, cycloalkyl, heterocycloalkyl, heteroaryl, heteroarylalkyl, -R b -OR a , -R b -OC(O)-R a , -R b -OC(O)-OR a , -R b -OC(O)-N(R a )2, -R b -N(R a )2, -R b -C(O)R a , -Rb -C(O)OR a , -R b -C(O)N(R a )2, -R b -OR c -C(O)N(R a )2, -R b -N(R a )C(O)OR a , -R b -N(R a )C(O)R a , -R b -N(R a )S(O) t R a (t is 1 or 2), -R b -S(O) t OR a (t is 1 or 2), -R b -S(O) t R a (t is 1 or 2), and -R b -S(O) t N(R a )2 (t is 1 or 2), (where R a are each independently hydrogen, alkyl, haloalkyl, cycloalkyl, cycloalkylalkyl, aryl, aralkyl, heterocycloalkyl, heteroaryl, or heteroarylalkyl; R b are each independently a direct bond, or a linear or branched alkylene or alkenylene chain; R c is meant to include heterocycloalkyl radicals, as defined above, optionally substituted with one or more substituents selected from: a straight or branched alkylene or alkenylene chain.

[0054] "Heteroaryl" refers to a radical derived from a 3- to 18-membered aromatic ring radical containing 1 to 17 carbon atoms and 1 to 6 heteroatoms selected from nitrogen, oxygen, and sulfur. As used herein, a heteroaryl radical is a monocyclic, bicyclic, tricyclic, or tetracyclic ring system, where at least one ring in the ring system is fully unsaturated, i.e., contains a cyclic delocalized (4n+2) π-electron system according to Hückel theory. Heteroaryl includes fused or bridged ring systems. Heteroatoms in a heteroaryl radical are optionally oxidized. One or more nitrogen atoms, if present, are optionally quaternized. A heteroaryl is attached to the rest of the molecule through any atom of the ring. Unless otherwise defined herein, the term "heteroaryl" includes any of the following: alkyl, alkenyl, alkynyl, halo, haloalkyl, oxo, thioxo, cyano, nitro, aryl, aralkyl, aralkenyl, aralkynyl, cycloalkyl, heterocycloalkyl, heteroaryl, heteroarylalkyl, -R b -OR a , -R b -OC(O)-R a , -R b -OC(O)-OR a , -R b -OC(O)-N(R a )2, -R b -N(R a )2, -R b -C(O)R a , -R b -C(O)OR a , -R b -C(O)N(R a )2, -R b -OR c -C(O)N(R a )2, -R b -N(R a )C(O)OR a , -R b -N(R a )C(O)R a , -R b -N(R a )S(O) t R a (t is 1 or 2), -Rb -S(O) t OR a (t is 1 or 2), -R b -S(O) t R a (t is 1 or 2), and -R b -S(O) t N(R a )2 (t is 1 or 2), (where R a are each independently hydrogen, alkyl, haloalkyl, cycloalkyl, cycloalkylalkyl, aryl, aralkyl, heterocycloalkyl, heteroaryl, or heteroarylalkyl; R b are each independently a direct bond, or a linear or branched alkylene or alkenylene chain; R c is meant to include heteroaryl radicals, as defined above, optionally substituted with one or more substituents selected from: a straight or branched alkylene or alkenylene chain.

[0055] "N-heteroaryl" refers to a heteroaryl radical as defined above containing at least one nitrogen, and the point of attachment of the heteroaryl radical to the rest of the molecule is through the nitrogen atom of the heteroaryl radical. The N-heteroaryl radical is optionally substituted as described above for heteroaryl radicals.

[0056] "C-heteroaryl" refers to a heteroaryl radical as defined above, where the point of attachment of the heteroaryl radical to the rest of the molecule is through a carbon atom of the heteroaryl radical. The C-heteroaryl radical is optionally substituted as described above for heteroaryl radicals.

[0057] "Heteroaryloxy" refers to a radical attached through an oxygen atom of the formula --O-heteroaryl, where heteroaryl is as defined above.

[0058] "Heteroarylalkyl" means a group of the formula -Rc - refers to the heteroaryl radical, R c is an alkylene chain as defined above. If the heteroaryl is a nitrogen-containing heteroaryl, the heteroaryl is optionally attached to the alkyl radical at the nitrogen atom. The alkylene chain of the heteroarylalkyl radical is optionally substituted as defined above for an alkylene chain. The heteroaryl portion of the heteroarylalkyl radical is optionally substituted as defined above for a heteroaryl group.

[0059] "Heteroarylalkoxy" means a heteroaryl group of the formula -OR c - refers to a heteroaryl radical attached by an oxygen atom, R c is an alkylene chain as defined above. If the heteroaryl is a nitrogen-containing heteroaryl, the heteroaryl is optionally attached to the alkyl radical at the nitrogen atom. The alkylene chain of the heteroarylalkoxy radical is optionally substituted as defined above for an alkylene chain. The heteroaryl portion of the heteroarylalkoxy radical is optionally substituted as defined above for a heteroaryl group.

[0060] In some embodiments, the compounds disclosed herein contain one or more asymmetric centers, thus giving rise to enantiomers, diastereomers, and other stereoisomeric forms defined in terms of absolute stereochemistry as (R)- or (S)-. Unless otherwise specified, all stereoisomeric forms of the compounds disclosed herein are contemplated by the present disclosure. When a compound described herein contains an alkene double bond, and unless otherwise specified, the present disclosure is intended to include both E and Z geometric isomers (e.g., cis or trans). Similarly, all possible isomers, their racemic and optically pure forms, and all tautomers are intended to be included. The term "geometric isomer" refers to E or Z geometric isomers (e.g., cis or trans) of the alkene double bond. The term "positional isomer" refers to structural isomers around a central ring, such as ortho, meta, and para isomers around a benzene ring.

[0061] "Tautomer" refers to a molecule that is capable of proton transfer from one atom of a molecule to another atom of the same molecule. In certain embodiments, the compounds provided herein exist as tautomers. In situations where tautomerization is possible, a chemical equilibrium of tautomers exists. The exact ratio of tautomers depends on various factors, including physical conditions, temperature, solvent, and pH. Some examples of tautomeric equilibrium are:

[0062] [ka] Includes:

[0063] "Optional" or "optionally" means that the subsequently described event or circumstance may or may not occur, and that the description includes examples when the event or circumstance occurs and examples when it does not occur. For example, "optionally substituted aryl" means that the aryl radical may be substituted or unsubstituted, and that the description includes both substituted and unsubstituted aryl radicals.

[0064] "Pharmaceutically acceptable salts" include both acid and base addition salts.

[0065] "Pharmaceutically acceptable acid addition salts" refer to those salts which retain the biological effectiveness and properties of the free base, which are not biologically or otherwise undesirable, and are formed with inorganic acids such as hydrochloric, hydrobromic, sulfuric, nitric, phosphoric, hydroiodic, hydrofluoric, phosphorous, etc. Also included are salts formed with organic acids such as aliphatic monocarboxylic and dicarboxylic acids, phenyl-substituted alkanoic acids, hydroxyalkanoic acids, alkanedioic acids, aromatic acids, aliphatic acids, and aromatic sulfonic acids, and with, for example, acetic acid, trifluoroacetic acid, propionic acid, glycolic acid, pyruvic acid, oxalic acid, maleic acid, malonic acid, succinic acid, fumaric acid, tartaric acid, citric acid, benzoic acid, cinnamic acid, mandelic acid, methanesulfonic acid, ethanesulfonic acid, p-toluenesulfonic acid, salicylic acid, etc. Thus, exemplary salts include sulfates, pyrosulfates, bisulfates, sulfites, bisulfites, nitrates, phosphates, monohydrogenphosphates, dihydrogenphosphates, metaphosphates, pyrophosphates, chlorides, bromides, iodides, acetates, trifluoroacetates, propionates, caprylates, isobutyrates, oxalates, malonates, succinates, suberates, sebacates, fumarates, maleates, mandelates, benzoates, chlorobenzoates, methylbenzoates, dinitrobenzoates, phthalates, benzenesulfonates, toluenesulfonates, phenylacetates, citrates, lactates, malates, tartrates, methanesulfonates, and the like. Similarly, salts of amino acids such as arginate, gluconate, and galacturonate are contemplated (see, e.g., Berge SM et al., "Pharmaceutical Salts," Journal of Pharmaceutical Science, 66:1-19 (1997)). Acid addition salts of basic compounds are prepared by contacting the free base form with a sufficient amount of the desired acid to produce the salt.

[0066] "Pharmaceutically acceptable base addition salts" refer to those salts that retain the biological effectiveness and properties of the free acid, which are not biologically or otherwise undesirable. These salts are prepared by adding an inorganic or organic base to the free acid. In some embodiments, pharmaceutically acceptable base addition salts are formed with metals or amines, such as alkali and alkaline earth metals or organic amines. Salts derived from inorganic bases include, but are not limited to, sodium, potassium, lithium, ammonium, calcium, magnesium, iron, zinc, copper, manganese, aluminum salts, and the like. Salts derived from organic bases include, but are not limited to, salts of primary amines, secondary amines, tertiary amines, substituted amines including naturally occurring substituted amines, cyclic amines, and basic ion exchange resins such as isopropylamine, trimethylamine, diethylamine, triethylamine, tripropylamine, ethanolamine, diethanolamine, 2-dimethylaminoethanol, 2-diethylaminoethanol, dicyclohexylamine, lysine, arginine, histidine, caffeine, procaine, N,N-dibenzylethylenediamine, chloroprocaine, hydrabamine, choline, betaine, ethylenediamine, ethylenedianiline, N-methylglucamine, glucosamine, methylglucamine, theobromine, purines, piperazine, piperidine, N-ethylpiperidine, polyamine resins, etc. See Berge et al., supra.

[0067] The term "subject" or "patient" includes mammals. Examples of mammals include, but are not limited to, members of the following classes of mammals: humans, non-human primates such as chimpanzees, and other ape and monkey species; livestock such as cows, horses, sheep, goats, and pigs; domestic animals such as rabbits, dogs, and cats; and laboratory animals, including rodents such as rats, mice, and guinea pigs. In one embodiment, the mammal is a human.

[0068] As used herein, "treatment" or "treating" or "alleviating" or "ameliorating" are used interchangeably herein. These terms refer to an approach for obtaining a beneficial or desired result, including, but not limited to, a therapeutic benefit and / or a prophylactic benefit. A "therapeutic benefit" refers to the eradication or amelioration of the underlying disease being treated. Similarly, a therapeutic benefit is achieved by the eradication or amelioration of one or more physiological symptoms associated with an underlying disease, such that an improvement is observed in a patient even though the patient still suffers from the underlying disease. For a prophylactic benefit, the composition is administered to a patient at risk of developing a particular disease or who reports one or more physiological symptoms of a disease, even if the patient has not been diagnosed with the disease.

[0069] compound The compounds of Formula (I), (Ia), (Ib), (Ic), (Id), (Ie), (If), (Ig), or (Ih) described herein are opioid receptor modulators. In some embodiments, the compounds of Formula (I), (Ia), (Ib), (Ic), (Id), (Ie), (If), (Ig), or (Ih) described herein are μ opioid receptor antagonists. In some embodiments, the compounds of Formula (I) described herein are δ opioid receptor antagonists. In some embodiments, the compounds of Formula (I), (Ia), (Ib), (Ic), (Id), (Ie), (If), (Ig), or (Ih) described herein are κ opioid receptor antagonists. In some embodiments, the compounds of Formula (I), (Ia), (Ib), (Ic), (Id), (Ie), (If), (Ig), or (Ih) described herein are selective opioid receptor antagonists. In some embodiments, the compounds of Formula (I), (Ia), (Ib), (Ic), (Id), (Ie), (If), (Ig), or (Ih) described herein are useful for treating one or more conditions selected from neuropsychiatric disorders, depression, obsessive-compulsive disorder, alcoholism, gambling addiction, pain, opioid overdose, opioid use disorder, and addiction.

[0070] In some embodiments, there is a compound of formula (I), or a pharmaceutically acceptable salt or solvate thereof:

[0071] [ka] During the ceremony, R 1 is C 6-10 Aryl and C 1-9 heteroaryl, wherein C 6-10 Aryl and C 1-9 Heteroaryl can be one, two, three, four, or five R 7 is optionally replaced by R 2 is C 6-10 Aryl and C 1-9 heteroaryl, wherein C 6-10 Aryl and C 1-9 Heteroaryl can be one, two, three, four, or five R 8 is optionally replaced by R 3 Ha-XR 3a , C2-C8 alkyl, C2-C8 haloalkyl, or C2-C8 alkenyl; X is a bond or C 1-6 is alkylene, R 3a is one, two, three, four, or five R 9 C optionally replaced with 3-8 is cycloalkyl, R 4 is hydrogen, C1-C6 alkyl, or C1-C6 haloalkyl; R 5 and R 6 are each independently selected from hydrogen, C-C alkyl, and C-C haloalkyl; or R 5 and R 6 are combined to form an azetidinyl, pyrrolidinyl, piperidinyl, or piperazinyl ring; R 7are each independently halogen, -CN, or C 1-6 Alkyl, C 1-6 Haloalkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 3-6 Cycloalkyl, C 2-9 Heterocycloalkyl, C 6-10 Aryl, C 1-9 Heteroaryl, -OR 10 , -SR 10 , -C(O)OR 10 , -OC(O)N(R 10 )(R 11 ), -N(R 12 )C(O)N(R 10 )(R 11 ), -N(R 12 )C(O)R 13 , -N(R 12 )C(O)OR 13 , -N(R 12 )S(O)2R 13 , -C(O)R 13 , -OC(O)R 13 , -C(O)N(R 10 )(R 11 ), -C(O)C(O)N(R 10 )(R 11 ), -S(O)R 13 , -S(O)2R 13 , and -S(O)N(R 10 )(R 11 ), where C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 3-6 Cycloalkyl, C 2-9 Heterocycloalkyl, C 6-10 Aryl, and C 1-9 Heteroaryl is substituted with halogen, -CN, C 1-6 Alkyl, C 1-6 Haloalkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 3-6 Cycloalkyl, C 2-9 Heterocycloalkyl, C 6-10 Aryl, C 1-9 Heteroaryl, -OR14 , -SR 14 , -C(O)OR 14 , -OC(O)N(R 14 )(R 15 ), -N(R 16 )C(O)N(R 14 )(R 15 ), -N(R 16 )C(O)R 17 , -N(R 16 )C(O)OR 17 , -N(R 16 )S(O)2R 17 , -C(O)R 17 , -OC(O)R 17 , -C(O)N(R 14 )(R 15 ), -C(O)C(O)N(R 14 )(R 15 ), -S(O)R 17 , -S(O)2R 17 , and -S(O)N(R 14 )(R 15 Optionally substituted with one, two, or three groups selected from two R 7 are combined to form a heterocycloalkyl ring optionally substituted with oxo, or R 7 and R 6 are combined to form a heterocycloalkyl ring; Each R 8 and each R 9 are each independently halogen, -CN, or C 1-6 Alkyl, C 1-6 Haloalkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 3-6 Cycloalkyl, C 2-9 Heterocycloalkyl, C 6-10 Aryl, C 1-9 Heteroaryl, -OR 10 , -SR 10 , -C(O)OR 10 , -OC(O)N(R 10 )(R 11 ), -N(R 12 )C(O)N(R 10 )(R 11), -N(R 12 )C(O)R 13 , -N(R 12 )C(O)OR 13 , -N(R 12 )S(O)2R 13 , -C(O)R 13 , -OC(O)R 13 , -C(O)N(R 10 )(R 11 ), -C(O)C(O)N(R 10 )(R 11 ), -S(O)R 13 , -S(O)2R 13 , and -S(O)N(R 10 )(R 11 ), where C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 3-6 Cycloalkyl, C 2-9 Heterocycloalkyl, C 6-10 Aryl, and C 1-9 Heteroaryl is substituted with halogen, -CN, C 1-6 Alkyl, C 1-6 Haloalkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 3-6 Cycloalkyl, C 2-9 Heterocycloalkyl, C 6-10 Aryl, C 1-9 Heteroaryl, -OR 14 , -SR 14 , -C(O)OR 14 , -OC(O)N(R 14 )(R 15 ), -N(R 16 )C(O)N(R 14 )(R 15 ), -N(R 16 )C(O)R 17 , -N(R 16 )C(O)OR 17 , -N(R 16 )S(O)2R 17 , -C(O)R 17 , -OC(O)R 17 , -C(O)N(R 14 )(R 15), -C(O)C(O)N(R 14 )(R 15 ), -S(O)R 17 , -S(O)2R 17 , and -S(O)N(R 14 )(R 15 Optionally substituted with one, two, or three groups selected from R 10 are each independently hydrogen, C 1-6 Alkyl, C 1-6 Haloalkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 3-6 Cycloalkyl, C 2-9 Heterocycloalkyl, C 6-10 Aryl, and C 1-9 heteroaryl, wherein C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 3-6 Cycloalkyl, C 2-9 Heterocycloalkyl, C 6-10 Aryl, and C 1-9 Heteroaryl is substituted with halogen, C 1-6 Alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, C 3-6 Cycloalkyl, C 2-9 Heterocycloalkyl, C 6-10 Aryl, and C 1-9 optionally substituted with one, two, or three groups selected from heteroaryl; R 11 are each independently hydrogen, C 1-6 Alkyl, and C 1-6 haloalkyl; R 12 are each independently hydrogen, C 1-6 Alkyl, and C 1-6 haloalkyl; R 13 are each independently, C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C3-6 Cycloalkyl, C 2-9 Heterocycloalkyl, C 6-10 Aryl, and C 1-9 heteroaryl, wherein C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 3-6 Cycloalkyl, C 2-9 Heterocycloalkyl, C 6-10 Aryl, and C 1-9 Heteroaryl is substituted with halogen, C 1-6 Alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, C 3-6 Cycloalkyl, C 2-9 Heterocycloalkyl, C 6-10 Aryl, and C 1-9 optionally substituted with one, two, or three groups selected from heteroaryl; R 14 are each independently hydrogen, C 1-6 Alkyl, C 1-6 Haloalkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 3-6 Cycloalkyl, C 2-9 Heterocycloalkyl, C 6-10 Aryl, and C 1-9 heteroaryl, wherein C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 3-6 Cycloalkyl, C 2-9 Heterocycloalkyl, C 6-10 Aryl, and C 1-9 Heteroaryl is substituted with halogen, C 1-6 Alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, C 3-6 Cycloalkyl, C 2-9 Heterocycloalkyl, C 6-10 Aryl, and C 1-9 optionally substituted with one, two, or three groups selected from heteroaryl; R 15 are each independently hydrogen, C 1-6 Alkyl, and C 1-6 haloalkyl; R 16 are each independently hydrogen, C 1-6 Alkyl, and C 1-6 haloalkyl, and R 17 are each independently, C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 3-6 Cycloalkyl, C 2-9 Heterocycloalkyl, C 6-10 Aryl, and C 1-9 heteroaryl, wherein C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 3-6 Cycloalkyl, C 2-9 Heterocycloalkyl, C 6-10 Aryl, and C 1-9 Heteroaryl is substituted with halogen, C 1-6 Alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, C 3-6 Cycloalkyl, C 2-9 Heterocycloalkyl, C 6-10 Aryl, and C 1-9 It is optionally substituted with one, two, or three groups selected from heteroaryl.

[0072] In some embodiments, there is a compound of formula (I), or a pharmaceutically acceptable salt or solvate thereof, wherein R 1 is one, two, three, four, or five R 7 C optionally replaced with 6-10 In some embodiments, there are compounds of formula (I), or pharmaceutically acceptable salts or solvates thereof, wherein R 1 is one, two, three, four, or five R 7In some embodiments, there are compounds of formula (I), or pharmaceutically acceptable salts or solvates thereof, wherein R 1 is one, two, three, four, or five R 7 In some embodiments, there are compounds of formula (I), or pharmaceutically acceptable salts or solvates thereof, wherein R 1 is one, two, or three R 7 In some embodiments, there are compounds of formula (I), or pharmaceutically acceptable salts or solvates thereof, wherein R 1 is one, two, three, four, or five R 7 C optionally replaced with 1-9 In some embodiments, there are compounds of formula (I), or a pharmaceutically acceptable salt or solvate thereof, wherein R 1 is one, two, three, four, or five R 7 C replaced with 1-9 In some embodiments, there are compounds of formula (I), or a pharmaceutically acceptable salt or solvate thereof, wherein R 1 is one, two, or three R 7 C replaced with 1-9 In some embodiments, there are compounds of formula (I), or a pharmaceutically acceptable salt or solvate thereof, wherein R 1 is unsubstituted C 1-9 It is heteroaryl.

[0073] In some embodiments, there is a compound of Formula (I) having the structure of Formula (Ia) or a pharmaceutically acceptable salt thereof:

[0074] [ka] wherein n is 0, 1, 2, 3, or 4.

[0075] In some embodiments, there is a compound of formula (Ia), or a pharmaceutically acceptable salt or solvate thereof, wherein R 10 are independently hydrogen and C 1-6 In some embodiments, there are compounds of Formula (Ia), or a pharmaceutically acceptable salt or solvate thereof, wherein R 10 is hydrogen. In some embodiments, there are compounds of formula (Ia), or a pharmaceutically acceptable salt or solvate thereof, wherein R 10 is C 1-6 In some embodiments, there are compounds of formula (Ia), or a pharmaceutically acceptable salt or solvate thereof, wherein R 10 is hydrogen, and R 11 is hydrogen. In some embodiments, there are compounds of Formula (Ia), or a pharmaceutically acceptable salt or solvate thereof, wherein at least one R 7 The substituent is -C(O)N(R 10 )(R 11 ) and exists ortho to R 10 is hydrogen and R 11 is hydrogen and at least one ortho R 7 In some embodiments, there is a compound of Formula (Ia), or a pharmaceutically acceptable salt or solvate thereof, wherein R 10 is C 1-6 alkyl, and R 11 is hydrogen.

[0076] In another embodiment, there is a compound of formula (I) having the structure of formula (Ib) or a pharmaceutically acceptable salt thereof:

[0077] [ka] wherein n is 0, 1, 2, 3, or 4.

[0078] In some embodiments, there is a compound of Formula (I) having the structure of Formula (Ic) or a pharmaceutically acceptable salt thereof:

[0079] [ka] wherein n is 0, 1, 2, 3, or 4.

[0080] In some embodiments, there is a compound of Formula (I) having the structure of Formula (Id) or a pharmaceutically acceptable salt thereof:

[0081] [ka] wherein n is 0, 1, 2, or 3.

[0082] In some embodiments, there is a compound of Formula (I) having the structure of Formula (Ie) or a pharmaceutically acceptable salt thereof:

[0083] [ka] wherein n is 0, 1, 2, or 3.

[0084] In some embodiments, there is a compound of formula (I) having the structure of formula (If) or a pharmaceutically acceptable salt thereof:

[0085] [ka] wherein n is 0, 1, 2, or 3.

[0086] In some embodiments, there is a compound of Formula (I) having the structure of Formula (Ig) or a pharmaceutically acceptable salt thereof:

[0087] [ka] wherein n is 0, 1, 2, or 3.

[0088] In some embodiments, there is a compound of formula (I), or a pharmaceutically acceptable salt or solvate thereof, wherein R 10 are independently hydrogen and C 1-6 In some embodiments, there is a compound of formula (Ig), or a pharmaceutically acceptable salt or solvate thereof, wherein R 10 is hydrogen. In some embodiments, there is a compound of formula (Ig), or a pharmaceutically acceptable salt or solvate thereof, wherein R 10 is C 1-6 In some embodiments, there is a compound of formula (Ig), or a pharmaceutically acceptable salt or solvate thereof, wherein R 10 is hydrogen, and R 11 is hydrogen. In some embodiments, there is a compound of formula (Ig), or a pharmaceutically acceptable salt or solvate thereof, wherein at least one R 7 The substituent is -C(O)N(R 10 )(R 11 ) and exists ortho to R 10 is hydrogen and R 11 is hydrogen and at least one ortho R 7 In some embodiments, there is a compound of formula (Ig), or a pharmaceutically acceptable salt or solvate thereof, wherein R 10 is C 1-6 alkyl, and R 11 is hydrogen.

[0089] In some embodiments, there is a compound of Formula (I) having the structure of Formula (Ih) or a pharmaceutically acceptable salt thereof:

[0090] [ka] wherein n is 0, 1, 2, or 3.

[0091] In another embodiment, there is a compound of Formula (I), (Ia), (Ib), (Ic), (Id), (Ie), (If), (Ig), or (Ih), or a pharmaceutically acceptable salt or solvate thereof, wherein R 10 are independently hydrogen and C 1-6 In another embodiment is a compound of Formula (I), (Ia), (Ib), (Ic), (Id), (Ie), (If), (Ig), or (Ih), or a pharmaceutically acceptable salt or solvate thereof, wherein R 10 is hydrogen. In another embodiment is a compound of Formula (I), (Ia), (Ib), (Ic), (Id), (Ie), (If), (Ig), or (Ih), or a pharmaceutically acceptable salt or solvate thereof, wherein R 10 is C 1-6 In another embodiment is a compound of Formula (I), (Ia), (Ib), (Ic), (Id), (Ie), (If), (Ig), or (Ih), or a pharmaceutically acceptable salt or solvate thereof, wherein R 11 is hydrogen. In another embodiment are compounds of Formula (I), (Ia), (Ib), (Ic), (Id), (Ie), (If), (Ig), or (Ih), or a pharmaceutically acceptable salt or solvate thereof, wherein n is 3. In another embodiment are compounds of Formula (I), (Ia), (Ib), (Ic), (Id), (Ie), (If), (Ig), or (Ih), or a pharmaceutically acceptable salt or solvate thereof, wherein n is 2. In another embodiment are compounds of Formula (I), (Ia), (Ib), (Ic), (Id), (Ie), (If), (Ig), or (Ih), or a pharmaceutically acceptable salt or solvate thereof, wherein n is 1. In another embodiment is a compound of Formula (I), (Ia), (Ib), (Ic), (Id), (Ie), (If), (Ig), or (Ih), or a pharmaceutically acceptable salt or solvate thereof, wherein n is 0. In another embodiment is a compound of Formula (I), (Ia), (Ib), (Ic), (Id), (Ie), (If), (Ig), or (Ih), or a pharmaceutically acceptable salt or solvate thereof, wherein n is 1 and R 7is a halogen, C 1-6 Alkyl, C 1-6 Haloalkyl, -OR 10 , and -C(O)N(R 10 )(R 11 In another embodiment is a compound of Formula (I), (Ia), (Ib), (Ic), (Id), (Ie), (If), (Ig), or (Ih), or a pharmaceutically acceptable salt or solvate thereof, wherein n is 1 and R 7 is a halogen, C 1-6 Alkyl, C 1-6 Haloalkyl, -OR 10 , and -C(O)N(R 10 )(R 11 ) and each R 10 and each R 11 are independently hydrogen and C 1-6 In another embodiment is a compound of Formula (I), (Ia), (Ib), (Ic), (Id), (Ie), (If), (Ig), or (Ih), or a pharmaceutically acceptable salt or solvate thereof, wherein n is 1 and R 7 is halogen and C 1-6 In another embodiment is a compound of Formula (I), (Ia), (Ib), (Ic), (Id), (Ie), (If), (Ig), or (Ih), or a pharmaceutically acceptable salt or solvate thereof, wherein n is 1 and R 7 is halogen. In another embodiment is a compound of Formula (I), (Ia), (Ib), (Ic), (Id), (Ie), (If), (Ig), or (Ih), or a pharmaceutically acceptable salt or solvate thereof, wherein n is 1 and R 7 is C 1-6 In another embodiment is a compound of Formula (I), (Ia), (Ib), (Ic), (Id), (Ie), (If), (Ig), or (Ih), or a pharmaceutically acceptable salt or solvate thereof, wherein n is 2 and R 7 are each independently a halogen, C 1-6 Alkyl, C 1-6 Haloalkyl, -OR 10, and -C(O)N(R 10 )(R 11 In another embodiment is a compound of Formula (I), (Ia), (Ib), (Ic), (Id), (Ie), (If), (Ig), or (Ih), or a pharmaceutically acceptable salt or solvate thereof, wherein n is 2 and R 7 are each independently a halogen, C 1-6 Alkyl, C 1-6 Haloalkyl, -OR 10 , and -C(O)N(R 10 )(R 11 ) and each R 10 and each R 11 are independently hydrogen and C 1-6 In another embodiment is a compound of Formula (I), (Ia), (Ib), (Ic), (Id), (Ie), (If), (Ig), or (Ih), or a pharmaceutically acceptable salt or solvate thereof, wherein n is 2 and R 7 are each independently a halogen and C 1-6 In another embodiment is a compound of Formula (I), (Ia), (Ib), (Ic), (Id), (Ie), (If), (Ig), or (Ih), or a pharmaceutically acceptable salt or solvate thereof, wherein n is 2 and R 7 and R are each halogen. In another embodiment are compounds of Formula (I), (Ia), (Ib), (Ic), (Id), (Ie), (If), (Ig), or (Ih), or a pharmaceutically acceptable salt or solvate thereof, wherein n is 2 and R 7 are C 1-6 In another embodiment is a compound of Formula (I), (Ia), (Ib), (Ic), (Id), (Ie), (If), (Ig), or (Ih), or a pharmaceutically acceptable salt or solvate thereof, wherein n is 3 and R 7 are each independently a halogen, C 1-6 Alkyl, C 1-6 Haloalkyl, -OR 10 , and -C(O)N(R 10 )(R 11In another embodiment is a compound of Formula (I), (Ia), (Ib), (Ic), (Id), (Ie), (If), (Ig), or (Ih), or a pharmaceutically acceptable salt or solvate thereof, wherein n is 3 and R 7 are each independently a halogen, C 1-6 Alkyl, C 1-6 Haloalkyl, -OR 10 , and -C(O)N(R 10 )(R 11 ) and each R 10 and each R 11 are independently hydrogen and C 1-6 In another embodiment are compounds of Formula (I), (Ia), (Ib), (Ic), (Id), (Ie), (If), (Ig), or (Ih), or a pharmaceutically acceptable salt or solvate thereof, wherein n is 3 and R 7 are each independently a halogen and C 1-6 In another embodiment is a compound of Formula (I), (Ia), (Ib), (Ic), (Id), (Ie), (If), (Ig), or (Ih), or a pharmaceutically acceptable salt or solvate thereof, wherein n is 3 and R 7 and R are each halogen. In another embodiment are compounds of Formula (I), (Ia), (Ib), (Ic), (Id), (Ie), (If), (Ig), or (Ih), or a pharmaceutically acceptable salt or solvate thereof, wherein n is 3 and R 7 are C 1-6 It is alkyl.

[0092] In another embodiment, there is a compound of Formula (I), (Ia), (Ib), (Ic), (Id), (Ie), (If), (Ig), or (Ih), or a pharmaceutically acceptable salt or solvate thereof, wherein R 3 Ha-XR 3aIn another embodiment are compounds of Formula (I), (Ia), (Ib), (Ic), (Id), (Ie), (If), (Ig), or (Ih), or a pharmaceutically acceptable salt or solvate thereof, wherein X is a bond. In another embodiment are compounds of Formula (I), (Ia), (Ib), (Ic), (Id), (Ie), (If), (Ig), or (Ih), or a pharmaceutically acceptable salt or solvate thereof, wherein X is C 1-6 In another embodiment, there is a compound of Formula (I), (Ia), (Ib), (Ic), (Id), (Ie), (If), (Ig), or (Ih), or a pharmaceutically acceptable salt or solvate thereof, wherein X is -CH2-. In another embodiment, there is a compound of Formula (I), (Ia), (Ib), (Ic), (Id), (Ie), (If), (Ig), or (Ih), or a pharmaceutically acceptable salt or solvate thereof, wherein R 3a One, two, or three R 9 C optionally replaced with 3-8 In another embodiment is a compound of Formula (I), (Ia), (Ib), (Ic), (Id), (Ie), (If), (Ig), or (Ih), or a pharmaceutically acceptable salt or solvate thereof, wherein R 3a One, two, or three R 9 C replaced with 3-8 In another embodiment is a compound of Formula (I), (Ia), (Ib), (Ic), (Id), (Ie), (If), (Ig), or (Ih), or a pharmaceutically acceptable salt or solvate thereof, wherein R 3a One, two, or three R 9 C replaced with 3-8 In another embodiment is a compound of Formula (I), (Ia), (Ib), (Ic), (Id), (Ie), (If), (Ig), or (Ih), or a pharmaceutically acceptable salt or solvate thereof, wherein R 9 are each independently halogen, -CN, or C 1-6 Alkyl, and C 1-6In another embodiment, there is a compound of Formula (I), (Ia), (Ib), (Ic), (Id), (Ie), (If), (Ig), or (Ih), or a pharmaceutically acceptable salt or solvate thereof, wherein R 3a is one R 9 In another embodiment is a compound of Formula (I), (Ia), (Ib), (Ic), (Id), (Ie), (If), (Ig), or (Ih), or a pharmaceutically acceptable salt or solvate thereof, wherein R 3a is C 1-6 In another embodiment is a compound of Formula (I), (Ia), (Ib), (Ic), (Id), (Ie), (If), (Ig), or (Ih), or a pharmaceutically acceptable salt or solvate thereof, wherein R 3a is cyclopropyl substituted with -CF. In another embodiment is a compound of Formula (I), (Ia), (Ib), (Ic), (Id), (Ie), (If), (Ig), or (Ih), or a pharmaceutically acceptable salt or solvate thereof, wherein R 3a is unsubstituted C 3-8 In another embodiment is a compound of Formula (I), (Ia), (Ib), (Ic), (Id), (Ie), (If), (Ig), or (Ih), or a pharmaceutically acceptable salt or solvate thereof, wherein R 3a is unsubstituted cyclopropyl.

[0093] In some embodiments of a compound of Formula (I), (Ia), (Ib), (Ic), (Id), (Ie), (If), (Ig), or (Ih), or a pharmaceutically acceptable salt or solvate thereof, R 3a is cyclopropyl substituted with -CF3, and R 3a R has one or more enhanced pharmacokinetic properties compared to embodiments where R is unsubstituted cyclopropyl. 3a In some embodiments, R is cyclopropyl substituted with —CF. 3ais an unsubstituted cyclopropyl. In some embodiments, the enhanced pharmacokinetic property is increased permeability (e.g., cell permeability, tissue permeability, blood-brain barrier permeability, CNS permeability, etc.). In some embodiments, the enhanced pharmacokinetic property is increased lipophilicity or logP. In some embodiments, the enhanced pharmacokinetic property is increased bioavailability (e.g., oral bioavailability). In some embodiments, the enhanced pharmacokinetic property is increased metabolic stability. In some embodiments, the enhanced pharmacokinetic property is decreased elimination. In some embodiments, the enhanced pharmacokinetic property is decreased clearance. In some embodiments, the enhanced pharmacokinetic property is decreased nonspecific binding (e.g., plasma protein binding). In some embodiments, the enhanced pharmacokinetic property is decreased off-target binding (e.g., to cytochrome P450 enzymes or other metabolic enzymes).

[0094] In some embodiments of a compound of Formula (I), (Ia), (Ib), (Ic), (Id), (Ie), (If), (Ig), or (Ih), or a pharmaceutically acceptable salt or solvate thereof, R 3a is cyclopropyl substituted with -CF3, and R 3ais unsubstituted cyclopropyl. In some embodiments, the enhanced pharmacological property is increased μ opioid receptor binding. In some embodiments, the enhanced pharmacological property is decreased μ opioid receptor binding. In some embodiments, the enhanced pharmacological property is increased δ opioid receptor binding. In some embodiments, the enhanced pharmacological property is decreased δ opioid receptor binding. In some embodiments, the enhanced pharmacological property is increased κ opioid receptor binding. In some embodiments, the enhanced pharmacological property is decreased κ opioid receptor binding. In some embodiments, the enhanced pharmacological property is increased selectivity for μ over δ and / or κ opioid receptors. In some embodiments, the enhanced pharmacological property is modulated efficacy at the μ opioid receptor (e.g., increased or decreased activation (e.g., β-arrestin activation, G protein activation)). In some embodiments, the enhanced pharmacological property is increased μ opioid receptor efficacy. In some embodiments, the enhanced pharmacological property is a decrease in mu opioid receptor efficacy (eg, G protein activation).

[0095] In another embodiment, there is a compound of Formula (I), (Ia), (Ib), (Ic), (Id), (Ie), (If), (Ig), or (Ih), or a pharmaceutically acceptable salt or solvate thereof, wherein R 3 is C2-C8 alkyl. In another embodiment is a compound of Formula (I), (Ia), (Ib), (Ic), (Id), (Ie), (If), (Ig), or (Ih), or a pharmaceutically acceptable salt or solvate thereof, wherein R 3 is -CH2CH3, -CH(CH3)2, -C(CH3)3, -CH2CH(CH3)2, or -CH2CH2CH2CH3. In another embodiment, there is a compound of Formula (I), (Ia), (Ib), (Ic), (Id), (Ie), (If), (Ig), or (Ih), or a pharmaceutically acceptable salt or solvate thereof, wherein R3 is -CH(CH3)2, -C(CH3)3, -CH2CH(CH3)2, or -CH2CH2CH2CH3. In another embodiment is a compound of Formula (I), (Ia), (Ib), (Ic), (Id), (Ie), (If), (Ig), or (Ih), or a pharmaceutically acceptable salt or solvate thereof, wherein R 3 is —CH2CH3. In another embodiment is a compound of Formula (I), (Ia), (Ib), (Ic), (Id), (Ie), (If), (Ig), or (Ih), or a pharmaceutically acceptable salt or solvate thereof, wherein R 3 is —CH(CH3)2. In another embodiment is a compound of Formula (I), (Ia), (Ib), (Ic), (Id), (Ie), (If), (Ig), or (Ih), or a pharmaceutically acceptable salt or solvate thereof, wherein R 3 is —C(CH3)3. In another embodiment is a compound of Formula (I), (Ia), (Ib), (Ic), (Id), (Ie), (If), (Ig), or (Ih), or a pharmaceutically acceptable salt or solvate thereof, wherein R 3 is —CH2CH(CH3)2. In another embodiment is a compound of Formula (I), (Ia), (Ib), (Ic), (Id), (Ie), (If), (Ig), or (Ih), or a pharmaceutically acceptable salt or solvate thereof, wherein R 3 is —CH 2 CH 2 CH 2 CH 3 In another embodiment is a compound of Formula (I), (Ia), (Ib), (Ic), (Id), (Ie), (If), (Ig), or (Ih), or a pharmaceutically acceptable salt or solvate thereof, wherein R 3 is -CH2CH2CH3.

[0096] In another embodiment, there is a compound of Formula (I), (Ia), (Ib), (Ic), (Id), (Ie), (If), (Ig), or (Ih), or a pharmaceutically acceptable salt or solvate thereof, wherein R 3is C2-C8 alkenyl. In another embodiment is a compound of Formula (I), (Ia), (Ib), (Ic), (Id), (Ie), (If), (Ig), or (Ih), or a pharmaceutically acceptable salt or solvate thereof, wherein R 3 is -CH2CH2CH=CH.

[0097] In another embodiment, there is a compound of Formula (I), (Ia), (Ib), (Ic), (Id), (Ie), (If), (Ig), or (Ih), or a pharmaceutically acceptable salt or solvate thereof, wherein R 3 is a C2-C8 haloalkyl.

[0098] In another embodiment, there is a compound of Formula (I), (Ia), (Ib), (Ic), (Id), (Ie), (If), (Ig), or (Ih), or a pharmaceutically acceptable salt or solvate thereof, wherein R 2 is one, two, three, four, or five R 8 C optionally replaced with 6-10 In another embodiment is a compound of Formula (I), (Ia), (Ib), (Ic), (Id), (Ie), (If), (Ig), or (Ih), or a pharmaceutically acceptable salt or solvate thereof, wherein R 2 is one, two, three, four, or five R 8 In another embodiment is a compound of Formula (I), (Ia), (Ib), (Ic), (Id), (Ie), (If), (Ig), or (Ih), or a pharmaceutically acceptable salt or solvate thereof, wherein R 2 One, two, or three R 8 In another embodiment is a compound of Formula (I), (Ia), (Ib), (Ic), (Id), (Ie), (If), (Ig), or (Ih), or a pharmaceutically acceptable salt or solvate thereof, wherein R 2 is one, two, three, four, or five R 8 C optionally replaced with 1-9In another embodiment is a compound of Formula (I), (Ia), (Ib), (Ic), (Id), (Ie), (If), (Ig), or (Ih), or a pharmaceutically acceptable salt or solvate thereof, wherein R 2 One, two, or three R 8 C replaced with 1-9 In another embodiment is a compound of Formula (I), (Ia), (Ib), (Ic), (Id), (Ie), (If), (Ig), or (Ih), or a pharmaceutically acceptable salt or solvate thereof, wherein R 2 is pyridinyl, pyrimidinyl, or thiazolyl, and pyridinyl, pyrimidinyl, and thiazolyl are substituted with one, two, or three R 8 In another embodiment is a compound of Formula (I), (Ia), (Ib), (Ic), (Id), (Ie), (If), (Ig), or (Ih), or a pharmaceutically acceptable salt or solvate thereof, wherein R 8 are each independently a halogen, C 1-6 Alkyl, C 1-6 Haloalkyl, and -OR 10 In another embodiment, a compound of Formula (I), (Ia), (Ib), (Ic), (Id), (Ie), (If), (Ig), or (Ih), or a pharmaceutically acceptable salt or solvate thereof, wherein R 10 are C 1-6 In another embodiment is a compound of Formula (I), (Ia), (Ib), (Ic), (Id), (Ie), (If), (Ig), or (Ih), or a pharmaceutically acceptable salt or solvate thereof, wherein R 2 is unsubstituted phenyl. In another embodiment is a compound of Formula (I), (Ia), (Ib), (Ic), (Id), (Ie), (If), (Ig), or (Ih), or a pharmaceutically acceptable salt or solvate thereof, wherein R 2 is unsubstituted C 1-9In another embodiment is a compound of Formula (I), (Ia), (Ib), (Ic), (Id), (Ie), (If), (Ig), or (Ih), or a pharmaceutically acceptable salt or solvate thereof, wherein R 2 is unsubstituted pyridinyl, unsubstituted pyrimidinyl, or unsubstituted thiazolyl.

[0099] In another embodiment, there is a compound of Formula (I), (Ia), (Ib), (Ic), (Id), (Ie), (If), (Ig), or (Ih), or a pharmaceutically acceptable salt or solvate thereof, wherein R 5 and R 6 are each independently selected from hydrogen, C1-C6 alkyl, and C1-C6 haloalkyl. In another embodiment, there is a compound of Formula (I), (Ia), (Ib), (Ic), (Id), (Ie), (If), (Ig), or (Ih), or a pharmaceutically acceptable salt or solvate thereof, wherein R 5 is selected from hydrogen and C1-C6 alkyl. In another embodiment is a compound of Formula (I), (Ia), (Ib), (Ic), (Id), (Ie), (If), (Ig), or (Ih), or a pharmaceutically acceptable salt or solvate thereof, wherein R 6 is selected from hydrogen and C1-C6 alkyl. In another embodiment is a compound of Formula (I), (Ia), (Ib), (Ic), (Id), (Ie), (If), (Ig), or (Ih), or a pharmaceutically acceptable salt or solvate thereof, wherein R 5 and R 6 and R are each hydrogen. In another embodiment, there is a compound of Formula (I), (Ia), (Ib), (Ic), (Id), (Ie), (If), (Ig), or (Ih), or a pharmaceutically acceptable salt or solvate thereof, wherein R 5 and R 6 and each is C1-C6 alkyl. In another embodiment is a compound of Formula (I), (Ia), (Ib), (Ic), (Id), (Ie), (If), (Ig), or (Ih), or a pharmaceutically acceptable salt or solvate thereof, wherein R 5 and R6 is C1-C6 alkyl. In another embodiment is a compound of Formula (I), (Ia), (Ib), (Ic), (Id), (Ie), (If), (Ig), or (Ih), or a pharmaceutically acceptable salt or solvate thereof, wherein R 5 and R 6 are combined to form an azetidinyl, pyrrolidinyl, piperidinyl, or piperazinyl ring. In another embodiment are compounds of Formula (I), (Ia), (Ib), (Ic), (Id), (Ie), (If), (Ig), or (Ih), or a pharmaceutically acceptable salt or solvate thereof, wherein R 5 and R 6 are combined to form an azetidinyl ring. In another embodiment are compounds of Formula (I), (Ia), (Ib), (Ic), (Id), (Ie), (If), (Ig), or (Ih), or a pharmaceutically acceptable salt or solvate thereof, wherein R 5 and R 6 are combined to form a pyrrolidinyl ring. In another embodiment are compounds of Formula (I), (Ia), (Ib), (Ic), (Id), (Ie), (If), (Ig), or (Ih), or a pharmaceutically acceptable salt or solvate thereof, wherein R 5 and R 6 are combined to form a piperidinyl ring. In another embodiment are compounds of Formula (I), (Ia), (Ib), (Ic), (Id), (Ie), (If), (Ig), or (Ih), or a pharmaceutically acceptable salt or solvate thereof, wherein R 5 and R 6 are combined to form a piperazinyl ring.

[0100] In another embodiment, there is a compound of Formula (I), (Ia), (Ib), (Ic), (Id), (Ie), (If), (Ig), or (Ih), or a pharmaceutically acceptable salt or solvate thereof, wherein R 4 is hydrogen.

[0101] Further embodiments provided herein include combinations of one or more of the specific embodiments set forth above.

[0102] In some embodiments,

[0103] [ka]

[0104] [ka]

[0105] [ka]

[0106] [ka]

[0107] [ka]

[0108] [ka]

[0109] [ka]

[0110] [ka]

[0111] [ka]

[0112] [ka]

[0113] [ka]

[0114] [ka]

[0115] [ka]

[0116] [ka]

[0117] [ka]

[0118] [ka]

[0119] [ka]

[0120] [ka]

[0121] [ka] or a pharmaceutically acceptable salt thereof.

[0122] In some embodiments,

[0123] [ka]

[0124] [ka] or a pharmaceutically acceptable salt thereof.

[0125] In some embodiments, a compound of Formula (I), (Ia), (Ib), (Ic), (Id), (Ie), (If), (Ig), or (Ih) described herein is a μ opioid receptor modulator. In some embodiments, a compound described herein is a μ opioid receptor superagonist. In some embodiments, a compound described herein is a μ opioid receptor agonist. In some embodiments, a compound described herein is a μ opioid receptor partial agonist. In some embodiments, a compound described herein is a μ opioid receptor weak partial agonist. In some embodiments, a compound described herein is a μ opioid receptor weak partial agonist / antagonist. In some embodiments, a compound described herein is a μ opioid receptor antagonist.

[0126] In some embodiments, the compounds described herein are μ opioid receptor partial agonists with at least about 10%, about 20%, about 30%, about 40%, about 50%, about 60%, about 70%, about 80%, or more cAMP activation compared to a standard full agonist (e.g., DAMGO). In some embodiments, the compounds described herein are weak μ opioid receptor partial agonists with about 10% to about 50% (e.g., about 10% to about 30%) cAMP activation compared to a standard full agonist (e.g., DAMGO). In some embodiments, the compounds described herein are μ opioid receptor partial agonists with about 30% to about 70% cAMP activation compared to a standard full agonist (e.g., DAMGO). In some embodiments, the compounds described herein are μ opioid receptor partial agonists with about 50% to about 70% cAMP activation compared to a standard full agonist (e.g., DAMGO). In some embodiments, the compounds described herein are μ opioid receptor partial agonists with about 40% cAMP activation compared to a standard full agonist (e.g., DAMGO). In some embodiments, the compounds described herein are μ opioid receptor agonists with about 50% cAMP activation compared to a standard full agonist (e.g., DAMGO). In some embodiments, the compounds described herein are μ opioid receptor agonists with about 60% cAMP activation compared to a standard full agonist (e.g., DAMGO). In some embodiments, the compounds described herein are μ opioid receptor agonists with about 70% cAMP activation compared to a standard full agonist (e.g., DAMGO). In some embodiments, the compounds described herein are μ-opioid receptor agonists with about 80% cAMP activation compared to a standard full agonist (eg, DAMGO).

[0127] In some embodiments, the compounds described herein are μ-opioid receptor antagonists / weak partial agonists with efficacy lower than that of buprenorphine. In some embodiments, the compounds described herein are μ-opioid receptor antagonists / weak partial agonists with efficacy greater than that of naltrexone. In some embodiments, the compounds described herein are μ-opioid receptor antagonists / weak partial agonists with efficacy less than that of buprenorphine and greater than that of naltrexone. In some embodiments, the compounds described herein are μ-opioid receptor antagonists / weak partial agonists with efficacy less than that of morphine and greater than that of buprenorphine.

[0128] In some embodiments, a compound of Formula (I), (Ia), (Ib), (Ic), (Id), (Ie), (If), (Ig), or (Ih) described herein is a biased μ-opioid receptor modulator (e.g., a partial agonist, a weak partial agonist, an antagonist, etc.). In some embodiments, a compound described herein is a G protein-biased μ-opioid receptor modulator. In some embodiments, a compound described herein is a β-arrestin-biased μ-opioid receptor modulator.

[0129] In some embodiments, a compound of Formula (I), (Ia), (Ib), (Ic), (Id), (Ie), (If), (Ig), or (Ih) described herein is a δ opioid receptor modulator. In some embodiments, a compound described herein is a δ opioid receptor agonist. In some embodiments, a compound described herein is a δ opioid receptor partial agonist. In some embodiments, a compound described herein is a weak partial agonist / antagonist of the δ opioid receptor. In some embodiments, a compound described herein is a δ opioid receptor antagonist.

[0130] In some embodiments, a compound of Formula (I), (Ia), (Ib), (Ic), (Id), (Ie), (If), (Ig), or (Ih) described herein is a kappa opioid receptor modulator. In some embodiments, a compound described herein is a kappa opioid receptor agonist. In some embodiments, a compound described herein is a kappa opioid receptor partial agonist. In some embodiments, a compound described herein is a kappa opioid receptor weak partial agonist / antagonist. In some embodiments, a compound described herein is a kappa opioid receptor antagonist.

[0131] In some embodiments, a compound of Formula (I), (Ia), (Ib), (Ic), (Id), (Ie), (If), (Ig), or (Ih) described herein is a selective opioid receptor modulator. In some embodiments, a compound of Formula (I), (Ia), (Ib), (Ic), (Id), (Ie), (If), (Ig), or (Ih) described herein is a selective μ-opioid receptor modulator.

[0132] In some embodiments, the compounds of Formula (I), (Ia), (Ib), (Ic), (Id), (Ie), (If), (Ig), or (Ih) described herein, and compositions comprising these compounds, are useful for treating one or more diseases selected from neuropsychiatric disorders, depression, obsessive-compulsive disorder, alcoholism, gambling addiction, pain, opioid overdose, opioid use disorder, and addiction. In some embodiments, the compounds of Formula (I), (Ia), (Ib), (Ic), (Id), (Ie), (If), (Ig), or (Ih) described herein, and compositions comprising these compounds, are useful for treating one or more diseases or conditions without substantial respiratory depression (i.e., less than about 75%, less than about 50%, less than about 25%, less than about 20%, less than about 10%, or less than about 5% compared to standard of care opiates, e.g., fentanyl, morphine, oxycodone, etc.). In some embodiments, the compounds described herein do not depress respiration (e.g., at dosages effective to treat one or more diseases or conditions described herein). In some embodiments, the compounds described herein do not substantially depress respiration at dosages effective to treat one or more conditions selected from neuropsychiatric disorders, depression, obsessive-compulsive disorder, alcoholism, gambling addiction, pain, opioid overdose, opioid use disorder, and addiction.

[0133] In some embodiments, the compounds described herein are not self-administered. In some embodiments, the compounds described herein are not self-administered at a dosage effective to treat one or more diseases or conditions described herein, e.g., neuropsychiatric disorders, depression, obsessive-compulsive disorder, alcoholism, gambling addiction, pain, opioid overdose, opioid use disorder, addiction, or a combination thereof. In some embodiments, the compounds described herein are not habit-forming. In some embodiments, the compounds described herein are not rewarding. In some embodiments, the compounds described herein are not self-administered. In some embodiments, the compounds described herein are not addictive. In some embodiments, the compounds described herein are not addictive at a dosage effective to treat one or more diseases or conditions described herein, e.g., neuropsychiatric disorders, depression, obsessive-compulsive disorder, alcoholism, gambling addiction, pain, opioid overdose, opioid use disorder, addiction, or a combination thereof. In some embodiments, the compounds described herein are not as addictive as standard of care opiates (e.g., morphine, oxycodone, etc.).

[0134] In some embodiments, the compounds described herein (at a dosage effective to treat one or more diseases or conditions described herein, e.g., neuropsychiatric disorders, depression, obsessive-compulsive disorder, alcoholism, gambling addiction, pain, opioid overdose, opioid use disorder, addiction, or a combination thereof) have a reduced likelihood of respiratory depression (e.g., compared to standard of care). In some embodiments, the compounds described herein (at a dosage effective to treat one or more diseases or conditions described herein, e.g., neuropsychiatric disorders, depression, obsessive-compulsive disorder, alcoholism, gambling addiction, pain, opioid overdose, opioid use disorder, addiction, or a combination thereof) have a reduced likelihood of addiction (e.g., compared to standard of care). In some embodiments, the compounds described herein (at a dosage effective to treat one or more diseases or conditions described herein, e.g., neuropsychiatric disorders, depression, obsessive-compulsive disorder, alcoholism, gambling addiction, pain, opioid overdose, opioid use disorder, addiction, or a combination thereof) have a reduced likelihood of tolerance (e.g., compared to standard of care). In some embodiments, the compounds described herein have a reduced propensity for sedation (e.g., compared to standard of care) (at a dosage effective to treat one or more diseases or conditions described herein, e.g., neuropsychiatric disorders, depression, obsessive-compulsive disorder, alcoholism, gambling addiction, pain, opioid overdose, opioid use disorder, addiction, or a combination thereof). In some embodiments, the compounds described herein are analgesics with a reduced propensity for respiratory depression, tolerance, addiction, and / or sedation (e.g., compared to standard of care) (at a dosage effective to treat one or more diseases or conditions described herein, e.g., neuropsychiatric disorders, depression, obsessive-compulsive disorder, alcoholism, gambling addiction, pain, opioid overdose, opioid use disorder, addiction, or a combination thereof).

[0135] In some embodiments, a compound of Formula (I), (Ia), (Ib), (Ic), (Id), (Ie), (If), (Ig), or (Ih) described herein has high CNS exposure. In some embodiments, a compound described herein is orally bioavailable. In some embodiments, a compound described herein has three H-bond donors or less (e.g., two H-bond donors or less (e.g., one H-bond donor or less)). In some embodiments, a compound described herein has high permeability (e.g., cell permeability, tissue permeability, blood-brain barrier permeability). In some embodiments, a compound described herein has high stability (e.g., heat resistance, shelf stability, solution stability, plasma stability, lysosomal stability, liver stability, etc.). In some embodiments, a compound described herein has high metabolic stability. In some embodiments, a compound described herein has low excretion.

[0136] Preparation of compounds The compounds used in the reactions described herein are made according to organic synthesis techniques starting from commercially available chemicals and / or compounds described in the chemical literature. "Commercially available chemicals" include those obtained from the following companies: Acros Organics (Geel, Belgium), Aldrich Chemical (Milwaukee, Wisconsin).(including Sigma Chemical and Fluka), Apin Chemicals Ltd. (Melton Park, UK), Ark Pharm, Inc. (Libertyville, IL), Avocado Research (Lancashire, UK), BDH Inc. (Toronto, Canada), Bionet (Cornwell, UK), Chemservice Inc. (West Chester, PA), Combi-blocks (San Diego, CA), Crescent Chemical Co. (Hauppauge, NY), eMolecules (San Diego, CA), Fisher Scientific Co. (Pittsburgh, PA), Fisons Chemicals (Leicestershire, UK), Frontier Scientific (Logan, UT), ICN Biomedicals, Inc. (Costa Mesa, CA), Key Organics (Cornwell, UK), Lancaster Synthesis (Windham, NH), Matrix Scientific, (Columbia, SC), Maybridge Chemical Co. Ltd. (Cornwell, UK), Parish Chemical Co. (Orem, UT), Pfaltz & Bauer, Inc. (Waterbury, CT), Polyorganix (Houston, TX), Pierce Chemical Co. (Rockford, IL), Riedel de Haen AG (Hannover, Germany), Ryan Scientific, Inc. (Mount Pleasant, SC), Spectrum Chemicals (Gardena, CA), Sundia Meditech, (Shanghai, China), TCI America (Portland, OR), Trans World Chemicals, Inc. (Rockville, MD), and WuXi (Shanghai, China).

[0137] Suitable references and papers detailing the synthesis of reactants useful in preparing the compounds described herein or providing references to articles describing their preparation include, for example, "Synthetic Organic Chemistry," John Wiley & Sons, Inc., New York; S.R. Sandler et al., "Organic Functional Group Preparations," 2nd Ed., Academic Press, New York, 1983; H.O. House, "Modern Synthetic Reactions," 2nd Ed., W.A. Benjamin, Inc. Menlo Park, Calif., 1972; T.L. Gilchrist, "Heterocyclic Chemistry," 2nd Ed., John Wiley & Sons, New York, 1992; and J. March, "Advanced Organic Chemistry: Reactions, Mechanisms and Structure," 4th Ed., Wiley Interscience, New York, 1992. Additional suitable references and articles detailing the synthesis of or referencing articles describing the preparation of reactants useful in the preparation of the compounds described herein include, for example, Fuhrhop, J. and Penzlin G. "Organic Synthesis: Concepts, Methods, Starting Materials", Second, Revised and Enlarged Edition (1994) John Wiley & Sons ISBN: 3 527-29074-5; Hoffman, RV "Organic Chemistry, An Intermediate Text" (1996) Oxford University Press, ISBN 0-19-509618-5; Larock, RCMarch, J. “Advanced Organic Chemistry: Reactions, Mechanisms, and Structure” 4th Edition (1992) John Wiley & Sons, ISBN: 0-471-60180-2; Otera, J. (editor) “Modern Carbonyl Chemistry” (2000) Wiley-VCH, ISBN: 3-527-29871-1; Patai, S. “Patai's 1992 Guide to the Chemistry of Functional Groups” (1992) Interscience ISBN: 0-471-93022-9; Solomons, TWG “Organic Chemistry” 7th Edition (2000) John Wiley & Sons, ISBN: 0-471-19095-0; Stowell, JC, “Intermediate Organic Chemistry” 2nd Edition (1993) Wiley-Interscience, ISBN: 0-471-57456-2; the 8-volume “Industrial Organic Chemicals: Starting Materials and Intermediates: An Ullmann's Encyclopedia” (1999) John Wiley & Sons, ISBN: 3-527-29645-X; the 55-volume “Organic Reactions” (1942-2000) John Wiley & Sons, and the 73-volume “Chemistry of Functional Groups” John Wiley & Sons.

[0138] Specific and similar reactants may also be identified through the index of known chemicals prepared by the Chemical Abstract Service of the American Chemical Society (Washington, DC), available in most public and university libraries and online databases. Chemicals that are known but not sold in catalogs are optionally prepared by custom chemical synthesis houses, and many of the standard drug supply companies (e.g., those listed above) offer custom synthesis services. For information on the preparation and selection of pharmaceutical salts of the compounds described herein, see P.H. Stahl & C.G. Wermuth, "Handbook of Pharmaceutical Salts," Verlag Helvetica Chimica Acta, Zurich, 2002.

[0139] In some embodiments, the following synthetic method may be utilized.

[0140] [ka]

[0141] Synthesis of compounds containing an amide-substituted aryl group, such as those described in Formula (Ia), can be accomplished according to General Scheme I. Generally, an appropriate aryl halide (e.g., an aryl bromide) is subjected to conditions sufficient for coupling to a functionalized amino acid, as shown in step (a). This can be accomplished by means known to those skilled in the art, including, but not limited to, Negishi coupling. In some embodiments, suitable reagents for step (a) include Zn, I2, Pd2(dba)3, and S-Phos in a suitable solvent (e.g., DMF) and temperature (e.g., about 80°C). The methyl ester can then be reduced to an alcohol and the nitrile can be hydrolyzed (preferably in that order), as shown in step (b). Reduction can be carried out using a number of hydride reagents, including, for example, LiBH4. Hydrolysis can be carried out using a suitable base and aqueous solvent (e.g., NaOH and HO). In step (c) of General Scheme I, the alcohol functionality can be displaced with a suitable nucleophile (e.g., phthalimide) using a variety of conditions. In some instances, these conditions include Mitsunobu conditions (e.g., PPh3 and DIAD in THF at 0°C to room temperature). This transformation can be effected using a variety of suitable reagents, solvents, and temperatures known to those skilled in the art. In step (d), the Boc group on the nitrogen can be removed under acidic conditions, e.g., 4N HCl in dioxane. After Boc deprotection, the amine can be further functionalized to form R 5 and R 6 Substituents can be introduced. In some embodiments, the nitrogen is functionalized using formaldehyde, acetic acid, and sodium cyanoborohydride. In other embodiments, the nitrogen is functionalized using a dibromide (e.g., Br-(CH) nThe phthalimide group may be functionalized using —Br, where n is an integer from 2 to 10, preferably n is 4 or 5, and the nitrogen forms a pyrrolidine or piperidine. Such di-bromide functionalization is typically carried out with a suitable base (e.g., potassium carbonate) in a suitable solvent system (e.g., DMF). The phthalimide group may, in some embodiments, be removed using a hydrazine reagent (e.g., NH) in a suitable solution (e.g., HO), optionally diluted in another solvent (e.g., EtOH).

[0142] [ka]

[0143] In addition to General Scheme I, compounds of formula (Ia) can be further synthesized using optionally substituted benzoic acids as outlined in General Scheme II. In step (a) of General Scheme II, a bromo-benzoic acid is reacted with an appropriate amine, NHR 10 R 11or its cation (e.g., NHOH, NHCH, NH(CH), etc.) to an amide (e.g., a primary amide). In some embodiments, such conversion is preceded by an activation step, whereby the acid forms an activated ester upon coupling with an appropriate coupling reagent (e.g., CDI). Other coupling agents (e.g., peptide coupling reagents) are commercially available and can be exchanged to optimize yields or kinetics. Alternative amines may also be used in step (a), as would be known to one skilled in the art. The amide coupling of step (a) may, in some embodiments, also include the use of a base (e.g., triethylamine, etc.) in a suitable solvent (e.g., dichloromethane). Steps (b)-(f) of General Scheme II can be carried out using methods similar to those previously described in General Scheme I or other suitable methods known to one skilled in the art. The processes described herein can be carried out to produce either primary, secondary, or tertiary amides, depending on the amine used in step (a). Alternatively, the primary amide may be further substituted at a later stage.

[0144] [ka]

[0145] Compounds of Formula (Ib) can be prepared using methodologies similar to those described above, using the appropriate phenol starting material. For example, Negishi coupling conditions (e.g., Zn, I2, Pd2(dba)3, and S-Phos in DMF at 80°C) can be used in step (a) to introduce modified amino acids as described above. In some instances, it may be advantageous or necessary to protect the phenol to prevent side reactions. In some embodiments, step (b) involves protecting the phenol (e.g., with TBSCl and imidazole) prior to reduction of the ester to prevent undesired coupling to multiple alcohols. In some embodiments, the TBS protecting group is removed after the Mitsunobu reaction in step (c). In other embodiments of General Scheme III (not shown), the phenol alcohol can be functionalized with additional substituents. In some embodiments, the phenol is unsubstituted, and the -OH group is involved in the relevant receptor-ligand interaction.

[0146] [ka]

[0147] In preparing a compound of formula (Ic), steps such as those described in general scheme IV can be carried out to achieve the desired chemical scaffold and substituents. For example, in preparing a compound of formula (Ic), an optionally substituted aniline can be functionalized (e.g., cyclized) in the first step. Such cyclization conditions can include t-Bu-nitrile and acetic anhydride in combination with a suitable base (e.g., potassium acetate). Step (a) can further include the use of a crown ether (e.g., 18-C-6). In some embodiments, step (a) can further include the use of a base or hydride reagent (e.g., NaH) and a sulfonyl chloride (e.g., tosyl chloride) in a suitable solvent (e.g., DMF), which produces a tosylated indazole as shown in general scheme IV. The starting material can be an additional R 7After cyclization of the optionally substituted indazole as outlined in step (a), compounds of formula (Ic) can be prepared according to similar steps as described herein.

[0148] [ka]

[0149] In preparing compounds of formula (Id), for example, nitrophenols as shown in general Scheme V can be functionalized using reagents and conditions known to those skilled in the art. In some embodiments, the phenol moiety of the nitrophenol starting reagent is first protected (e.g., with TBSCl) prior to the Negishi coupling, which occurs in step (b) of general Scheme V (as described herein). Subsequent steps (c)-(e) are as described herein, with appropriate modifications as will be understood by those skilled in the art. After reduction of the nitro group, the resulting amine is treated with 2-chloroacetyl chloride, which is then deprotected as described above.

[0150] [ka]

[0151] In some embodiments, compounds of the present disclosure have the R 3In some embodiments, chirality is introduced by the use of a chiral oxazolidinone, commonly known as an Evans auxiliary. In some embodiments, the chirality is known and assigned. In other embodiments, the chirality is known to be a single isomer, but the exact (R) or (S) stereochemical assignment is unknown. In some embodiments, the compounds disclosed herein are single diastereomers or enantiomers. As outlined in general Scheme VI, an aldehyde can be converted to an α-β unsaturated carbonyl compound as described in step (a). In some embodiments, step (a) comprises a Horner-Wadsworth-Emmons reaction or a Wittig reaction. For example, in some instances, step (a) comprises treatment with a phosphonoacetic acid (e.g., trimethyl phosphonoacetate) and a suitable base (e.g., sodium hydride) in a suitable solvent (e.g., THF). The α-β unsaturated ester of General Scheme VI can be hydrolyzed to the corresponding carboxylic acid (e.g., using LiOH in THF / HO) and then coupled to a chiral auxiliary using appropriate amide coupling conditions. Either an (R) or (S) chiral auxiliary can be used according to General Scheme VI. Suitable amide coupling conditions for step (b) can include the use of coupling reagents (e.g., DIC and DMAP) in a suitable solvent (e.g., dichloromethane). The α-β unsaturated amide can then be alkylated using any suitable alkylation conditions, including conjugate addition (e.g., via a Grignard reagent or magnesium bromide reagent). In some embodiments, the alkylation reaction further includes the use of copper(I) halide (e.g., CuI). In some embodiments, the alkylation reaction further includes dimethyl sulfide. Such reactions can be carried out in a suitable solvent (e.g., THF) at low temperatures (e.g., −40° C.). In step (d) of General Scheme VI, the chiral auxiliary is cleaved under conditions that result in the terminal carboxylic acid (eg, LiOH / H2O2 in THF).

[0152] [ka]

[0153] In some embodiments, R 3 Chirality is introduced starting with the appropriate carboxylic acid, as shown in general Scheme VII. In some embodiments, the chirality is known and assigned. In other embodiments, the chirality is known to be a single isomer, but the exact (R) or (S) stereochemical assignment is unknown. In some embodiments, the compounds disclosed herein are single diastereomers or enantiomers. In some embodiments, the carboxylic acid is activated (e.g., via CDI) to form an activated ester that facilitates amide coupling. Such activation reactions are carried out in a suitable solvent system (e.g., dichloromethane). The activated acid can then be converted to a Weinreb amide, as shown in step (a) of general Scheme VII. Step (b) involves the addition of an R 3 In some embodiments, the alkylation of the Weinreb amide with an R 3is added via an organolithium or organomagnesium species. Step (c) of General Scheme VII involves an addition reaction to a ketone, such as the Horner-Wadsworth-Emmons reaction or the Wittig reaction, as previously described. In some embodiments, this reaction is facilitated by the use of trimethyl phosphonoacetate. In some embodiments, a suitable base (e.g., NaH or KHMDS) is also used. In some embodiments, the reaction further involves the use of a crown ether (e.g., 18-C-6). The double bond conformation (e.g., E or Z and subsequent stereochemical orientation) can be controlled using techniques known to those skilled in the art. Step (d) provides the stereochemistry shown in Formula (I) through the use of a chiral ligand (e.g., R-DTBM-SEGPHOS or S-DTBM-SEGPHOS). Referring to General Scheme VII, in rows (i) and (iii), the reagent R-DTBM SEGPHOS is used, and in rows (ii) and (iv), S-DTBM SEGPHOS is used to obtain the specific enantiomers shown above. In some embodiments, step (d) further comprises the use of a copper species (e.g., Cu(OAc)). In some embodiments, step (d) further comprises DMMS, tert-BuOH, and / or toluene. In some embodiments, the alkene produced in step (c) of General Scheme VII is reduced using hydrogen (H) over a catalyst (e.g., Pd / C) in a suitable solvent (e.g., EtOH). In some embodiments, the resulting ester is a mixture of R and S isomers. In some embodiments, the mixture of isomers is unresolved. In some embodiments, the mixture of isomers is resolved in a subsequent step by chiral chromatography. The final step of General Scheme VII, step (e), comprises cleavage of the ester to provide the indicated carboxylic acid. In some embodiments, the ester is cleaved under basic conditions (eg, with LiOH) in a suitable solvent or solvent system (eg, MeOH / THF / H2O).

[0154] The amines and acids disclosed herein can be combined in any combination to provide a wide range of compounds that fall within the genus of formula (I). The methods described herein are merely exemplary. Additional methods can be utilized to provide additional compounds disclosed herein.

[0155] Further forms of the compounds disclosed herein Isomers Furthermore, in some embodiments, the compounds described herein exist as geometric isomers. In some embodiments, the compounds described herein contain one or more double bonds. The compounds provided herein include all cis, trans, syn, anti, entgegen (E), and zusammen (Z) isomers, as well as their corresponding mixtures. In some circumstances, the compounds exist as tautomers. The compounds described herein include all possible tautomers within the formulae described herein. In some circumstances, the compounds described herein contain one or more chiral centers, with each center existing in the R or S configuration. The compounds described herein include all diastereomeric, enantiomeric, and epimeric forms, as well as their corresponding mixtures. In further embodiments of the compounds and methods provided herein, mixtures of enantiomers and / or diastereoisomers derived from a single preparative step, combination, or interconversion are useful for the applications described herein. In some embodiments, the compounds described herein are prepared as optically pure enantiomers by chiral chromatographic separation of a racemic mixture. In some embodiments, the compounds described herein are prepared as individual stereoisomers of the compound by reacting a racemic mixture of the compound with an optically active resolving agent to form a pair of diastereoisomeric compounds, separating the diastereomers, and recovering the optically pure enantiomers. In some embodiments, dissociable complexes are preferred (e.g., crystalline diastereomeric salts). In some embodiments, diastereomers have distinct physical properties (e.g., melting points, boiling points, solubilities, reactivity, etc.) and are separated by taking advantage of these dissimilarities. In some embodiments, diastereomers are separated by chiral chromatography, or preferably, separation / resolution techniques based on differences in solubility.In some embodiments, the optically pure enantiomer is recovered, along with the resolving agent, by any practical means that does not result in racemization.

[0156] labeled compound In some embodiments, the compounds described herein exist in their isotopically labeled form. In some embodiments, the methods disclosed herein include methods of treating disease by administering such isotopically labeled compounds. In some embodiments, the methods disclosed herein include methods of treating disease by administering such isotopically labeled compounds as pharmaceutical compositions. Thus, in some embodiments, the compounds disclosed herein include isotopically labeled compounds, which are identical to the compounds listed herein, except that one or more atoms are replaced with atoms having an atomic mass or mass number different from the atomic mass or mass number normally found in nature. Examples of isotopes incorporated into the compounds described herein are, respectively: 2 H, 3 H, 13 C. 14 C. 15 N, 18 O. 17 O. 31 P, 32 P, 35 S, 18 F, and 36 The present invention also encompasses isotopes of hydrogen, carbon, nitrogen, oxygen, phosphorus, sulfur, fluorine, and chloride, such as Cl. Compounds described herein, and pharmaceutically acceptable salts, esters, solvates, hydrates, or derivatives thereof, that contain the aforementioned isotopes and / or other isotopes of other atoms, are within the scope of the present invention. Certain isotopically labeled compounds, e.g., 3 H and 14 Compounds into which radioactive isotopes such as C are incorporated are useful in drug and / or substrate tissue distribution assays. 3 H) and carbon-14 (i.e., 14 C) isotopes are particularly preferred for their ease of preparation and detectability.2 Substitution with heavy isotopes, such as H, offers certain therapeutic advantages due to increased metabolic stability, for example, increased in vivo half-life or reduced dosage requirements. In some embodiments, isotopically-labeled compounds, pharmaceutically acceptable salts, esters, solvates, hydrates, or derivatives thereof are prepared by any suitable method.

[0157] In some embodiments, the compounds described herein are labeled by other means, including but not limited to, a chromophore or fluorescent moiety, a bioluminescent label, or a chemiluminescent label.

[0158] Pharmaceutically acceptable salts In some embodiments, the compounds described herein are present as their pharmaceutically acceptable salts. In some embodiments, the methods disclosed herein include methods of treating diseases by administering such pharmaceutically acceptable salts. In some embodiments, the methods disclosed herein include methods of treating diseases by administering such pharmaceutically acceptable salts as pharmaceutical compositions.

[0159] In some embodiments, the compounds described herein possess acidic or basic groups and thus form pharmaceutically acceptable salts by reacting with any of a number of inorganic or organic bases, and inorganic and organic acids. In some embodiments, these salts are prepared in situ during the final isolation and purification of the compounds disclosed herein, or by separately reacting the purified compound in free form with a suitable acid or base and isolating the salt thus formed.

[0160] solvate In some embodiments, the compounds described herein exist as solvates. In some embodiments, there are methods of treating diseases by administering such solvates. Further described herein are methods of treating diseases by administering such solvates as pharmaceutical compositions.

[0161] Solvates contain stoichiometric or non-stoichiometric amounts of solvent, and in some embodiments, are formed during the crystallization process using pharmaceutically acceptable solvents such as water or ethanol. Hydrates are formed when the solvent is water, or alcoholates are formed when the solvent is alcohol. Solvates of the compounds described herein are preferably prepared or formed during the processes described herein. By way of example only, hydrates of the compounds described herein are preferably prepared by recrystallization from aqueous / organic solvent mixtures using organic solvents, including, but not limited to, dioxane, tetrahydrofuran, or MeOH. Furthermore, the compounds provided herein exist in both solvated and unsolvated forms. Generally, solvated forms are considered equivalent to unsolvated forms for the purposes of the compounds and methods provided herein.

[0162] Pharmaceutical Composition In certain embodiments, a compound of Formula (I), (Ia), (Ib), (Ic), (Id), (Ie), (If), (Ig), or (Ih) as described herein is administered as a pure chemical. In some embodiments, a compound of Formula (I), (Ia), (Ib), (Ic), (Id), (Ie), (If), (Ig), or (Ih) as described herein is combined with a pharmaceutically suitable or acceptable carrier (also referred to herein as a pharmaceutically suitable (or acceptable) excipient, a physiologically suitable (or acceptable) excipient, or a physiologically suitable (or acceptable) carrier) selected based on the chosen route of administration and standard pharmaceutical practice, e.g., as described in Remington: The Science and Practice of Pharmacy (Gennaro, 21st Ed. Mack Pub. Co., Easton, PA (2005)).

[0163] Accordingly, provided herein are pharmaceutical compositions comprising at least one compound of Formula (I), (Ia), (Ib), (Ic), (Id), (Ie), (If), (Ig), or (Ih) as described herein, or a stereoisomer, pharmaceutically acceptable salt, hydrate, solvate, or N-oxide thereof, together with one or more pharmaceutically acceptable carriers. A carrier (or excipient) is acceptable or suitable if it is compatible with the other ingredients of the composition and not deleterious to the recipient (i.e., subject) of the composition.

[0164] One embodiment provides a pharmaceutical composition comprising a pharmaceutically acceptable excipient and a compound of Formula (I), or a pharmaceutically acceptable salt or solvate thereof. Another embodiment provides a pharmaceutical composition comprising a pharmaceutically acceptable excipient and a compound of Formula (Ia), or a pharmaceutically acceptable salt or solvate thereof. Another embodiment provides a pharmaceutical composition comprising a pharmaceutically acceptable excipient and a compound of Formula (Ib), or a pharmaceutically acceptable salt or solvate thereof. Another embodiment provides a pharmaceutical composition comprising a pharmaceutically acceptable excipient and a compound of Formula (Ic), or a pharmaceutically acceptable salt or solvate thereof. Another embodiment provides a pharmaceutical composition comprising a pharmaceutically acceptable excipient and a compound of Formula (Id), or a pharmaceutically acceptable salt or solvate thereof. Another embodiment provides a pharmaceutical composition comprising a pharmaceutically acceptable excipient and a compound of Formula (Ie), or a pharmaceutically acceptable salt or solvate thereof. Another embodiment provides a pharmaceutical composition comprising a pharmaceutically acceptable excipient and a compound of formula (If), or a pharmaceutically acceptable salt or solvate thereof. Another embodiment provides a pharmaceutical composition comprising a pharmaceutically acceptable excipient and a compound of formula (Ig), or a pharmaceutically acceptable salt or solvate thereof. Another embodiment provides a pharmaceutical composition comprising a pharmaceutically acceptable excipient and a compound of formula (Ih), or a pharmaceutically acceptable salt or solvate thereof.

[0165] Another embodiment provides a pharmaceutical composition consisting essentially of a pharmaceutically acceptable carrier and a compound of Formula (I), or a pharmaceutically acceptable salt thereof. Another embodiment provides a pharmaceutical composition consisting essentially of a pharmaceutically acceptable carrier and a compound of Formula (Ia), or a pharmaceutically acceptable salt thereof. Another embodiment provides a pharmaceutical composition consisting essentially of a pharmaceutically acceptable carrier and a compound of Formula (Ib), or a pharmaceutically acceptable salt thereof. Another embodiment provides a pharmaceutical composition consisting essentially of a pharmaceutically acceptable carrier and a compound of Formula (Ic), or a pharmaceutically acceptable salt thereof. Another embodiment provides a pharmaceutical composition consisting essentially of a pharmaceutically acceptable carrier and a compound of Formula (Id), or a pharmaceutically acceptable salt thereof. Another embodiment provides a pharmaceutical composition consisting essentially of a pharmaceutically acceptable carrier and a compound of Formula (Ie), or a pharmaceutically acceptable salt thereof. Another embodiment provides a pharmaceutical composition consisting essentially of a pharmaceutically acceptable carrier and a compound of Formula (If), or a pharmaceutically acceptable salt thereof. Another embodiment provides a pharmaceutical composition consisting essentially of a pharmaceutically acceptable carrier and a compound of formula (Ig), or a pharmaceutically acceptable salt thereof.Another embodiment provides a pharmaceutical composition consisting essentially of a pharmaceutically acceptable carrier and a compound of formula (Ih), or a pharmaceutically acceptable salt thereof.

[0166] In certain embodiments, a compound of Formula (I), (Ia), (Ib), (Ic), (Id), (Ie), (If), (Ig), or (Ih) as described herein is substantially pure, in that it contains less than about 5%, or less than about 1%, or less than about 0.1%, of other small organic molecules, such as, for example, contaminating intermediates or by-products made in one or more of the steps of the synthetic method.

[0167] In certain embodiments, compounds of Formula (I), (Ia), (Ib), (Ic), (Id), (Ie), (If), (Ig), or (Ih) described herein are formulated for oral, rectal, topical, buccal, parenteral (e.g., subcutaneous, intramuscular, intradermal, or intravenous), vaginal, ocular, or aerosol administration, although the most appropriate form of administration in any given case will depend on the degree and severity of the condition being treated and the nature of the particular compound being used. For example, the disclosed compositions are formulated as a unit dosage and / or are formulated for oral or subcutaneous administration.

[0168] Typical pharmaceutical compositions are used in the form of pharmaceutical preparations, e.g., solid, semi-solid, or liquid forms, which contain one or more of the disclosed compounds as active ingredients in admixture with organic or inorganic carriers or excipients suitable for external, enteral, or parenteral use. In some embodiments, the active ingredient is typically compounded with a non-toxic, pharmaceutically acceptable carrier, for example, as a tablet, pellet, capsule, suppository, solution, emulsion, suspension, or other form suitable for use. The active subject compound is included in the pharmaceutical composition in an amount sufficient to exert the desired effect on the disease process or condition.

[0169] In some embodiments for preparing solid compositions such as tablets, the primary active ingredient is mixed with a pharmaceutical carrier, e.g., conventional tableting ingredients such as corn starch, lactose, sucrose, sorbitol, talc, stearic acid, magnesium stearate, dicalcium phosphate, or gums, and other pharmaceutical diluents, e.g., water, to form a solid preformulation composition containing a homogeneous mixture of the disclosed compound or a non-toxic pharmaceutically acceptable salt thereof. When such a preformulation composition is referred to as homogeneous, it means that the active ingredient is evenly dispersed throughout the composition so that the composition may be readily subdivided into equally effective unit dosage forms such as tablets, pills, and capsules.

[0170] In solid dosage forms for oral administration (e.g., capsules, tablets, pills, dragees, powders, granules, etc.), the subject compositions may be formulated with one or more pharmaceutically acceptable carriers, such as sodium citrate or dicalcium phosphate, and / or the following: (1) fillers or extenders, such as starch, cellulose, microcrystalline cellulose, silicified microcrystalline cellulose, lactose, sucrose, glucose, mannitol, and / or silicic acid; (2) sugars, e.g., carboxymethylcellulose, hypromellose, alginates, gelatin, polyvinylpyrrolidone, sucrose, and / or (3) a binder such as acacia, (4) a humectant such as glycerin, (5) a disintegrant such as crospovidone, croscarmellose sodium, sodium starch glycolate, agar, calcium carbonate, potato starch or tapioca starch, alginic acid, certain silicates, and sodium carbonate, (6) a solution retardant such as paraffin, (7) an absorption enhancer such as quaternary ammonium compounds, (8) a humectant such as docusate sodium, cetyl alcohol, and glycerol monostearate, (9) an absorbent such as kaolin and bentonite clay, (10) a lubricant such as talc, calcium stearate, magnesium stearate, solid polyethylene glycol, sodium lauryl sulfate, and mixtures thereof, and (11) a coloring agent. In the case of capsules, tablets, and pills, in some embodiments, the composition includes a buffering agent. In some embodiments, solid compositions of a similar type are also employed as fillers in soft and hard-filled gelatin capsules using such excipients as lactose or milk sugar, as well as high molecular weight polyethylene glycols and the like.

[0171] In some embodiments, tablets are made by compression or molding, optionally with one or more accessory ingredients. In some embodiments, compressed tablets are prepared using binders (e.g., gelatin or hydroxypropyl methylcellulose), lubricants, inert diluents, preservatives, disintegrants (e.g., sodium starch glycolate or cross-linked sodium carboxymethylcellulose), surface active agents, or dispersing agents. In some embodiments, molded tablets are made by molding, in a suitable machine, a mixture of the subject composition moistened with an inert liquid diluent. In some embodiments, tablets and other solid dosage forms, such as dragees, capsules, pills, and granules, are scored or prepared with coatings and shells, such as enteric coatings and other coatings.

[0172] Compositions for inhalation or insufflation include solutions and suspensions in pharmaceutically acceptable aqueous or organic solvents, or mixtures thereof, and powders. Liquid dosage forms for oral administration include pharmaceutically acceptable emulsions, microemulsions, solutions, suspensions, syrups, and elixirs. In addition to the subject composition, in some embodiments, the liquid dosage form contains an inert diluent, such as water or other solvent, a solubilizing agent and an emulsifier, such as ethyl alcohol, isopropyl alcohol, ethyl carbonate, ethyl acetate, benzyl alcohol, benzyl benzoate, propylene glycol, 1,3-butylene glycol, oil (optionally cottonseed oil, peanut oil, corn oil, germ oil, olive oil, castor oil, and sesame oil), glycerol, tetrahydrofuryl alcohol, polyethylene glycol, and fatty acid esters of sorbitan, cyclodextrin, and mixtures thereof.

[0173] In some embodiments, the suspension comprises, in addition to the subject composition, a suspending agent such as, for example, ethoxylated isostearyl alcohol, polyoxyethylene sorbitol and sorbitan esters, microcrystalline cellulose, aluminum metahydroxide, bentonite, agar, and tragacanth, and mixtures thereof.

[0174] In some embodiments, formulations for rectal or vaginal administration are presented as suppositories, which are prepared by mixing the subject compositions with one or more suitable non-irritating excipients or carriers, including, for example, cocoa butter, polyethylene glycol, a suppository wax, or a salicylate, and which are solid at room temperature but liquid at body temperature, thereby melting in the body cavity and releasing the active agent(s).

[0175] Dosage forms for transdermal administration of the subject compositions include powders, sprays, ointments, pastes, creams, lotions, gels, solutions, patches, and inhalants. In some embodiments, the active composition is mixed under sterile conditions with a pharmaceutically acceptable carrier, and any preservatives, buffers, or propellants, as may be required.

[0176] In some embodiments, ointments, pastes, creams, and gels comprise, in addition to the subject composition, excipients such as animal and vegetable fats, oils, waxes, paraffin, starch, tragacanth, cellulose derivatives, polyethylene glycols, silicones, bentonite, silicic acid, talc, and zinc oxide, or mixtures thereof.

[0177] In some embodiments, powders and sprays contain, in addition to the subject composition, excipients such as lactose, talc, silicic acid, aluminum hydroxide, calcium silicate, and polyamide powder, or mixtures of these substances. In some embodiments, the propellant further comprises conventional propellants such as chlorofluorohydrocarbons and volatile unsubstituted hydrocarbons, such as butane and propane.

[0178] In some embodiments, the compounds described herein are formulated as eye drops for ocular administration.

[0179] The compositions and compounds disclosed herein are optionally administered by aerosol. This is accomplished by preparing aqueous aerosols, liposomal preparations, or solid microparticles containing the compounds. In some embodiments, non-aqueous (e.g., fluorocarbon propellant) suspensions are used. In some embodiments, sonic nebulizers are used to minimize exposure of the drug to shear, which can result in degradation of the compounds contained in the subject compositions. Aqueous aerosols are typically made by formulating an aqueous solution or suspension of the subject compositions with conventional pharmaceutically acceptable carriers and stabilizers. Carriers and stabilizers vary depending on the requirements of the particular subject composition, but typically include non-ionic surfactants (Tween, Pluronic, or polyethylene glycol), sorbitan esters, oleic acid, lecithin, amino acids such as glycine, buffers, salts, sugars, or sugar alcohols. Aerosols are generally prepared from isotonic solutions.

[0180] Pharmaceutical compositions suitable for parenteral administration include the subject composition in combination with one or more pharmaceutically acceptable sterile, isotonic, aqueous or non-aqueous solutions, dispersions, suspensions, or emulsions, or sterile powders to be reconstituted immediately before use into sterile injectable solutions or dispersions, which in some embodiments contain antioxidants, buffers, bacteriostats, solutes that render the intended recipient's blood isotonic, or suspending or thickening agents.

[0181] Examples of suitable water-soluble and non-water-soluble carriers used in pharmaceutical compositions include water, ethanol, polyols (glycerin, propylene glycol, polyethylene glycol, etc.) and suitable mixtures thereof, vegetable oils such as olive oil, and injectable organic esters such as ethyl oleate and cyclodextrin. The appropriate fluidity is maintained, for example, by the use of coating materials such as lecithin, by maintaining the required particle size in the case of dispersions, and by the use of surfactants.

[0182] Furthermore, enteral pharmaceutical formulations are contemplated, comprising the disclosed compounds and enteric materials, and pharmaceutically acceptable carriers or excipients. The enteric materials refer to polymers that are substantially insoluble in the acidic environment of the stomach and predominantly soluble in intestinal fluids at a specific pH. The small intestine is the portion of the gastrointestinal tract (intestine) between the stomach and the large intestine, and includes the duodenum, jejunum, and ileum. The pH of the duodenum is about 5.5, the pH of the jejunum is about 6.5, and the pH of the distal ileum is about 7.5. Accordingly, the enteric material is not soluble in water up to a pH of about 5.0, about 5.2, about 5.4, about 5.6, about 5.8, about 6.0, about 6.2, about 6.4, about 6.6, about 6.8, about 7.0, about 7.2, about 7.4, about 7.6, about 7.8, about 8.0, about 8.2, about 8.4, about 8.6, about 8.8, about 9.0, about 9.2, about 9.4, about 9.6, about 9.8, or about 10.0. Typical enteric materials are cellulose acetate phthalate (CAP), hydroxypropyl methylcellulose phthalate (HPMCP), polyvinyl acetate phthalate (PVAP), hydroxypropyl methylcellulose acetate succinate (HPMCAS), cellulose acetate trimellitate, hydroxypropyl methylcellulose succinate, cellulose acetate succinate, cellulose acetate hexahydrophthalate, cellulose phthalate propionate, cellulose acetate maleate, cellulose acetate butyrate, cellulose acetate propionate, copolymers of methyl methacrylate and methyl methacrylate, copolymers of methyl acrylate, methyl methacrylate, and methacrylic acid, copolymers of methyl vinyl ether and maleic anhydride (Gantrez ES series), ethyl methyacrylate-methyl methacrylate-chlorotrimethylammonium ethyl acrylate copolymer, natural resins such as zein, shellac, and copal collophorium. collophorium), as well as several commercially available enteric dispersions (e.g., Eudragit L30D55, Eudragit FS30D, Eudragit L100, Eudragit S100, Kollicoat EMM30D, Estacryl 30D, Coateric, and Aquateric).The solubility of each of the above materials is known or can be readily determined in vitro.

[0183] The dosage of a composition comprising at least one compound of formula (I) as described herein will vary depending on the patient's (e.g., human) condition, i.e., stage of disease, general health, age, and other factors.

[0184] The pharmaceutical composition is administered in a manner appropriate to the disease to be treated (or prevented). The appropriate dose and the appropriate duration and frequency of administration are determined by factors such as the patient's disease, the type and severity of the patient's disease, the specific form of the active ingredient, and the method of administration. In general, an appropriate dose and treatment regimen provides the composition in an amount sufficient to bring about a therapeutic and / or preventive benefit (e.g., improved clinical outcome), such as more frequent complete or partial remissions, or longer disease-free and / or overall survival, or a reduction in the severity of symptoms. The optimal dose is generally determined using experimental models and / or clinical trials. In some embodiments, the optimal dose depends on the patient's body type, weight, or blood volume.

[0185] method In other aspects, described herein are methods of using a compound of Formula (I), (Ia), (Ib), (Ic), (Id), (Ie), (If), (Ig), or (Ih), or a pharmaceutically acceptable salt thereof, as described herein, for example, in methods of treating a disease or condition. In some embodiments, there are methods of treating one or more diseases or conditions selected from neuropsychiatric disorders, depression, obsessive-compulsive disorder, alcoholism, gambling addiction, pain, opioid overdose, opioid use disorder, and addiction in a patient in need of such treatment, comprising administering to the patient a therapeutically effective amount of a compound of Formula (I), (Ia), (Ib), (Ic), (Id), (Ie), (If), (Ig), or (Ih), or a pharmaceutically acceptable salt or solvate thereof. In some embodiments, there are methods for treating a neuropsychiatric disorder in a patient in need of such treatment, comprising administering to the patient a therapeutically effective amount of a compound of Formula (I), (Ia), (Ib), (Ic), (Id), (Ie), (If), (Ig), or (Ih) described herein, or a pharmaceutically acceptable salt or solvate thereof. In some embodiments, there are methods for treating depression in a patient in need of such treatment, comprising administering to the patient a therapeutically effective amount of a compound of Formula (I), (Ia), (Ib), (Ic), (Id), (Ie), (If), (Ig), or (Ih) described herein, or a pharmaceutically acceptable salt thereof. In some embodiments, there are methods of treating obsessive-compulsive disorder in a patient in need thereof, comprising administering to the patient a therapeutically effective amount of a compound of Formula (I), (Ia), (Ib), (Ic), (Id), (Ie), (If), (Ig), or (Ih) described herein, or a pharmaceutically acceptable salt thereof. In some embodiments, there are methods of treating alcoholism in a patient in need thereof, comprising administering to the patient a therapeutically effective amount of a compound of Formula (I), (Ia), (Ib), (Ic), (Id), (Ie), (If), (Ig), or (Ih) described herein, or a pharmaceutically acceptable salt thereof.In some embodiments, there are methods for treating gambling addiction in a patient in need thereof, comprising administering to the patient a therapeutically effective amount of a compound of Formula (I), (Ia), (Ib), (Ic), (Id), (Ie), (If), (Ig), or (Ih) described herein, or a pharmaceutically acceptable salt thereof. In some embodiments, there are methods for treating pain in a patient in need thereof, comprising administering to the patient a therapeutically effective amount of a compound of Formula (I), (Ia), (Ib), (Ic), (Id), (Ie), (If), (Ig), or (Ih) described herein, or a pharmaceutically acceptable salt thereof. In some embodiments, there are methods of treating opioid overdose in a patient in need thereof, comprising administering to the patient a therapeutically effective amount of a compound of Formula (I), (Ia), (Ib), (Ic), (Id), (Ie), (If), (Ig), or (Ih) described herein, or a pharmaceutically acceptable salt thereof. In some embodiments, there are methods of treating opioid use disorder in a patient in need thereof, comprising administering to the patient a therapeutically effective amount of a compound of Formula (I), (Ia), (Ib), (Ic), (Id), (Ie), (If), (Ig), or (Ih) described herein, or a pharmaceutically acceptable salt thereof. In some embodiments, there is a method of treating addiction in a patient in need thereof, comprising administering to the patient a therapeutically effective amount of a compound of Formula (I), (Ia), (Ib), (Ic), (Id), (Ie), (If), (Ig), or (Ih) described herein, or a pharmaceutically acceptable salt thereof.

[0186] In certain embodiments, the disclosed compound utilized by one or more of the foregoing methods is one of the generic, subgeneric, or specific compounds described herein, such as a compound of formula (I), (Ia), (Ib), (Ic), (Id), (Ie), (If), (Ig), or (Ih).

[0187] The disclosed compounds are administered to patients (animals and humans) in need of such treatment at dosages that provide optimal pharmacological efficacy. It will be understood that the dosage required for any particular application will vary from patient to patient, depending not only on the particular compound or composition selected, but also on the route of administration, the nature of the disease being treated, the age and condition of the patient, concomitant medications, or special diets followed by the patient, and other factors, and that proper dosing is ultimately at the discretion of the attending physician. To treat the above-mentioned clinical conditions and diseases, contemplated compounds disclosed herein are administered orally, subcutaneously, topically, parenterally, by inhalation spray, or rectally in dosage unit formulations containing conventional non-toxic pharmaceutically acceptable carriers, adjuvants, and vehicles. Parenteral administration includes subcutaneous injection, intravenous or intramuscular injection, or infusion techniques.

[0188] The following examples are provided merely as illustrations of various embodiments and are not to be construed as limiting the invention in any way. [Example]

[0189] chemical synthesis Unless otherwise specified, reagents and solvents were used as obtained from commercial sources. Anhydrous solvents and oven-dried glassware were used for moisture- and / or oxygen-sensitive synthetic transformations. Yields were not optimized. Reaction times are approximate and not optimized. Column chromatography and thin-layer chromatography (TLC) were performed on silica gel unless otherwise specified. Spectra are given in ppm (δ) and coupling constants J are reported in Hertz. For proton spectra, the solvent peak was used as the reference peak.

[0190] Synthesis Example A: Intermediates Example A1: Preparation of (S)-4-(3-amino-2-(dimethylamino)propyl)-2-fluorobenzamide (1G, "Intermediate 1"):

[0191] [ka]

[0192] Preparation of methyl (S)-2-((tert-butoxycarbonyl)amino)-3-(4-cyano-3-fluorophenyl)propanoate (1B): To an oven-dried 100 mL RBF was added zinc (2.29 g, 35 mmol) and dry DMF (4 mL). To the reaction mixture was added a solution of iodine (159 mg, 1.25 mmol) in DMF (0.5 mL). The reaction mixture was stirred for 10 min, after which a solution of methyl (2R)-2-{[(tert-butoxy)carbonyl]amino}-3-iodopropanoate (3.95 g, 12 mmol) in DMF (10 mL) and a solution of iodine (159 mg, 1.25 mmol) in DMF (0.5 mL) were added, resulting in an exotherm. The reaction mixture was stirred for 20 minutes, cooled to room temperature, and then 4-bromo-2-fluorobenzonitrile (2.00 g, 10 mmol), Pd(dba) (458 mg, 0.50 mmol), and SPhos (411 mg, 1 mmol) were added to the reaction mixture. The reaction mixture was stirred at 70 °C for 16 hours. The crude reaction mixture was cooled to room temperature, quenched with water, diluted with EtOAc, and filtered through Celite. The organic layer was washed with brine (5x), dried over MgSO, and then concentrated. The resulting residue was adsorbed onto silica and then purified by column chromatography (100 g silica, 0-30% EtOAc / hex) to give the title compound (2.75 g, 85%) as a white solid. MS (m / z) = 345.1 [M+H].

[0193] Preparation of tert-butyl (S)-(1-(4-cyano-3-fluorophenyl)-3-hydroxypropan-2-yl)carbamate (1C): To a 250 mL round-bottom flask was added methyl (2S)-2-{[(tert-butoxy)carbonyl]amino}-3-(4-cyano-3-fluorophenyl)propanoate (2.75 g, 8.53 mmol) and THF (30 mL). The reaction mixture was cooled to 0 °C, and a solution of lithium borohydride (4 M in THF, 5.0 mL) was added dropwise. The reaction mixture was stirred for 30 minutes at 0 °C, then allowed to warm to room temperature with stirring for 16 hours. The reaction mixture was then cooled to 0 °C and quenched by the dropwise addition of water. The crude reaction mixture was diluted with brine, and the product was extracted with EtOAc (3x). The combined organic layers were washed with brine, dried over Na2SO4, and concentrated. The resulting residue was purified by column chromatography (80 g silica, 10-70% EtOAc / hex) to give the title compound as a white solid (1.77 g, 60%). MS (m / z) = 317.1 [M+Na].

[0194] Preparation of tert-butyl (S)-(1-(4-carbamoyl-3-fluorophenyl)-3-hydroxypropan-2-yl)carbamate (1D): To a 250 mL round-bottom flask was added tert-butyl N-[(2S)-1-(4-cyano-3-fluorophenyl)-3-hydroxypropan-2-yl]carbamate (1.45 g, 4.93 mL), MeOH (30 mL), 10 M aqueous NaOH (1.45 mL), and 27% HO in water (4.8 mL). The reaction mixture was stirred at 50 °C for 1 h, after which additional 10 M aqueous NaOH (0.64 mL) and 27% HO in water (1.9 mL) were added. The crude reaction mixture was neutralized with saturated NH Cl (aq), and MeOH was removed under reduced pressure. The product was extracted with EtOAc (3x) and the combined organic layers were washed with brine, dried over MgSO4 and concentrated. The product was further dried with a toluene azeotrope to give the title compound (1.35 g, 88%) as a white solid.

[0195] Preparation of tert-butyl (S)-(1-(4-carbamoyl-3-fluorophenyl)-3-(1,3-dioxoisoindolin-2-yl)propan-2-yl)carbamate (1E): To a 250 mL round-bottom flask was added tert-butyl N-[(2S)-1-(4-carbamoyl-3-fluorophenyl)-3-hydroxypropan-2-yl]carbamate (1.35 g, 4.32 mmol), triphenylphosphine (1.25 g, 4.75 mmol), phthalimide (0.70 g, 4.75 mmol), and anhydrous THF (30 mL). The reaction mixture was cooled to 0 °C, and DIAD (0.94 mL, 4.75 mmol) was added dropwise. The reaction mixture was stirred at 0 °C for 1 hour and then at room temperature for 16 hours. A white precipitate was formed as a result. The precipitate was filtered, washed with THF, and dried to give the title compound as a white solid (2.03 g, 106%). MS (m / z) = 442.1 [M+H].

[0196] Preparation of (S)-4-(2-(dimethylamino)-3-(1,3-dioxoisoindolin-2-yl)propyl)-2-fluorobenzamide (1F): Step 1: To a 250 mL round-bottom flask was added tert-butyl N-[(2S)-1-(4-carbamoyl-3-fluorophenyl)-3-(1,3-dioxo-2,3-dihydro-1H-isoindol-2-yl)propan-2-yl]carbamate (2.03 g, 4.6 mmol), MeOH (25 mL), and formic acid (50 mL). The reaction mixture was stirred at 50 °C for 1 hour. The reaction mixture was concentrated, and the resulting residue was used directly in the next step. MS (m / z) = 342.1 [M+H]. Step 2: The crude reaction mixture was dissolved in MeCN / HO (5:1, 22 mL), followed by the addition of 37 wt% formaldehyde in water (1.03 mL, 13.8 mmol). The reaction mixture was stirred for 30 min, after which NaB(CN)H (1.03 g, 16.1 mmol) was added in one portion to the reaction mixture, and stirring was continued for an additional 30 min. The reaction mixture was cooled to 0 °C and quenched with saturated aqueous sodium bicarbonate (ca. 50 mL). The product was extracted with EtOAc (7x), and the combined organic layers were dried over MgSO and concentrated. The resulting residue was used in the next step without further purification. MS (m / z) = 370.1 [M+H].

[0197] Preparation of (S)-4-(3-amino-2-(dimethylamino)propyl)-2-fluorobenzamide (1G): To the crude (S)-4-(2-(dimethylamino)-3-(1,3-dioxoisoindolin-2-yl)propyl)-2-fluorobenzamide (1F) was added anhydrous EtOH (50 mL) and 80 wt% aqueous hydrazine hydrate (1.40 mL, 23 mmol). The reaction mixture was stirred at 75 °C for 3 h. The crude reaction mixture was concentrated and adsorbed onto silica, then purified by column chromatography (40 g silica, 0-20% MeOH / DCM + 1% NH4OH) to give the title compound as a white solid (0.46 g, 42%). MS (m / z): 240.2 [M+H].

[0198] Example A2: Preparation of (S)-4-(3-amino-2-(dimethylamino)propyl)-2-fluorobenzamide (2H, "Intermediate 2"):

[0199] [ka]

[0200] Preparation of 4-bromo-2-fluorobenzamide (2B): 4-Bromo-2-fluorobenzoic acid (44 g, 200 mmol) was taken up in dichloromethane (500 ml) and carbonyldiimidazole (65 g, 200 mmol) was added in small portions over 15 minutes. The suspension became a thick solid and gradually became clear over the next 45 minutes. Ammonium hydroxide solution (150 ml) was then added very slowly over 15 minutes. The biphasic solution was then stirred for the next 14 hours. The two layers were separated, and the organic layer was washed with 2N HCl solution and then with water. The organic layer was filtered through magnesium sulfate, and the filtrate was concentrated to give the product as a white powder (40.9 g, 94%). MS (m / z): 218, 220 [M+H].

[0201] Preparation of methyl (S)-2-((tert-butoxycarbonyl)amino)-3-(4-carbamoyl-3-fluorophenyl)propanoate (2C): Granular zinc (37 g, 560 mmol, 20 mesh) was taken in DMF (190 ml) under nitrogen, and iodine (1.2 g, 9.4 mmol) was added to it. The suspension was stirred for 15 minutes, during which time the initial brown color disappeared. Solid methyl (2R)-2-{[(tert-butoxy)carbonyl]amino}-3-iodopropanoate (93 g, 281 mmol) was then added along with iodine (1.2 g, 9.4 mmol). The suspension turned brown and darkened as the temperature increased. It was stirred for 1 hour until the temperature returned to room temperature and the color disappeared as well. In a separate flask, 4-bromo-2-fluorobenzamide (40.9 g, 188 mmol) was added along with bis(di-tert-butyl(4-dimethylaminophenyl)phosphine)dichloropalladium(II) (8.0 g, 11.3 mmol) in 1,4-dioxane (190 mL). The solution of "N-Boc-β-Zn-Ala-OMe" produced in the first flask was transferred to the second flask via cannula, and nitrogen was bubbled through the solution for 15 minutes. The solution was then heated at 100 °C for the next 18 hours. TLC and LCMS indicated the reaction was complete. The solution was allowed to cool to room temperature, after which saturated ammonium hydroxide solution (6 × 60 mL) was added to it, causing the precipitation of a white solid. Water (3 × 60 mL) was added, and the suspension was stirred for 30 minutes. The solid was then collected by filtration and washed with hexane to give the product as an off-white powder (47.1 g, 74%). MS (m / z): 363 [M+Na].

[0202] Preparation of tert-butyl (S)-(1-(4-carbamoyl-3-fluorophenyl)-3-hydroxypropan-2-yl)carbamate (2D): Methyl (2S)-2-{[(tert-butoxy)carbonyl]amino}-3-(4-carbamoyl-3-fluorophenyl)propanoate (47.1 g, 138 mmol) was taken up in THF (500 ml) under nitrogen and cooled in an ice bath. A solution of lithium borohydride solution (70 ml, 4 M in THF, 280 mmol) was added dropwise to it over 20 minutes. The ice bath was removed after 30 minutes, and the solution was stirred at room temperature overnight. TLC and LCMS showed the reaction was complete. The flask was cooled in an ice bath, and the reaction was quenched by slowly adding saturated ammonium chloride solution. The reaction mixture was filtered to remove black insoluble material. The solution was extracted into ethyl acetate (4 x 150 mL). The organic layer was dried over magnesium sulfate, and the filtrate was concentrated. The light brown solid was then dried under high vacuum to give the product (41.9 g, 97%) as a light brown powder. MS (m / z): 335 [M+Na].

[0203] Preparation of tert-butyl (S)-(1-(1,3-dioxoisoindolin-2-yl)-3-(3-fluoro-4-((oxo-13-methyl)-14-azanyl)phenyl)propan-2-yl)carbamate (2E): tert-butyl N-[(2S)-1-(4-carbamoyl-3-fluorophenyl)-3-hydroxypropan-2-yl]carbamate (41.9 g, 134 mmol) was taken in THF (700 ml) along with phthalimide (23.7 g, 161 mmol) and triphenylphosphine (42.2 g, 161 mmol). The solution was cooled in an ice bath, and then diisopropyl azodicarboxylate (31.7 ml, 161 mmol) was added dropwise to it. The ice bath was removed, and the solution was stirred for 24 hours. It was diluted with MTBE (500 ml) and the precipitated solid was collected by filtration. The solid was washed with a 1:1 mixture of MTBE and ethyl acetate to give the product (41.1 g, 70%) as a white solid. MS (m / z): 464 [M+Na].

[0204] Preparation of (S)-4-(2-amino-3-(1,3-dioxoisoindolin-2-yl)propyl)-2-fluorobenzamide formate (2F): tert-butyl N-[(2S)-1-(4-carbamoyl-3-fluorophenyl)-3-(1,3-dioxo-2,3-dihydro-1H-isoindol-2-yl)propan-2-yl]carbamate (41.1 g, 93 mmol) was taken in 1,4-dioxane (500 ml), and then formic acid (200 ml) was added thereto. The solution was stirred for the next 18 hours. Acetonitrile (500 ml) was slowly added, and the precipitated solid was collected by filtration to give the product (28.1 g, 78%) as a white powder. MS (m / z): 342 [M+H].

[0205] Preparation of (S)-4-(2-(dimethylamino)-3-(1,3-dioxoisoindolin-2-yl)propyl)-2-fluorobenzamide (2G): 4-[(2S)-2-amino-3-(1,3-dioxo-2,3-dihydro-1H-isoindol-2-yl)propyl]-2-fluorobenzamide, formic acid (28.1 72.7 mmol) was taken up in acetonitrile / water (50 ml / 10 ml). Aqueous formalin solution (6.0 ml, 37% solution, 218 mmol) was then added, and the solution was stirred at room temperature for 1 hour. Sodium borohydride triacetate (61 g, 291 mmol) was then added, causing it to effervescent. The solution was stirred for the next 45 minutes. LCMS indicated the reaction was complete. The solution was quenched by slow addition of sodium bicarbonate solution and then extracted into ethyl acetate (3 times). The combined organic layers were filtered through magnesium sulfate and the filtrate was concentrated to give the product (23.6 g, 88%). MS (m / z): 370.2 [M+H].

[0206] Preparation of (S)-4-(3-amino-2-(dimethylamino)propyl)-2-fluorobenzamide (2H): 4-[(2S)-2-(dimethylamino)-3-(1,3-dioxo-2,3-dihydro-1H-isoindol-2-yl)propyl]-2-fluorobenzamide (23.6 g, 64 mmol) was taken in ethanol (500 ml) and hydrazine hydrate solution (11.7 ml, 35% solution, 128 mmol) was added to it. The solution was heated to reflux for 3 hours. LCMS showed the reaction was complete. The solution was diluted with ethyl acetate and the precipitated solid was removed by filtration. The filtrate was concentrated and the residue was purified by Combiflash using a gradient of dichloromethane / methanol / ammonium hydroxide to give the product (13.6 g, 89%). MS (m / z): 240.2 [M+H].

[0207] The following intermediates were synthesized in a manner analogous to that described in Example A2, Intermediate 2, and general Scheme II.

[0208] [Table 1-1]

[0209] [Table 1-2]

[0210] [Table 1-3]

[0211] Example A3: Preparation of (R)-3-phenyl-3-(1-(trifluoromethyl)cyclopropyl)propanoic acid (3F, "Intermediate 3"):

[0212] [ka]

[0213] Preparation of N-methoxy-N-methyl-1-(trifluoromethyl)cyclopropane-1-carboxamide (3B): 1-(trifluoromethyl)cyclopropane-1-carboxylic acid (25 g, 162 mmol) was taken up in dichloromethane (250 ml), and carbonyldiimidazole (32 g, 200 mmol) was added portionwise, allowing it to bubble rapidly. The solution was stirred at room temperature for the next 30 minutes. Triethylamine (45 ml, 324 mmol) was added, followed by N,O-dimethylhydroxylamine hydrochloride (17.4 g, 180 mmol), and the solution was stirred for the next 24 hours. TLC showed the reaction was complete. The reaction was quenched by adding 2N HCl solution. After stirring for 15 minutes, the two layers were separated. The organic layer was washed with saturated sodium bicarbonate and then with brine. The organic layer was filtered through magnesium sulfate and the filtrate was concentrated to give the title compound as an oil (30 g, 94%).

[0214] Preparation of phenyl(1-(trifluoromethyl)cyclopropyl)methanone (3C): To an oven-dried 500 mL RBF containing N-methoxy-N-methyl-1-(trifluoromethyl)cyclopropane-1-carboxamide (20.6 g, 104 mmol) and an egg-shaped stir bar under a N balloon atmosphere, THF (200 mL) was added. The resulting mixture was cooled to −78 °C in a dry ice acetone bath for approximately 15 minutes. A pale yellow solution was observed. Phenylmagnesium bromide (41.8 mL, 3 M in ether, 125 mmol) was added dropwise over 10 minutes with vigorous shaking to prevent sticking of the stir bar. The reaction mixture was maintained at −78 °C for 20 minutes and then stirred at 0 °C for 30 minutes. The mixture was then stirred at room temperature overnight. Most of the volatiles were then evaporated, and the resulting crude material was cooled to 0 °C, followed by the addition of NH Cl (80 mL) and water (100 mL). Then it was extracted twice with EtOAc, washed three times with water and with brine. It was dried over MgSO4 and concentrated. The crude product was obtained as a slightly yellow oil (27.7 g, about 80% purity). The crude product was used directly in the next step without further purification.

[0215] Preparation of methyl (Z)-3-phenyl-3-(1-(trifluoromethyl)cyclopropyl)acrylate (3D): To a 500 mL RBF containing methyl 2-(dimethoxyphosphoryl)acetate (13.3 g, 73.2 mmol) and 18-crown-6 (19.3 g, 73.2 mmol) was added dry THF (200 mL). The reaction mixture was then cooled to 0 °C, and potassium bis(trimethylsilyl)amide (73.2 mL, 1 M in THF) was added dropwise over 10 min. After the addition (yellow, clear solution), the reaction mixture was warmed and stirred at room temperature for 40 min. A solution of phenyl[1-(trifluoromethyl)cyclopropyl]methanone (14.0 g) in THF (25 mL) was then added dropwise over 2 min at room temperature. After the addition, more THF (30 mL) was added. The reaction mixture was stirred overnight at room temperature, and H-NMR indicated complete conversion (Z / E ratio approximately 5 / 1 in CDCl3). The crude material was then evaporated to remove approximately half of the THF, and the residue was worked up with EtOAc and water. The aqueous layer was extracted three times with EtOAc. The combined organic layers were dried over MgSO4, concentrated, and purified on a 220 g silica gel column (the sample was mixed with silica gel and the column was eluted with 0-25% 10% EtOAc / hexane) to give the top spot (major product) methyl (2Z)-3-phenyl-3-[1-(trifluoromethyl)cyclopropyl]prop-2-enoate (10.6 g, 75% over two steps) as a colorless oil. MS (m / z): 271.2 (M+H). The NOE between the alkene C-H and the phenyl ring H confirmed the double bond geometry.

[0216] Preparation of methyl (R)-3-phenyl-3-(1-(trifluoromethyl)cyclopropyl)propanoate (3E): To a stirred mixture of (R)-DTBM-SEGPHOS® (375 mg, 0.32 mmol) and Cu(OAc) (173 mg, 0.955 mmol) in toluene (40 mL) at 0 °C under a N balloon, (dimethoxymethyl)silane (9.7 mL, 79 mmol) was added, followed by t-BuOH (6 mL, 63 mmol). A solution of methyl (2Z)-3-phenyl-3-[1-(trifluoromethyl)cyclopropyl]prop-2-enoate (8.6 g, 31.8 mmol) in toluene (15 mL) was then added dropwise over 5 min. The mixture was stirred for 45 min at 0 °C and then at room temperature for an additional 45 min; LC-MS and H-NMR indicated complete conversion. Saturated ammonium chloride solution (100 mL) was added. After stirring for 30 min, extraction with EtOAc (2x) was performed. The combined extracts were washed with water, 1N HCl, water, saturated NaHCO3 solution, and brine. The residue was dried over MgSO4, concentrated, and purified on a 220 g silica gel column (0-100% 10% EtOAc / hexanes in hexanes) using ESLD with combi-flash detection to give methyl (3R)-3-phenyl-3-[1-(trifluoromethyl)cyclopropyl]propanoate (6 g, 69%) as a colorless oil. MS (m / z): 273.2 (M+H).

[0217] Preparation of (R)-3-phenyl-3-(1-(trifluoromethyl)cyclopropyl)propanoic acid (3F): Lithium hydroxide monohydrate (2.78 g, 66 mmol) was added to a solution of methyl (3S)-3-phenyl-3-[1-(trifluoromethyl)cyclopropyl]propanoate (6.0 g, 22 mmol) in THF-MeOH-water (v / v / v 1:1:1, 75 mL) at room temperature. The mixture was stirred overnight at room temperature. LC-MS showed complete conversion. Most of the volatiles were removed by rotary evaporation. Water (30 mL) was added to the crude product. After cooling in an ice-water bath, the pH was adjusted to 5 by dropwise addition of 1 N HCl (approximately 72 mL). The mixture was extracted four times with EtOAc, and the combined extracts were washed with brine. Drying over Na2SO4, filtration, and concentration gave (3R)-3-phenyl-3-[1-(trifluoromethyl)cyclopropyl]propanoic acid (5.65 g, 99%) as a colorless oil. MS (m / z): 259.1 M+H).

[0218] Example A4: Preparation of (S)-3-phenyl-3-(1-(trifluoromethyl)cyclopropyl)propanoic acid (4D, "Intermediate 4"):

[0219] [ka]

[0220] Preparation of ethyl (Z)-3-phenyl-3-(1-(trifluoromethyl)cyclopropyl)acrylate (4A): To a stirred suspension of NaH (60%, 1.51 g, 37.8 mmol) in THF (50 mL) at 0 °C, ethyl 2-(diethoxyphosphoryl)acetate (9.68 g, 43.2 mmol) was added dropwise. After the addition was complete, the ice bath was removed and the mixture was stirred at room temperature for 1 h. Phenyl[1-(trifluoromethyl)cyclopropyl]methanone (5.64 g, 21.6 mmol) in THF (20 mL) was added. The reaction mixture was heated to reflux for 16 h. The reaction mixture was cooled to room temperature, saturated aqueous NH4Cl was added, and the mixture was extracted with EtOAc (3x). The combined extracts were dried over MgSO, concentrated, and purified by flash chromatography (0–5% EtOAc / hexanes) to give ethyl (2Z)-3-phenyl-3-[1-(trifluoromethyl)cyclopropyl]prop-2-enoate (4A, 2.41 g, 39%) and ethyl (2E)-3-phenyl-3-[1-(trifluoromethyl)cyclopropyl]prop-2-enoate (4B, 2.27 g, 37%). MS (m / z): 285.1 (M+H).

[0221] Preparation of ethyl (3S)-3-phenyl-3-[1-(trifluoromethyl)cyclopropyl]propanoate (4C): To a stirred mixture of (S)-DTBM-SEGPHOS® (20.7 mg, 0.017 mmol) and Cu(OAc) (16 mg, 0.088 mmol) in toluene (4 mL) at 0 °C under a N balloon, (dimethoxymethyl)silane (0.645 mL, 5.28 mmol) was added, followed by t-BuOH (0.334 mL, 3.52 mmol). Then, a solution of ethyl (2Z)-3-phenyl-3-[1-(trifluoromethyl)cyclopropyl]prop-2-enoate (0.5 g, 1.76 mmol, compound 4A) in toluene (4 mL) was added dropwise over 5 min. The mixture was stirred for 45 min at 0 °C, then for an additional 45 min at room temperature; LC-MS and H-NMR indicated complete conversion. Saturated ammonium chloride solution (10 mL) was added. After stirring for 30 min, it was extracted with EtOAc (2x). The combined extracts were washed with water, 1N HCl, water, saturated NaHCO3 solution, and brine. It was dried over MgSO4, concentrated, and purified by silica gel column (0-100% 10% EtOAc / hexane in hexane) using ESLD with combi-flash detection to give ethyl (3S)-3-phenyl-3-[1-(trifluoromethyl)cyclopropyl]propanoate (0.546 g, 87%) as a colorless oil. MS (m / z): 287.1 (M+H).

[0222] Preparation of (3S)-3-phenyl-3-[1-(trifluoromethyl)cyclopropyl]propanoic acid (4D): Lithium hydroxide monohydrate (2.78 g, 66 mmol) was added to a solution of ethyl (3R)-3-phenyl-3-[1-(trifluoromethyl)cyclopropyl]propanoate (0.5 g, 1.41 mmol) in EtOH-water (1:1, 4 mL) at room temperature. The mixture was stirred overnight at room temperature. LC-MS showed complete conversion. Most of the volatiles were removed by rotary evaporation. Water (5 mL) was added to the crude product. After cooling in an ice-water bath, the pH was adjusted to 5 by dropwise addition of 1 N HCl (approximately 72 mL). The mixture was extracted four times with EtOAc, and the combined extracts were washed with brine. Drying over anhydrous NaSO, filtration, and concentration gave (3S)-3-phenyl-3-[1-(trifluoromethyl)cyclopropyl]propanoic acid (0.354 g, 96%) as a colorless oil. MS (m / z): 259.1 (M+H).

[0223] Example A5: Preparation of (S)-4-(3-amino-2-(dimethylamino)propyl)-2,3-difluorobenzamide (5E, "Intermediate 5")

[0224] [ka]

[0225] Preparation of (S)-4-(3-amino-2-(dimethylamino)propyl)-2,3-difluorobenzamide (5E): The title compound (670 mg, 67%) was prepared in the same manner as Intermediate 1, as described in Example A1. MS (m / z): 258.1 (M+H).

[0226] Example A6: Preparation of (S)-3-(2-methylthiazol-5-yl)-3-(1-(trifluoromethyl)cyclopropyl)propanoic acid (6D, "Intermediate 6"):

[0227] [ka]

[0228] Preparation of (2-methylthiazol-5-yl)(1-(trifluoromethyl)cyclopropyl)methanone (6A): 5-Bromo-2-methyl-1,3-thiazole (7.67 g, 43.1 mmol) in THF (30 mL) was added dropwise (over 20 min) to a solution of n-BuLi in hexane (2.5 M, 19.0 mL, 47.4 mmol) in THF (30 mL) at −78° C. The reaction mixture appeared cloudy and light brown. Intermediate 3B (9.34 g, 47.4 mmol) was added dropwise and stirred at −78° C. for 2 h. The reaction was quenched with saturated NH4Cl (aq) (150 mL), extracted with EtOAc (3x), dried over MgSO4, filtered, concentrated, and purified on a 330 g gold silica gel column (0-50% EtOAc / hexanes) to give the title compound (6.47 g, 63%) as a brown oil. MS (m / z): 236.0 (M+H).

[0229] Preparation of methyl (E)-3-(2-methylthiazol-5-yl)-3-(1-(trifluoromethyl)cyclopropyl)acrylate (6B): To a stirred solution of trimethylphosphonoacetate (6.49 g, 35.6 mmol) and 18-crown-6-ether (Combi-Blocks, SS-7385, B43822, FW 264.3, 9.41 g, 35.6 mmol) in THF (40 mL) at 0 °C was added dropwise KHMDS in THF (Oakwood Chemical lot 104258M05H, 1.0 M, 35.6 mL). The reaction mixture was allowed to warm to room temperature for 30 min. A solution of the ketone (6A, 6.45 g, 27.4 mmol) in THF (20 mL) was added dropwise. After the addition was complete, the reaction was continued for 16 h from 0 °C to room temperature. The reaction mixture was cooled, NaHCO3 (30 mL) was added, and extracted with EtOAc (3x). The combined extracts were washed with water (1x), brine (1x), dried over MgSO4, concentrated, and purified on a 220 g silica gel column (0-100% MTBE / hexanes) to give the title compound (3.67 g, 45%). MS (m / z): 292.0 (M+H).

[0230] Preparation of methyl (3S)-3-(2-methyl-1,3-thiazol-5-yl)-3-[1-(trifluoromethyl)cyclopropyl]propanoate (6C): To a stirred mixture of (R)-DTBM-SEGPHOS® (MW 1180, 22.8 mg, 0.0193 mmol, 0.01 equiv) and Cu(OAc) (MW 181.6, 10.5 mg, 0.0580 mmol, 0.03 equiv) in toluene (5 mL) at 0 °C under a N balloon was added DMHS (508 mg, 4.83 mmol, 2.5 equiv) followed by t-BuOH (MW 74.12, d = 0.781, 0.367 mL, 3.87 mmol, 2.0 equiv). Then, a solution of 6B (563 mg, 1.93 mmol) in toluene (5 mL) was added dropwise over 3 min. The mixture was stirred for 30 min at 0 °C to room temperature. The color changed from light blue to green to dark brown. Saturated NaHCO3 (5 mL) was added, stirred for 30 min at room temperature, and extracted with EtOAc (2x). The combined extracts were washed with water, brine, dried over MgSO4, concentrated, and purified by a 40 g silica gel column (0-50% EtOAc in hexanes) to give the title compound (491 mg, 87%). MS (m / z): 294.0 (M+H).

[0231] Preparation of (S)-3-(2-methylthiazol-5-yl)-3-(1-(trifluoromethyl)cyclopropyl)propanoic acid (6D): A solution of 6C (486 mg, 1.66 mmol) in MeOH (3 mL) / THF (3 mL) was treated with LiOH (2N, 2.6 mL) at room temperature. The reaction mixture was stirred at room temperature for 1 h. LCMS: Reaction complete. The solvent was removed on a rotary evaporator. Water (3 mL) was added, cooled in an ice-water bath, and the pH was adjusted to approximately 4 by adding 1N HCl and extracted with DCM (3x). The combined extracts were dried over MgSO4, filtered, and concentrated to give the title compound (360 mg, 78%). MS (m / z): 280.0 (M+H).

[0232] The following intermediates were synthesized in a manner analogous to that described in Example A6, Intermediate 6, and general Scheme VII.

[0233] [Table 2-1]

[0234] [Table 2-2]

[0235] [Table 2-3]

[0236] [Table 2-4]

[0237] [Table 2-5]

[0238] [Table 2-6]

[0239] [Table 2-7]

[0240] Example A7: Preparation of 2-(pyrimidin-2-yl)cyclopropane-1-carboxylic acid (7D, "Intermediate 7"):

[0241] [ka]

[0242] Preparation of tert-butyl (2E)-3-(pyrimidin-2-yl)prop-2-enoate (7B). To a stirred suspension of NaH (1.69 g, 42.2 mmol) in THF (50 mL) at 0 °C, tert-butyl 2-(diethoxyphosphoryl)acetate (9.75 g, 38.7 mmol) was added dropwise. After the addition was complete, the reaction mixture was stirred for 30 min at 0 °C. Pyrimidine-2-carbaldehyde (3.8 g, 35.2 mmol) was then added, and stirring was continued for 2 h at room temperature. The reaction was diluted with EtOAc and quenched with saturated NH4Cl. The organic layer was separated, dried over MgSO, concentrated, and purified by flash chromatography (0-60% EtOAc / hexanes) to give 7B, tert-butyl (2E)-3-(pyrimidin-2-yl)prop-2-enoate (5.5 g, 75.9%). MS (m / z): 207.1 (M+H).

[0243] Preparation of tert-butyl 2-(pyrimidin-2-yl)cyclopropane-1-carboxylate (7C). To a stirred solution of trimethylsulfoxonium iodide (3.07 g, 14.0 mmol) in DMSO (20 mL) was added K₄t-Bu in one portion. Stirring was continued for 30 min, after which tert-butyl (2E)-3-(pyrimidin-2-yl)prop-2-enoate (2.40 g, 11.6 mmol) was added in one portion. The reaction mixture was stirred for 2 h at room temperature. Saturated aqueous NH₄Cl was added and extracted with EtOAc (3x). The extract was dried over MgSO₄, concentrated, and purified by flash chromatography (0–40% EtOAc / hexanes) to give tert-butyl 2-(pyrimidin-2-yl)cyclopropane-1-carboxylate (1.1 g, 42.9%). MS(m / z):221.2(M+H).

[0244] Preparation of 2-(pyrimidin-2-yl)cyclopropane-1-carboxylic acid (7D). A solution of tert-butyl 2-(pyrimidin-2-yl)cyclopropane-1-carboxylate (1.1 g, 4.99 mmol) in 4 M HCl (10 mL) and HO (0.3 mL) was stirred at room temperature for 3 h. The mixture was concentrated to dryness to give 2-(pyrimidin-2-yl)cyclopropane-1-carboxylic acid hydrochloride (1.2 g, 100%). MS (m / z): 165.1 (M+H).

[0245] Example A8: Preparation of (S)-3-cyclopropyl-3-phenylpropanoic acid (8D, "Intermediate 8"):

[0246] [ka]

[0247] Preparation of tert-butyl (2E)-3-cyclopropyl-3-phenylprop-2-enoate (8B). To a stirred suspension of NaH (60%, 2.05 g, 51.3 mmol) in THF (50 mL) at 0 °C, tert-butyl 2-(diethoxyphosphoryl)acetate (12 mL, 51.3 mmol) was added. After the addition, the mixture was stirred for 30 min. Cyclopropyl(phenyl)methanone (5 g, 34.2 mmol) was added, and the reaction mixture was stirred for 16 h at 50 °C. The mixture was cooled to room temperature, saturated aqueous NH4Cl was added, and the mixture was extracted with EtOAc (3x). The combined extracts were washed with HO, brine, dried over MgSO, concentrated, and purified by flash chromatography (0–20% MTBE / hexanes) to give tert-butyl (2E)-3-cyclopropyl-3-phenylprop-2-enoate (1.76 g, 21%).

[0248] Preparation of tert-butyl (3R)-3-cyclopropyl-3-phenylpropanoate (8C). To a stirred mixture of (S)-DTBM-SEGPHOS® (164 mg, 6.96 mmol) and (triphenylphosphine)copper hydride hexamer (95.5 mg, 0.139 mmol) in toluene (8 mL) at 0 °C, PMHS (1.6 g, 139 mmol) was added, followed by t-BuOH (567 mg, 7.76 mmol). A solution of tert-butyl (2E)-3-cyclopropyl-3-phenylprop-2-enoate (1.7 g, 6.96 mmol) in toluene (5 mL) was then added dropwise. The mixture was then stirred at 0 °C for 16 h. LC / MS showed only 50% conversion. The same amount of catalyst and solvent was added this time and allowed to warm gradually to room temperature. After the second addition was complete, the reaction mixture was stirred for 4 h. Saturated NH4Cl was added slowly and stirred for 1 h. Extraction with EtOAc (3x) was performed. The combined extracts were dried over MgSO4, filtered, concentrated, and purified by flash chromatography (0-20% EtOAc / hexanes) to give tert-butyl (3R)-3-cyclopropyl-3-phenylpropanoate (1.7 g, 99%). MS (m / z): 247.1 (M+H).

[0249] Preparation of (3R)-3-cyclopropyl-3-phenylpropanoic acid (8D). To a stirred solution of tert-butyl (3R)-3-cyclopropyl-3-phenylpropanoate (1.7 g, 6.9 mmol) in DCM (10 mL) was added TFA (7.9 g, 69.6 mmol). Stirring was continued for 4 h. The mixture was concentrated to dryness to give (3R)-3-cyclopropyl-3-phenylpropanoic acid (1.15 g, 86%).

[0250] Example A9: Preparation of (3S)-4-cyclobutyl-3-phenylbutanoic acid (57C, "Intermediate 57"):

[0251] [ka]

[0252] Preparation of (4S)-4-phenyl-3-[(2E)-3-phenylprop-2-enoyl]-1,3-oxazolidin-2-one (57A). To a stirred mixture of (2E)-3-phenylprop-2-enoic acid (5 g, 33.7 mmol), DMAP (412 mg, 3.37 mmol), and (S)-4-phenyloxazolidin-2-one (5.5 g, 33.7 mmol) in DCM (80 mL) was added N,N'-diisopropylcarbodiimide (6.39 g, 50.6 mmol) dropwise at 0 °C. Stirring was continued for 16 h, and the precipitated solid was filtered. The filtrate was washed with 2 N HCl, saturated NaHCO3, brine, dried over Na2SO4, and concentrated to dryness. The crude product was triturated with i-PrOH. The precipitated solid was collected and dried to give (4S)-4-phenyl-3-[(2E)-3-phenylprop-2-enoyl]-1,3-oxazolidin-2-one (8.01 g, 80.9%). MS (m / z): 294.2 (M+H).

[0253] Preparation of (4S)-3-[(3S)-4-cyclobutyl-3-phenylbutanoyl]-4-phenyl-1,3-oxazolidin-2-one (57B). To a stirred suspension of Mg (1.1 g, 45.1 mmol) in THF (20 mL) in a two-necked RBF equipped with a condenser, iodine (382 mg, 1.5 mmol) was added. After the addition was complete, the mixture was stirred for 10 minutes, after which (bromomethyl)cyclobutane (2.69 g, 18 mmol) was added, followed by another iodine (382 mg, 1.5 mmol). Stirring was continued for 1 hour. The mixture was then added dropwise to a stirred portion of a suspension of copper(I) bromide dimethyl sulfide (4.02 g, 19.5 mmol) in THF (20 mL) at −40° C. After the addition, the mixture was stirred for 1 hour at −40° C. Finally, a solution of (4S)-4-phenyl-3-[(2E)-3-phenylprop-2-enoyl]-1,3-oxazolidin-2-one (4.41 g, 15 mmol) in THF (40 mL) was added dropwise from the addition funnel to the stirred mixture at -40 °C. After the addition was complete, the reaction mixture was stirred at -40 °C for 1 h, then gradually warmed to room temperature and stirred overnight. Saturated aqueous NH4Cl was added and stirred for 15 min. Extraction with EtOAc (3x) was performed. The combined extracts were dried over MgSO4, concentrated, and purified by flash chromatography (0–20% EtOAc / hexanes) to give (4S)-3-[(3S)-4-cyclobutyl-3-phenylbutanoyl]-4-phenyl-1,3-oxazolidin-2-one (354 mg, 6.5%). MS (m / z): 364.2 (M+H).

[0254] Preparation of (3S)-4-cyclobutyl-3-phenylbutanoic acid (57C). To a stirred solution of (4S)-3-[(3S)-4-cyclobutyl-3-phenylbutanoyl]-4-phenyl-1,3-oxazolidin-2-one (1.20 g, 3.30 mmol) in THF (20 mL) was added lithium hydroxide monohydrate (2.64 mL, 1.6 equiv., 5.28 mmol), followed by HO (1.51 mL, 4 equiv., 13.2 mmol). After the addition was complete, the reaction mixture was stirred at room temperature for 3 h. It was diluted with MTBE and water, and the layers were separated. The aqueous layer was cooled in an ice bath, acidified with 2 N HCl, and extracted with DCM (3x). The combined extracts were dried over Na2SO4, concentrated, and purified by flash chromatography (0-50% EtOAc / DCM) to give (3S)-4-cyclobutyl-3-phenylbutanoic acid (650 mg, 90%).

[0255] The following intermediates were synthesized in a manner analogous to that described in Example A9, Intermediate 57, and general Scheme VI.

[0256] [Table 3-1]

[0257] [Table 3-2]

[0258] Example A10: [(2S)-1-amino-3-(2-methoxyquinolin-6-yl)propan-2-yl]dimethylamine (58H, "Intermediate 58"):

[0259] [ka]

[0260] Preparation of 6-bromo-2-methoxyquinoline (58B): A mixture of 6-bromo-2-chloroquinoline (5.00 g, 20.6 mmol) and sodium methoxide (1.34 g, 1.2 equiv, 24.7 mmol) in MeOH (50 mL) was heated to reflux for 24 h. The reaction mixture was cooled to room temperature and poured into an ice-water beaker. The precipitated solid was collected, washed with HO, and dried to give the title compound (4.5 g, 92%), which was used in the next step.

[0261] Preparation of methyl (2S)-2-{[(tert-butoxy)carbonyl]amino}-3-(2-methoxyquinolin-6-yl)propanoate (58C). Step 1: To a stirred suspension of zinc (3.71 g, 3 equiv., 56.7 mmol) in DMF (20 mL) was added iodine (480 mg, 0.1 equiv., 1.89 mmol). Stirring was continued for 15 minutes until everything was clear, after which methyl (2R)-2-{[(tert-butoxy)carbonyl]amino}-3-iodopropanoate (7.47 g, 1.2 equiv., 22.7 mmol) was added in one portion, followed by another portion of iodine (480 mg, 0.1 equiv., 1.89 mmol). The mixture became warm and was continued stirring at room temperature for 1 hour. Step 2: The mixture from Step 1 was added to a stirred mixture of 6-bromo-2-methoxyquinoline (4.50 g, 18.9 mmol), S-Phos (543 mg, 0.07 equiv., 1.32 mmol), and Pd2(dba)3 (519 mg, 0.03 equiv., 567 μmol) in DMF (20 mL). After the addition was complete, the reaction mixture was degassed for 5 min and then heated to 70 °C for 24 h. The reaction mixture was cooled to room temperature, saturated NH4Cl was added, stirred for 15 min, and diluted with EtOAc. The layers were separated. The aqueous layer was extracted with EtOAc (2x). The combined extracts were dried over MgSO4, concentrated, and purified by flash chromatography (0–30% EtOAc hexanes) to give methyl (2S)-2-{[(tert-butoxy)carbonyl]amino}-3-(2-methoxyquinolin-6-yl)propanoate (2.50 g, 36%).

[0262] Preparation of tert-butyl N-[(2S)-1-hydroxy-3-(2-methoxyquinolin-6-yl)propan-2-yl]carbamate (58D). To a stirred solution of methyl (2S)-2-{[(tert-butoxy)carbonyl]amino}-3-(2-methoxyquinolin-6-yl)propanoate (2.50 g, 6.94 mmol) in THF (20 mL) at 0 °C was added lithium borohydride (2.60 mL, 1.5 equiv., 10.4 mmol) dropwise. After the addition was complete, the reaction mixture was stirred for 1 h at 0 °C and then for 2 h at room temperature. The reaction mixture was cooled in an ice bath, slowly quenched with saturated NH4Cl, and extracted with EtOAc (3x). The combined extracts were dried over MgSO4 and concentrated to give tert-butyl N-[(2S)-1-hydroxy-3-(2-methoxyquinolin-6-yl)propan-2-yl]carbamate (2.01 g, 87%), which was used in the next step.

[0263] Preparation of tert-butyl N-[(2S)-1-(1,3-dioxo-2,3-dihydro-1H-isoindol-2-yl)-3-(2-methoxyquinolin-6-yl)propan-2-yl]carbamate (58E). To a stirred mixture of tert-butyl N-[(2S)-1-hydroxy-3-(2-methoxyquinolin-6-yl)propan-2-yl]carbamate (1.99 g, 5.99 mmol), triphenylphosphine (1.88 g, 1.2 equiv., 7.18 mmol), and phthalimide (1.06 g, 1.2 equiv., 7.18 mmol) in THF (30 mL) at 0 °C, DIAD (1.42 mL, 1.2 equiv., 7.18 mmol) was added dropwise. After the addition was complete, the reaction mixture was stirred at room temperature for 16 h. The mixture was concentrated to dryness and purified by flash chromatography (40% EtOAc / hexanes) to give tert-butyl N-[(2S)-1-(1,3-dioxo-2,3-dihydro-1H-isoindol-2-yl)-3-(2-methoxyquinolin-6-yl)propan-2-yl]carbamate (1.50 g, 54%). MS (m / z): 462.2.

[0264] Preparation of 2-[(2S)-2-amino-3-(2-methoxyquinolin-6-yl)propyl]-2,3-dihydro-1H-isoindole-1,3-dione (58F). A solution of tert-butyl N-[(2S)-1-(1,3-dioxo-2,3-dihydro-1H-isoindol-2-yl)-3-(2-methoxyquinolin-6-yl)propan-2-yl]carbamate (1.50 g, 3.25 mmol) in formic acid (20 mL) was stirred at room temperature for 16 hours. The reaction mixture was concentrated to dryness to give the title compound (1.1 g, 100%), which was used in the next step. MS (m / z): 362.1 (M+H).

[0265] Preparation of 2-[(2S)-2-(dimethylamino)-3-(2-methoxyquinolin-6-yl)propyl]-2,3-dihydro-1H-isoindole-1,3-dione (58G). To a stirred solution of 2-[(2S)-2-amino-3-(2-methoxyquinolin-6-yl)propyl]-2,3-dihydro-1H-isoindole-1,3-dione (2.00 g, 5.53 mmol) in MeCN / HO (5:1, 24 mL) was added formaldehyde (1.28 mL, 3 equiv., 16.6 mmol). Stirring was continued for 30 minutes, after which sodium cyanoborohydride (696 mg, 2 equiv., 11.1 mmol) was added. After the addition was complete, the reaction mixture was stirred at room temperature for 1 hour. Saturated NaHCO was added to adjust the pH to 7-8 and extracted with EtOAc (3x). The combined extracts were dried over MgSO and concentrated to dryness to give the title compound (2 g, 92%), which was used in the next step. MS (m / z): 390.1 (M+H).

[0266] Preparation of [(2S)-1-amino-3-(2-methoxyquinolin-6-yl)propan-2-yl]dimethylamine (58H). To a stirred solution of 2-[(2S)-2-(dimethylamino)-3-(2-methoxyquinolin-6-yl)propyl]-2,3-dihydro-1H-isoindole-1,3-dione (2.00 g, 5.14 mmol) in EtOH (20 mL) was added hydrazine (1.57 mL, 5 equiv., 25.7 mmol). The reaction mixture was then heated to 80° C. for 2 h, cooled to room temperature, and diluted with EtOAc. The precipitated solid was filtered, and the filtrate was concentrated and purified by flash chromatography (0–15% MeOH / DCM in 1% NH4OH) to give [(2S)-1-amino-3-(2-methoxyquinolin-6-yl)propan-2-yl]dimethylamine (180 mg, 14%). MS (m / z): 260.2 (M+H).

[0267] Example A11: Preparation of 6-[(2S)-3-amino-2-(dimethylamino)propyl]-3-{[2-(trimethylsilyl)ethoxy]methyl}-2,3-dihydro-1,3-benzoxazol-2-one (75G, "Intermediate 75")

[0268] [ka]

[0269] Preparation of 6-bromo-3-((2-(trimethylsilyl)ethoxy)methyl)benzo[d]oxazol-2(3H)-one (75A): To a stirred suspension of NaH (0.45 g, 11.21 mmol) in DMF (20 mL) was added 6-bromobenzo[d]oxazol-2(3H)-one (2 g, 9.34 mmol). After the addition was complete, the mixture was stirred at room temperature for 30 minutes, after which SEM-Cl was added dropwise. The reaction mixture was stirred for 16 hours at room temperature. Saturated NH4Cl was added and extracted with EtOAc (3x). The combined extracts were dried over Na2SO4, filtered, concentrated, and purified by flash chromatography (0-30% EtOAc / hexanes) to give the title compound (7.85 g, 84%). MS (m / z): 345.1 (M+H).

[0270] Preparation of methyl (S)-2-((tert-butoxycarbonyl)amino)-3-(2-oxo-3-((2-(trimethylsilyl)ethoxy)methyl)-2,3-dihydrobenzo[d]oxazol-6-yl)propanoate (75B). The title compound (5.0 g, 48%) was prepared in the same manner as described in Intermediate 1, Step 1. MS (m / z): 489.3 (M+Na).

[0271] Preparation of tert-butyl (S)-(1-hydroxy-3-(2-oxo-3-((2-(trimethylsilyl)ethoxy)methyl)-2,3-dihydrobenzo[d]oxazol-6-yl)propan-2-yl)carbamate (75C). The title compound (3.0 g, 96%) was prepared in the same manner as described in Intermediate 1, Step 2. MS (m / z): 461.2 (M+Na).

[0272] Preparation of tert-butyl N-[(2S)-1-(1,3-dioxo-2,3-dihydro-1H-isoindol-2-yl)-3-(2-oxo-3-{[2-(trimethylsilyl)ethoxy]methyl}-2,3-dihydro-1,3-benzoxazol-6-yl)propan-2-yl]carbamate (75D). The title compound (3.3 g, 84%) was prepared in the same manner as described in Intermediate 1, Step 3. MS (m / z): 568.2 (M+H).

[0273] Preparation of 2-[(2S)-2-amino-3-(2-oxo-3-{[2-(trimethylsilyl)ethoxy]methyl}-2,3-dihydro-1,3-benzoxazol-6-yl)propyl]-2,3-dihydro-1H-isoindole-1,3-dione (75E). A mixture of tert-butyl N-[(2S)-1-(1,3-dioxo-2,3-dihydro-1H-isoindol-2-yl)-3-(2-oxo-3-{[2-(trimethylsilyl)ethoxy]methyl}-2,3-dihydro-1,3-benzoxazol-6-yl)propan-2-yl]carbamate (2.05 g, 3.61 mmol) and 4-methylbenzene-1-sulfonic acid hydrate (756 mg, 1.1 equiv, 3.97 mmol) in EtOH (40 ml) was heated at 60° C. for 2 hours. The mixture was cooled to room temperature and concentrated to dryness to give 2-[(2S)-2-amino-3-(2-oxo-3-{[2-(trimethylsilyl)ethoxy]methyl}-2,3-dihydro-1,3-benzoxazol-6-yl)propyl]-2,3-dihydro-1H-isoindole-1,3-dione (2.30 g, 100%) as the PTSA salt.

[0274] Preparation of 2-[(2S)-2-(dimethylamino)-3-(2-oxo-3-{[2-(trimethylsilyl)ethoxy]methyl}-2,3-dihydro-1,3-benzoxazol-6-yl)propyl]-2,3-dihydro-1H-isoindole-1,3-dione (75F). To a stirred solution of 2-[(2S)-2-amino-3-(2-oxo-3-{[2-(trimethylsilyl)ethoxy]methyl}-2,3-dihydro-1,3-benzoxazol-6-yl)propyl]-2,3-dihydro-1H-isoindole-1,3-dione (2.1 g, 4.49 mmol) in MeCN / HO (10:1, 22 mL) was added acetic acid (0.809 g, 13.5 mmol) and formaldehyde (0.405 mL, 13.5 mmol). The mixture was stirred for 30 min. Sodium cyanoborohydride (0.423 g, 6.74 mmol) was added. After the addition was complete, the reaction mixture was stirred for 30 min. Saturated aqueous NH4Cl was added and the mixture was extracted with EtOAc (3x). The combined extracts were dried over MgSO and concentrated to give 2-[(2S)-2-(dimethylamino)-3-(2-oxo-3-{[2-(trimethylsilyl)ethoxy]methyl}-2,3-dihydro-1,3-benzoxazol-6-yl)propyl]2,3-dihydro-1H-isoindole-1,3-dione (1.9 g, 85.3%). MS (m / z): 496.2 (M+H).

[0275] Preparation of 6-[(2S)-3-amino-2-(dimethylamino)propyl]-3-{[2-(trimethylsilyl)ethoxy]methyl}-2,3-dihydro-1,3-benzoxazol-2-one (75G). A mixture of 2-[(2S)-2-(dimethylamino)-3-(2-oxo-3-{[2-(trimethylsilyl)ethoxy]methyl}-2,3-dihydro-1,3-benzoxazol-6-yl)propyl]-2,3-dihydro-1H-isoindole-1,3-dione (380 mg, 0.767 mmol) and hydrazine (246 mg, 3.83 mmol) in EtOH (4 mL) was heated to 70° C. for 2 hours. The reaction was cooled to room temperature. Addition of silica gel, concentration to dryness, packing dry, and purification by flash chromatography (0-25% MeOH / DCM in 1% NH4OH) gave the title compound (1.15 g, 50%). MS (m / z): 366.3 (M+H).

[0276] The following intermediate was synthesized in a manner similar to that described in Example A11, Intermediate 77.

[0277] [Table 4]

[0278] Example A12: Preparation of (S)-5-(3-amino-2-(dimethylamino)propyl)-4-methylindolin-2-one (78F, "Intermediate 78")

[0279] [ka]

[0280] Preparation of methyl (2S)-2-{[(tert-butoxy)carbonyl]amino}-3-(4-methyl-2-oxo-2,3-dihydro-1H-indol-5-yl)propanoate (78A): Step 1: To a stirred suspension of zinc dust (1.4 g, 21.4 mmol, 3 equiv.) in DMF (20 mL) was added iodine (310 mg, 0.1 equiv., 1.2 mmol). After stirring for 15 minutes, methyl (2R)-2-{[(tert-butoxy)carbonyl]amino}-3-iodopropanoate (2.62 g, 1.3 equiv., 7.95 mmol) was added in one portion, followed by another addition of iodine (310 mg, 0.1 equiv., 1.2 mmol). The resulting mixture was stirred at room temperature for 1 hour. Step 2: The mixture from Step 1 was added to a stirred mixture of 5-iodo-4-methyl-2,3-dihydro-1H-indol-2-one (1.67 g, 6.12 mmol), S-Phos (251 mg, 0.1 equiv., 1.2 mmol), and Pd(dba) (280 mg, 0.05 equiv., 0.306 mmol) in DMF (20 mL). The reaction mixture was heated to 70 °C for 16 h. The reaction was cooled to room temperature, saturated NH Cl was added, and the mixture was extracted with EtOAc (3x). The extract was dried over MgSO, filtered, concentrated, and purified by flash chromatography (0–40% EtOAc / hexanes) to give methyl (2S)-2-{[(tert-butoxy)carbonyl]amino}-3-[4-methyl-1-(4-methylbenzenesulfonyl)-1H-indazol-5-yl]propanoate (681 mg, 31%). MS (488.2) (M+H).

[0281] Preparation of tert-butyl N-[(2S)-1-hydroxy-3-(4-methyl-2-oxo-2,3-dihydro-1H-indol-5-yl)propano-2-yl]carbamate (78B): Methyl (2S)-2-{[(tert-butoxy)carbonyl]amino}-3-(4-methyl-2-oxo-2,3-dihydro-1H-indol-5-yl)propanoate (681 mg, 1.95 mmol) was dissolved in anhydrous THF (20 mL) under nitrogen and cooled in an ice bath. Lithium borohydride (4 M in THF, 0.7 mL, 5.85 mmol) was added dropwise, and the mixture was allowed to stir at room temperature overnight. After completion of the reaction, the mixture was cooled in an ice bath and quenched with saturated aqueous NH4Cl. The aqueous layer was extracted with EtOAc (3x). The combined extracts were dried over MgSO, filtered, concentrated, and purified by silica gel chromatography (0-60% EtOAc / hexanes) to give the title compound (710 mg, 110%). MS (m / z): 321.2 (M+H).

[0282] Preparation of tert-butyl N-[(2S)-1-(1,3-dioxo-2,3-dihydro-1H-isoindol-2-yl)-3-(4-methyl-2-oxo-2,3-dihydro-1H-indol-5-yl)propan-2-yl]carbamate (78C): To a stirred mixture of tert-butyl N-[(2S)-1-hydroxy-3-(4-methyl-2-oxo-2,3-dihydro-1H-indol-5-yl)propan-2-yl]carbamate (714 mg, 2.23 mmol), triphenylphosphine (701 mg, 2.67 mmol), and phthalimide (393 mg, 2.67 mmol) in THF (20 mL) at 0 °C was added DIAD (0.52 mL, 2.67 mmol) dropwise. After the addition was complete, the reaction mixture was stirred at room temperature for 16 hours. The reaction mixture was then concentrated to dryness and purified by flash chromatography (0-60% EtOAc / hexanes) to give the title compound (600 mg, 60%). MS (m / z): 450.2 (M+H).

[0283] Preparation of 2-[(2S)-2-amino-3-(4-methyl-2-oxo-2,3-dihydro-1H-indol-5-yl)propyl]-2,3-dihydro-1H-isoindole-1,3-dione (78D): A solution of tert-butyl N-[(2S)-1-(1,3-dioxo-2,3-dihydro-1H-isoindol-2-yl)-3-(4-methyl-2-oxo-2,3-dihydro-1H-indol-5-yl)propan-2-yl]carbamate (600 mg, 1.33 mmol) in formic acid (10 mL) was heated to 50° C. for 1 h. The reaction mixture was cooled to room temperature and concentrated to dryness to give the title compound (600 mg, 100%), which was used in the next step. (MS (m / z): 350.2 (M+H).

[0284] Preparation of 2-[(2S)-2-(dimethylamino)-3-(4-methyl-2-oxo-2,3-dihydro-1H-indol-5-yl)propyl]-2,3-dihydro-1H-isoindole-1,3-dione (78E): To a stirred solution of 2-[(2S)-2-amino-3-(4-methyl-2-oxo-2,3-dihydro-1H-indol-5-yl)propyl]-2,3-dihydro-1H-isoindole-1,3-dione (600 mg, 1.33 mmol) in MeCN / HO (5:1, 24 mL) was added formaldehyde (300 μL, 3 equiv., 10.7 mmol). The mixture was stirred for 30 min, after which sodium cyanoborohydride (162 mg, 2 equiv., 2.66 mmol) was added in one portion. The resulting mixture was stirred for an additional 30 min. Saturated aqueous NaHCO3 was slowly added to adjust the pH to 7-8 and extracted with EtOAc (3x). The combined extracts were dried over MgSO4 and concentrated to dryness to give the title compound (360 mg, 65%), which was used in the next step without further purification. MS (m / z): 378.2 (M+H).

[0285] Preparation of (S)-5-(3-amino-2-(dimethylamino)propyl)-4-methylindolin-2-one (78F): To a stirred solution of 2-[(2S)-2-(dimethylamino)-3-(4-methyl-2-oxo-2,3-dihydro-1H-indol-5-yl)propyl]-2,3-dihydro-1H-isoindole-1,3-dione (360 mg, 0.954 mmol) in EtOH (10 mL) was added hydrazine (238 mmL, 5 equiv., 4.44 mmol). The reaction mixture was heated to 80 °C for 2 h. The reaction mixture was cooled to room temperature, and the precipitated solid was filtered and washed with EtOH. The filtrate was concentrated to dryness and purified by flash chromatography (0-15% MeOH / DCM in 1% NH4OH) to give the title compound (125 mg, 52%). MS(m / z):248.1(M+H).

[0286] The following intermediate was synthesized in a manner similar to that described in Example A12, Intermediate 78.

[0287] [Table 5]

[0288] Example A13: (2S)-1-amino-3-[4-methyl-1-(4-methylbenzenesulfonyl)-1H-indazol-5-yl]propan-2-yl]dimethylamine (81G, "Intermediate 81"):

[0289] [ka]

[0290] Preparation of 5-bromo-4-methyl-1-(4-methylbenzenesulfonyl)-1H-indazole (81A): To a stirred solution of 5-bromo-4-methyl-1H-indazole (5.50 g, 26.1 mmol) in DMF (40 mL) at 0 °C, sodium hydride (1.25 g, 1.2 equiv., 31.3 mmol) was added in small portions. After the addition was complete, the mixture was allowed to stir for 30 minutes, after which 4-methylbenzene-1-sulfonyl chloride (5.96 g, 1.2 equiv., 31.3 mmol) was added in one portion. The ice bath was removed, and the reaction mixture was stirred at room temperature for 16 hours. The reaction mixture was cooled in an ice bath, and saturated NH4Cl was added. The precipitated solid was collected, washed with H2O, and purified by flash chromatography (50% DCM / hexanes) to give 5-bromo-4-methyl-1-(4-methylbenzenesulfonyl)-1H-indazole (3.00 g, 31%).

[0291] Preparation of methyl (2S)-2-{[(tert-butoxy)carbonyl]amino}-3-[4-methyl-1-(4-methylbenzenesulfonyl)-1H-indazol-5-yl]propanoate (81B): Step 1: To a stirred suspension of zinc dust (1.61 g, 24.6 mmol, 3 equiv.) in DMF (20 mL) was added iodine (208 mg, 0.1 equiv., 821 μmol). After stirring for 15 min, methyl (2R)-2-{[(tert-butoxy)carbonyl]amino}-3-iodopropanoate (3.24 g, 1.2 equiv., 9.86 mmol) was added in one portion, followed by another addition of iodine (208 mg, 0.1 equiv., 821 μmol). The resulting mixture was stirred at room temperature for 1 h. Step 2: The mixture from Step 1 was added to a stirred mixture of 5-bromo-4-methyl-1-(4-methylbenzenesulfonyl)-1H-indazole (3.00 g, 8.21 mmol), S-Phos (337 mg, 0.1 equiv., 821 μmol), and Pd(dba) (376 mg, 0.05 equiv., 411 μmol) in DMF (20 mL). The reaction mixture was heated to 70° C. for 16 h. The reaction was cooled to room temperature, saturated NH4Cl was added, and the mixture was extracted with EtOAc (3×). The extract was dried over MgSO, filtered, concentrated, and purified by flash chromatography (0–40% EtOAc / hexanes) to give methyl (2S)-2-{[(tert-butoxy)carbonyl]amino}-3-[4-methyl-1-(4-methylbenzenesulfonyl)-1H-indazol-5-yl]propanoate (2.20 g, 55%). MS (m / z): 488.2 (M+H).

[0292] Preparation of tert-butyl N-[(2S)-1-hydroxy-3-[4-methyl-1-(4-methylbenzenesulfonyl)-1H-indazol-5-yl]propano-2-yl]carbamate (81C). To a stirred solution of methyl (2S)-2-{[(tert-butoxy)carbonyl]amino}-3-[4-methyl-1-(4-methylbenzenesulfonyl)-1H-indazol-5-yl]propanoate (2.20 g, 4.51 mmol) in THF (20 mL) at 0 °C was added lithium borohydride (1.69 mL, 1.5 equiv., 6.77 mmol) dropwise. After the addition was complete, the reaction mixture was stirred at room temperature for 16 h, cooled in an ice bath, slowly quenched with saturated NH4Cl, stirred for 10 min, diluted with HO, and extracted with EtOAc (3x). The combined extracts were dried over MgSO, filtered, and concentrated to dryness to give tert-butyl N-[(2S)-1-hydroxy-3-[4-methyl-1-(4-methylbenzenesulfonyl)-1H-indazol-5-yl]propan-2-yl]carbamate (2.00 g, 96%), which was used in the next step without further purification.

[0293] Preparation of tert-butyl N-[(2S)-1-(1,3-dioxo-2,3-dihydro-1H-isoindol-2-yl)-3-[4-methyl-1-(4-methylbenzenesulfonyl)-1H-indazol-5-yl]propan-2-yl]carbamate (81D). To a stirred mixture of tert-butyl N-[(2S)-1-hydroxy-3-[4-methyl-1-(4-methylbenzenesulfonyl)-1H-indazol-5-yl]propan-2-yl]carbamate (2 g, 4.35 mmol), triphenylphosphine (1.37 g, 5.22 mmol), and phthalimide (0.768 g, 5.22 mmol) in THF (40 mL) at 0 °C was added DIAD (1.06 g, 5.22 mmol) dropwise. After the addition was complete, the reaction mixture was stirred at room temperature for 16 hours, after which it was concentrated to dryness and purified by flash chromatography (0-60% EtOAc / hexanes) to give the title compound (2.1 g, 81%).

[0294] Preparation of 2-[(2S)-2-amino-3-[4-methyl-1-(4-methylbenzenesulfonyl)-1H-indazol-5-yl]propyl]-2,3-dihydro-1H-isoindole-1,3-dione (81E). A solution of tert-butyl N-[(2S)-1-(1,3-dioxo-2,3-dihydro-1H-isoindol-2-yl)-3-[4-methyl-1-(4-methylbenzenesulfonyl)-1H-indazol-5-yl]propan-2-yl]carbamate (2.10 g, 3.57 mmol) in formic acid (20 mL) was heated to 50 °C for 1 h. The reaction mixture was cooled to room temperature and concentrated to dryness to give the title compound (1.74 g, 99.8%), which was used in the next step. MS (m / z): 489.2 (M+H).

[0295] Preparation of 2-[(2S)-2-(dimethylamino)-3-[4-methyl-1-(4-methylbenzenesulfonyl)-1H-indazol-5-yl]propyl]-2,3-dihydro-1H-isoindole-1,3-dione (81F). To a stirred solution of 2-[(2S)-2-amino-3-[4-methyl-1-(4-methylbenzenesulfonyl)-1H-indazol-5-yl]propyl]-2,3-dihydro-1H-isoindole-1,3-dione (1.74 g, 3.56 mmol) in MeCN / HO (5:1, 24 mL) was added formaldehyde (827 μL, 3 equiv., 10.7 mmol). The mixture was stirred for 30 min, after which sodium cyanoborohydride (448 mg, 2 equiv., 7.13 mmol) was added in one portion. The resulting mixture was stirred for an additional 30 min. Saturated aqueous NaHCO3 was slowly added to adjust the pH to 7-8 and extracted with EtOAc (3x). The combined extracts were dried over MgSO4 and concentrated to dryness to give the title compound (1.84 g, 99.8%), which was used in the next step without further purification. MS (m / z): 517.2 (M+H).

[0296] Preparation of [(2S)-1-amino-3-[4-methyl-1-(4-methylbenzenesulfonyl)-1H-indazol-5-yl]propan-2-yl]dimethylamine (81G). To a stirred solution of 2-[(2S)-2-(dimethylamino)-3-[4-methyl-1-(4-methylbenzenesulfonyl)-1H-indazol-5-yl]propyl]-2,3-dihydro-1H-isoindole-1,3-dione (1.84 g, 3.56 mmol) in EtOH (20 mL) was added hydrazine (1.14 g, 5 equiv., 17.8 mmol). The reaction mixture was heated to 80 °C for 2 h. The reaction mixture was cooled to room temperature, and the precipitated solid was filtered and washed with EtOH. The filtrate was concentrated to dryness and purified by flash chromatography (0–15% MeOH / DCM in 1% NH4OH) to give [(2S)-1-amino-3-[4-methyl-1-(4-methylbenzenesulfonyl)-1H-indazol-5-yl]propano-2-yl]dimethylamine (900 mg, 65%). MS (m / z): 387.1 (M+H).

[0297] The following intermediates were synthesized in a manner analogous to that described in Example A13, Intermediate 81, and general Scheme IV.

[0298] [Table 6]

[0299] Example A14: Preparation of (S)-4-(3-amino-2-(dimethylamino)propyl)phenol (133E, "Intermediate 133"):

[0300] [ka]

[0301] Preparation of methyl (S)-2-((tert-butoxycarbonyl)amino)-3-(2,5-difluoro-4-hydroxyphenyl)propanoate (133A): To an oven-dried RBF was added zinc (26 g, 35 mmol), dry DMF (140 mL), and iodine (1.8 g, 140 mmol). The reaction mixture was stirred for 10 min, after which a solution of methyl (2R)-2-{[(tert-butoxy)carbonyl]amino}-3-iodopropanoate (46 g, 140 mmol) and iodine (1.8 g, 140 mmol) was added, resulting in an exotherm. The reaction mixture was stirred for 20 minutes, cooled to room temperature, and then 4-bromophenol (20 g, 116 mmol), Pd2(dba)3 (5.3 g, 5.8 mmol), and SPhos (4.8 g, 12 mmol) were added to the reaction mixture. The reaction mixture was stirred at 75 °C for 16 hours. The crude reaction mixture was cooled to room temperature, quenched with water, diluted with EtOAc, and filtered through Celite. The organic layer was washed with brine (5x), dried over MgSO4, and then concentrated. The resulting residue was adsorbed onto silica and then purified by column chromatography (silica, 0-50% EtOAc / hex) to give the title compound (27 g, 78%) as a white solid. MS (m / z) = 296.1 [M+H].

[0302] Preparation of tert-butyl (S)-(1-(4-((tert-butyldimethylsilyl)oxy)-2,5-difluorophenyl)-3-hydroxypropan-2-yl)carbamate (133B): Methyl (2S)-2-{[(tert-butoxy)carbonyl]amino}-3-(2,6-difluoro-4-hydroxyphenyl)propanoate (29 g, 98 mmol) was taken up in dichloromethane (600 ml) with tert-butyl(chloro)dimethylsilane (16 g, 107 mmol) and 1H-imidazole (20 g, 293 mmol). The solution was stirred for 24 hours at room temperature. The solution was diluted with dichloromethane and then washed with saturated sodium bicarbonate solution. The organic layer was filtered through magnesium sulfate, and the filtrate was concentrated to give the desired product (35 g). This product was dissolved in THF (300 mL), cooled to 0 °C, and a solution of lithium borohydride (4 M in THF, 43 mL, 170 mmol) was added dropwise. The reaction mixture was stirred at 0 °C for 30 minutes, then stirred while warming to room temperature for 6 hours. The reaction mixture was then cooled to 0 °C and quenched by the dropwise addition of ammonium chloride solution. The crude reaction mixture was diluted with brine, and the product was extracted with EtOAc (3 ×). The combined organic layers were washed with brine, dried over Na SO , and concentrated. The resulting residue was purified by column chromatography (80 g silica, 10% DCM / MeOH) to give the title compound as an oil (33 g, 60%). MS (m / z) = 382.1 [M + Na].

[0303] Preparation of tert-butyl (S)-(1-(4-((tert-butyldimethylsilyl)oxy)phenyl)-3-(1,3-dioxoisoindolin-2-yl)propan-2-yl)carbamate (133C): tert-butyl N-[(2S)-1-(4-carbamoyl-3-fluorophenyl)-3-hydroxypropan-2-yl]carbamate (32 g, 84 mmol), triphenylphosphine (24 g, 92 mmol), and phthalimide (13.6 g, 92 mmol) were dissolved in anhydrous THF (500 mL). The reaction mixture was cooled to 0° C., and DIAD (18.2 mL, 92 mmol) was added dropwise. The reaction mixture was stirred at 0° C. for 1 hour and then at room temperature for 16 hours. A white precipitate was formed as a result. The precipitate was filtered, washed with THF, and dried to give the title compound as a white solid (28 g, 65%). MS (m / z) = 511.1 [M+H].

[0304] Preparation of (S)-2-(3-(2,5-difluoro-4-hydroxyphenyl)-2-(dimethylamino)propyl)isoindoline-1,3-dione (133D): tert-butyl (S)-(1-(4-((tert-butyldimethylsilyl)oxy)phenyl)-3-(1,3-dioxoisoindolin-2-yl)propan-2-yl)carbamate (1.8 g, 3.2 mmol) was taken up in methanol (200 ml) followed by the addition of 4 M HCl in 1,4-dioxane (120 mL, 500 mmol). The reaction mixture was stirred for 1 h at 50° C. Complete conversion by LCMS. The reaction mixture was concentrated and the resulting residue was triturated with ethyl acetate to give the product (17 g, 94%) as a white solid which was used directly in the next step. MS (m / z) = 297.1 [M+H]. The solid was dissolved in MeCN / HO (240 ml / 60 ml), followed by the addition of 37 wt% formaldehyde in water (15 mL, 207 mmol). The reaction mixture was stirred for 30 minutes, after which NaCNBH (9.8 g, 156 mmol) was added to the reaction mixture in one portion. Complete conversion after 1 hour by LCMS. The reaction mixture was cooled to 0 °C and quenched with saturated aqueous sodium bicarbonate (ca. 500 mL). The product was extracted with EtOAc (7x), and the combined organic layers were dried over MgSO and concentrated. The resulting residue was purified by silica gel chromatography to give the desired product (8.4 g, 50%) as an oil. MS (m / z) = 325.1 [M+H].

[0305] Preparation of (S)-4-(3-amino-2-(dimethylamino)propyl)-2,5-difluorophenol (133E): (S)-2-(3-(2,5-difluoro-4-hydroxyphenyl)-2-(dimethylamino)propyl)isoindoline-1,3-dione (8.4 g, 26 mmol) was taken up in anhydrous EtOH (250 mL) with aqueous 50 wt% hydrazine hydrate (12 mL, 130 mmol). The reaction mixture was stirred at 75 °C for 3 h. The crude reaction mixture was concentrated and adsorbed onto silica, then purified by column chromatography (40 g silica, 0-20% MeOH / DCM + 1% NH4OH) to give the title compound as a white solid (3.0 g, 60%). MS (m / z): 195.2 [M+H].

[0306] The following intermediates were synthesized in a manner analogous to that described in Example A14, Intermediate 133, and general Scheme III.

[0307] [Table 7]

[0308] Example A15: Preparation of (S)-3-(aminomethyl)-2-methyl-1,2,3,4-tetrahydroisoquinolin-7-ol ("Intermediate 144"):

[0309] [ka]

[0310] Intermediate 144 was synthesized as described in WO2019195634A1.

[0311] Synthesis Example B: Compound Example B1: Preparation of 4-((S)-2-(dimethylamino)-3-((S)-3-(2-methylthiazol-5-yl)-3-(1-(trifluoromethyl)cyclopropyl)propanamido)propyl)-2,3-difluorobenzamide ("Compound 1")

[0312] [ka]

[0313] To a solution of the acid (Intermediate 6) (35 mg, 0.125 mmol) in DMF (0.25 mL) was added CDI (22 mg, 0.14 mmol). The mixture was stirred for 1 h at room temperature. DIEA (0.043 mL, 0.25 mmol) and amine (Intermediate 41, 35 mg, 0.138 mmol) were added to the mixture and stirred for 1 h at room temperature. The reaction mixture was diluted with ethyl acetate (20 mL) and saturated NaHCO3, water, and brine. The organic layer was dried over MgSO4, filtered, and concentrated on a rotary evaporator. The crude material was purified on a silica gel column (0-25% MeOH / DCM with 1% NH4OH). The pure fractions were concentrated and triturated with MTBE to give the title compound (44 mg, 67%). MS (m / z): 519.2 (M+H).

[0314] Example B2: Preparation of 4-((S)-2-(dimethylamino)-3-((S)-3-(triazol-5-yl)-3-(1-(trifluoromethyl)cyclopropyl)propanamido)propyl)-2,3-difluorobenzamide ("Compound 2")

[0315] [ka]

[0316] Compound 2 (78 mg, 70%) was synthesized from intermediate 41 and intermediate 40 as described in Example B1. MS (m / z): 505.1 (M+H).

[0317] Example B3: Preparation of 4-((S)-2-(dimethylamino)-3-((R)-3-(2-methylpyrimidin-5-yl)-3-(1-(trifluoromethyl)cyclopropyl)propanamido)propyl)-2,3-difluorobenzamide ("Compound 3")

[0318] [ka]

[0319] Compound 3 (19 mg, 51%) was synthesized from intermediate 41 and intermediate 9 as described in Example B1. MS (m / z): 514.2 (M+H).

[0320] Example B4: Preparation of 4-((S)-2-(dimethylamino)-3-((R)-3-(6-methylpyrimidin-3-yl)-3-(1-(trifluoromethyl)cyclopropyl)propanamido)propyl)-2,3-difluorobenzamide ("Compound 4")

[0321] [ka]

[0322] Compound 4 (38 mg, 68%) was synthesized from intermediate 41 and intermediate 10 as described in Example B1. MS (m / z): 513.2 (M+H).

[0323] Example B5: Preparation of 4-[(2S)-3-[(3R)-3-(5-chloropyrimidin-2-yl)-3-[1-(trifluoromethyl)cyclopropyl]propanamido]-2-(dimethylamino)propyl]-2,5-difluorobenzamide ("Compound 5")

[0324] [ka]

[0325] To a stirred mixture of (R)-DTBM-SEGPHOS (3.13 mg, 0.01 equiv., 2.65 μmol) and copper(2+) diacetate (2.41 mg, 0.05 equiv., 13.3 μmol) in toluene (1 mL) at 0 °C, dimethoxy(methyl)silyl (81.0 μL, 2.5 equiv., 663 μmol) was added, followed by 2-methylpropan-2-ol (85.4 μL, 2 equiv., 900 μmol). A solution of 4-[(2S)-3-[(2Z)-3-(5-chloropyrimidin-2-yl)-3-[1-(trifluoromethyl)cyclopropyl]prop-2-enamido]-2-(dimethylamino)propyl]-2,5-difluorobenzamide (141 mg, 265 μmol) in toluene (4 mL) was added dropwise. The reaction mixture was stirred slowly overnight at room temperature. LC / MS indicated approximately 13% conversion. The mixture was cooled in an ice bath, and 10 mol% S-DTBM-SEGPHOS, 10 mol% Cu(OAc)2, 5 equivalents of DMMS, and 4 equivalents of t-BuOH were added (a large amount of gas bubbles occurred during this time). The ice bath was removed and the mixture was stirred at room temperature for 3 hours. LC / MS indicated >95% conversion of the expected product. Solid NHF was added to the mixture, which was stirred vigorously for 15 minutes, HO was added, the mixture was stirred for an additional 10 minutes, and the mixture was extracted with EtOAc (3x). The combined extracts were dried over MgSO, concentrated to dryness, and purified by flash chromatography (0–15% MeOH / DCM) to give 4-[(2S)-3-[(3R)-3-(5-chloropyrimidin-2-yl)-3-[1-(trifluoromethyl)cyclopropyl]propanamido]-2-(dimethylamino)propyl]-2,5-difluorobenzamide (38.5 mg, 27%). MS (m / z): 534.1 (M+H).

[0326] Example B6: Preparation of 4-((2S)-2-(dimethylamino)-3-(2-(pyrimidin-2-yl)cyclopropane-1-carboxamido)propyl)-3,5-dimethylbenzamide ("Compound 6"):

[0327] [ka]

[0328] To a stirred mixture of (S)-4-(3-amino-2-(dimethylamino)propyl)-3,5-dimethylbenzamide (Intermediate 74, 120 mg, 0.48 mmol), 2-(pyrimidin-2-yl)cyclopropane-1-carboxylic acid (Intermediate 7, 95 mg, 0.58 mmol), and DIEA (0.17 mL, 2.5 equiv., 1.2 mmol) in DMF (2 mL) was added HATU (220 mg, 1.2 equiv., 0.58 mmol). After the addition was complete, the reaction mixture was stirred at room temperature for 1 h. HO was added, and the precipitated solid was collected, washed with HO, dried, and purified by flash chromatography (0–10% MeOH / DCM) to give 4-((2S)-2-(dimethylamino)-3-(2-(pyrimidin-2-yl)cyclopropane-1-carboxamido)propyl)-3,5-dimethylbenzamide (108 mg, 65%). MS (m / z): 396.2 (M+H).

[0329] Example B7: Preparation of 4-((S)-2-(dimethylamino)-3-((S)-3-phenyl-3-(1-(trifluoromethyl)cyclopropyl)propanamido)propyl)-3,5-dimethylbenzamide ("Compound 7")

[0330] [ka]

[0331] To a stirred mixture of 4-[(2S)-3-amino-2-(dimethylamino)propyl]-3,5-dimethylbenzamide (Intermediate 74, 56.2 mg, 1 equivalent, 225 μmol), (3S)-3-phenyl-3-[1-(trifluoromethyl)cyclopropyl]propanoic acid (Intermediate 4, 58.2 mg, 225 μmol), and DIEA (252 mg, 2.5 equivalents, 563 μmol) in DMF (2 mL) was added HATU (103 mg, 1.2 equivalents, 270 μmol). After the addition was complete, the reaction mixture was stirred at room temperature for 1 hour. HO was added, and the precipitated solid was collected, washed with HO, dried, and purified by flash chromatography (0–10% MeOH / DCM) to give 4-[(2S)-2-(dimethylamino)-3-[(3R)-3-phenyl-3-[1-(trifluoromethyl)cyclopropyl]propanamido]propyl]-3,5-dimethylbenzamide (37.3 mg, 76.2%). MS (m / z): 490.3 (M+H).

[0332] Example B8: Preparation of 4-((S)-2-(dimethylamino)-3-((R)-3-phenyl-3-(1-(trifluoromethyl)cyclopropyl)propanamido)propyl)-3,5-dimethylbenzamide ("Compound 8")

[0333] [ka]

[0334] Compound 8 (67.5 mg, 64%) was synthesized from intermediate 74 and intermediate 3 as described in Example B7. MS (m / z): 490.3 (M+H).

[0335] Example B9: Preparation of 4-[(2S)-2-(dimethylamino)-3-[(3S)-5-methyl-3-phenylhexanamido]propyl]-3,5-dimethylbenzamide ("Compound 9"):

[0336] [ka]

[0337] A solution of 4-[(2S)-3-amino-2-(dimethylamino)propyl]benzamide (Intermediate 74, 28.2 mg, 113 mmol) in DMF (1 ml) was added to (S)-5-methyl-3-phenylhexanoic acid (Intermediate 68, 25.6 mg, 124 mmol), EDC (24 mg, 124 mmol), 1-hydroxybenzotriazole (15.3 mg, 113 mmol), and N,N'-diisopropylethylamine (16.1 mg, 124 mmol). The solution was stirred for 3 h at room temperature. It was diluted with ethyl acetate and washed with water. The organic layer was filtered through magnesium sulfate and concentrated. The residue was purified by flash chromatography (0-25% MeOH / DCM in 1% NH4OH) to give the title compound (25 mg, 52%). MS (m / z): 438.3 (M+H).

[0338] Example B10: Preparation of 4-((S)-2-(dimethylamino)-3-((R)-4-methyl-phenylpentanamido)propyl)-3,5-dimethylbenzamide ("Compound 10"):

[0339] [ka]

[0340] Compound 10 (24.6 mg, 51%) was synthesized from intermediate 74 and intermediate 66 as described in Example B9. MS (m / z): 424.3 (M+H).

[0341] Example B11: Preparation of 4-((S)-3-((R)-3-cyclopropyl-3-phenylpropanamido)-2-(dimethylamino)propyl)-3,5-dimethylbenzamide ("Compound 11"):

[0342] [ka]

[0343] Compound 11 (10 mg, 21%) was synthesized from intermediate 74 and intermediate 64 as described in Example B9. MS (m / z): 422.3 (M+H).

[0344] Example B12: Preparation of 4-[(2S)-2-(dimethylamino)-3-[(3R)-5-methyl-3-phenylhexanamido]propyl]-3,5-dimethylbenzamide ("Compound 12"):

[0345] [ka]

[0346] Compound 12 (5.1 mg, 7%) was synthesized from intermediate 74 and intermediate 67 as described in Example B9. MS (m / z): 438.5 (M+H).

[0347] Example B13: Preparation of 4-[(2S)-3-[(3S)-4,4-dimethyl-3-phenylpentanamido]-2-(dimethylamino)propyl]-3,5-dimethylbenzamide ("Compound 13"):

[0348] [ka]

[0349] Compound 13 (25 mg, 35%) was synthesized from intermediate 74 and intermediate 70 as described in Example B9. MS (m / z): 438.3 (M+H).

[0350] Example B14: Preparation of 3-chloro-4-((S)-2-(dimethylamino)-3-((R)-3-phenylbutanamido)propyl)benzamide ("Compound 14"):

[0351] [ka]

[0352] Compound 14 (17.1 mg, 17%) was synthesized from intermediate 16 and intermediate 61 as described in Example B9. MS (m / z): 402.2 (M+H).

[0353] Example B15: Preparation of 3-chloro-4-((S)-2-(dimethylamino)-3-((S)-3-phenylbutanamido)propyl)benzamide ("Compound 15"):

[0354] [ka]

[0355] Compound 15 (32 mg, 37%) was synthesized from intermediate 16 and intermediate 62 as described in Example B9. MS (m / z): 402.2 (M+H).

[0356] Example B16: Preparation of 3-chloro-4-[(2S)-2-(dimethylamino)-3-[(3S)-3-(2-methyl-1,3-thiazol-5-yl)-3-[1-(trifluoromethyl)cyclopropyl]propanamido]propyl]-2-fluorobenzamide ("Compound 16"):

[0357] [ka]

[0358] Compound 16 (46 mg, 74%) was synthesized from intermediate 13 and intermediate 6 as described in Example B1. MS (m / z): 535.2 (M+H).

[0359] Example B17: Preparation of 3-chloro-4-[(2S)-2-(dimethylamino)-3-[(3S)-3-(6-methylpyridin-3-yl)-3-[1-(trifluoromethyl)cyclopropyl]propanamido]propyl]-2-fluorobenzamide ("Compound 17")

[0360] [ka]

[0361] To a solution of Intermediate 11 (22.8 mg, 0.0834 mmol) and DIEA (29.1 uL, 0.167 mmol) in DMF (0.25 mL) was added TSTU (25.1 mg, 0.0834 mmol). The mixture was stirred at room temperature for 1 hour. Intermediate 13 (25.1 mg, 0.0918 mmol) was added in one portion, and stirring was continued at room temperature for 1 hour. The reaction mixture was diluted with ethyl acetate (15 mL) and saturated NaHCO3, water, and brine. The organic layer was dried over MgSO4, filtered, and concentrated. The crude material was purified by silica gel column (0-10% MeOH / DCM with 1% NH4OH) to give the title compound (22 mg, 50%). MS (m / z): 529.2 (M+H).

[0362] Example B18: Preparation of 3-chloro-4-[(2S)-2-(dimethylamino)-3-[(3R)-3-(pyridin-3-yl)-3-[1-(trifluoromethyl)cyclopropyl]propanamido]propyl]-2-fluorobenzamide ("Compound 18"):

[0363] [ka]

[0364] Compound 18 (20.1 mg, 53%) was synthesized from intermediate 13 and intermediate 15 as described in Example B9. MS (m / z): 515.2 (M+H).

[0365] Example B19: Preparation of 3-chloro-4-[(2S)-2-(dimethylamino)-3-[3-(pyridin-4-yl)-3-[1-(trifluoromethyl)cyclopropyl]propanamido]propyl]-2-fluorobenzamide ("Compound 19"):

[0366] [ka]

[0367] Compound 19 (30 mg, 56%) was synthesized from intermediate 13 and intermediate 12 as described in Example B9. MS (m / z): 515.2 (M+H).

[0368] Example B20: Preparation of 3-chloro-4-((S)-2-(dimethylamino)-3-((R)-3-(6-methylpyridin-3-yl)-3-(1-(trifluoromethyl)cyclopropyl)propanamido)propyl)-2-fluorobenzamide ("Compound 20"):

[0369] [ka]

[0370] Compound 20 (42 mg, 77%) was synthesized from intermediate 13 and intermediate 10 as described in Example B17. MS (m / z): 529.1 (M+H).

[0371] Example B21: Preparation of 3-chloro-4-[(2S)-2-(dimethylamino)-3-[(3R)-3-(2-methylpyrimidin-5-yl)-3-[1-(trifluoromethyl)cyclopropyl]propanamido]propyl]-2-fluorobenzamide ("Compound 21"):

[0372] [ka]

[0373] Compound 21 (15.8 mg, 37%) was synthesized from intermediate 13 and intermediate 9 as described in Example B9. MS (m / z): 530.2 (M+H).

[0374] Example B22: Preparation of 3-chloro-4-[(2S)-3-[3-(5-chloropyrimidin-2-yl)-3-[1-(trifluoromethyl)cyclopropyl]propanamido]-2-(dimethylamino)propyl]-2-fluorobenzamide ("Compound 22"):

[0375] [ka]

[0376] Compound 22 (25.1 mg, 55%) was synthesized from intermediate 13 and intermediate 14 as described in Example B9. MS (m / z): 550.1 (M+H).

[0377] Example B23: Preparation of 3-chloro-4-((S)-3-((R)-3-(pyridin-3-yl)-3-(1-(trifluoromethyl)cyclopropyl)propanamido)-2-(pyrrolidin-1-yl)propyl)benzamide ("Compound 23"):

[0378] [ka]

[0379] Step 1: Methyl (2S)-2-{[(tert-butoxy)carbonyl]amino}-3-(2-chloro-4-cyanophenyl)propanoate (23B) was prepared in the same manner as described in Intermediate 1B.

[0380] Step 2: tert-Butyl N-[(2S)-1-(2-chloro-4-cyanophenyl)-3-hydroxypropan-2-yl]carbamate (23C) was prepared in the same manner as described in Intermediate 1C.

[0381] Step 3: tert-Butyl N-[(2S)-1-(4-carbamoyl-3-chlorophenyl)-3-hydroxypropan-2-yl]carbamate (23D) was prepared in the same manner as described in Intermediate 1D.

[0382] Step 4: tert-Butyl N-[(2S)-1-(4-carbamoyl-3-chlorophenyl)-3-(1,3-dioxo-2,3-dihydro-1H-isoindol-2-yl)propan-2-yl]carbamate (23E) was prepared in the same manner as described in Intermediate 1E.

[0383] Step 5: 3-Chloro-4-[(2S)-3-(1,3-dioxo-2,3-dihydro-1H-isoindol-2-yl)-2-(pyrrolidin-1-yl)propyl]benzamide (23F) was prepared in the same manner as described in Intermediate 1F. MS (m / z): 412.0 (M+H).

[0384] Step 6: 4-[(2S)-3-amino-2-(pyrrolidin-1-yl)propyl]-3-chlorobenzamide (23G) was prepared in the same manner as described in Intermediate 1G. MS (m / z): 282.0 (M+H).

[0385] Step 7: 3-chloro-4-((S)-3-((R)-3-(pyridin-3-yl)-3-(1-(trifluoromethyl)cyclopropyl)propanamido)-2-(pyrrolidin-1-yl)propyl)benzamide ("Compound 23"). To a 1-dram vial was added (3R)-3-(2-methylpyrimidin-5-yl)-3-[1-(trifluoromethyl)cyclopropyl]propanoic acid (30.0 mg, 0.11 mmol), DIPEA (0.04 mL, 0.2 mmol), and DMF (0.4 mL). To the reaction mixture was added TSTU (32.9 mg, 0.11 mmol). After stirring the reaction mixture for 40 min, the reaction mixture was added to 4-[(2S)-3-amino-2-(pyrrolidin-1-yl)propyl]-2-fluorobenzamide (31.9 mg, 0.12 mmol) in DMF (0.4 mL). The reaction mixture was stirred at room temperature for 1 h, diluted with EtOAc (10 mL), then washed with saturated NaHCO, brine (3x), dried over MgSO, and concentrated. The resulting residue was purified by column chromatography (4 g silica, 0-25% MeOH / DCM and 1% NHOH) eluted with 20% MeOH in DCM to give the title compound (30.1 mg, 53%). MS (m / z): 524.3 (M+H).

[0386] Example B24: Preparation of 3-chloro-4-[(2S)-2-(dimethylamino)-3-[(3R)-3-(2-methylpyrimidin-5-yl)-3-[1-(trifluoromethyl)cyclopropyl]propanamido]propyl]benzamide ("Compound 24"):

[0387] [ka]

[0388] Compound 24 (74.8 mg, 21%) was synthesized from intermediate 16 and intermediate 9 as described in Example B9. MS (m / z): 512.3 (M+H).

[0389] Example B25: Preparation of 3-chloro-4-[(2S)-3-[(3S)-3-cyclopropyl-3-(2-methylpyrimidin-5-yl)propanamido]-2-(dimethylamino)propyl]benzamide ("Compound 25"):

[0390] [ka]

[0391] Compound 25 (35 mg, 70%) was synthesized from intermediate 16 and intermediate 18 as described in Example B17. MS (m / z): 444.2 (M+H).

[0392] Example B26: Preparation of 3-chloro-4-[(2S)-2-(dimethylamino)-3-[3-(pyridin-4-yl)-3-[1-(trifluoromethyl)cyclopropyl]propanamido]propyl]benzamide ("Compound 26"):

[0393] [ka]

[0394] Compound 26 (34 mg, 64%) was synthesized from intermediate 16 and intermediate 12 as described in Example B9. MS (m / z): 497.2 (M+H).

[0395] Example B27: Preparation of 3-chloro-4-((2S)-2-(dimethylamino)-3-(3-(pyrimidin-2-yl)-3-(1-(trifluoromethyl(cyclopropyl)propanamido)propyl)benzamide ("Compound 27")

[0396] [ka]

[0397] Compound 27 (26 mg, 54%) was synthesized from intermediate 16 and intermediate 19 as described in Example B9. MS (m / z): 498.1 (M+H).

[0398] Example B28: Preparation of 3-chloro-4-((S)-2-(dimethylamino)-3-((R)-3-(pyridin-3-yl)-3-(1-(trifluoromethyl)cyclopropyl)propanamido)propyl)benzamide ("Compound 28"):

[0399] [ka]

[0400] Compound 28 (226 mg, 60%) was synthesized from intermediate 16 and intermediate 15 as described in Example B9. MS (m / z): 497.2 (M+H).

[0401] Example B29: Preparation of 3-chloro-4-[(2S)-2-(dimethylamino)-3-{3-[2-(dimethylamino)pyrimidin-5-yl]-3-[1-(trifluoromethyl)cyclopropyl]propanamido}propyl]benzamide ("Compound 29")

[0402] [ka]

[0403] Compound 29 (17.5 mg, 64%) was synthesized from intermediate 16 and intermediate 20 as described in Example B9. MS (m / z): 541.2 (M+H).

[0404] Example B30: Preparation of 3-chloro-4-[(2S)-2-(dimethylamino)-3-[3-(pyrimidin-5-yl)-3-[1-(trifluoromethyl)cyclopropyl]propanamido]propyl]benzamide ("Compound 30")

[0405] [ka]

[0406] Compound 30 (39.8 mg, 84%) was synthesized from intermediate 16 and intermediate 21 as described in Example B9. MS (m / z): 498.2 (M+H).

[0407] Example B31: Preparation of 3-chloro-4-[(2S)-3-[3-(5-chloropyrimidin-2-yl)-3-[1-(trifluoromethyl)cyclopropyl]propanamido]-2-(dimethylamino)propyl]benzamide ("Compound 31"):

[0408] [ka]

[0409] Compound 31 (43.3 mg, 64%) was synthesized from intermediate 16 and intermediate 14 as described in Example B9. MS (m / z): 532.2 (M+H).

[0410] Example B32: Preparation of 3-chloro-4-[(2S)-2-(dimethylamino)-3-{3-[1-(trifluoromethyl)cyclopropyl]-3-[6-(trifluoromethyl)pyridin-3-yl]propanamido}propyl]benzamide ("Compound 32")

[0411] [ka]

[0412] Compound 32 (36.3, 70%) was synthesized from intermediate 16 and intermediate 22 as described in Example B17. MS (m / z): 565.2 (M+H).

[0413] Example B33: Preparation of 3-chloro-4-[(2S)-2-(dimethylamino)-3-[3-(2-methoxypyrimidin-5-yl)-3-[1-(trifluoromethyl)cyclopropyl]propanamido]propyl]benzamide ("Compound 33"):

[0414] [ka]

[0415] Compound 33 (28.9 mg, 39%) was synthesized from intermediate 16 and intermediate 23 as described in Example B9. MS (m / z): 528.2 (M+H).

[0416] Example B34: Preparation of 3-chloro-4-[(2S)-2-(dimethylamino)-3-[3-(2-methylpyrimidin-5-yl)-3-[1-(trifluoromethyl)cyclopropyl]propanamido]propyl]benzamide ("Compound 34")

[0417] [ka]

[0418] Compound 34 (15.7 mg, 26%) was synthesized from intermediate 16 and intermediate 24 as described in Example B9. MS (m / z): 512.2 (M+H).

[0419] Example B35: Preparation of 3-chloro-4-[(2S)-2-(dimethylamino)-3-[3-(6-methoxypyridin-3-yl)-3-[1-(trifluoromethyl)cyclopropyl]propanamido]propyl]benzamide ("Compound 35"):

[0420] [ka]

[0421] Compound 35 (45 mg, 72%) was synthesized from intermediate 16 and intermediate 25 as described in Example B9. MS (m / z): 527.2 (M+H).

[0422] Example B36: Preparation of 3-chloro-4-[(2S)-2-(dimethylamino)-3-[3-(5-fluoropyridin-3-yl)-3-[1-(trifluoromethyl)cyclopropyl]propanamido]propyl]benzamide ("Compound 36"):

[0423] [ka]

[0424] Compound 36 (39.9 mg, 79%) was synthesized from intermediate 16 and intermediate 26 as described in Example B9. MS (m / z): 515.2 (M+H).

[0425] Example B37: Preparation of 3-chloro-4-[(2S)-3-[3-(5-chloropyridin-2-yl)-3-[1-(trifluoromethyl)cyclopropyl]propanamido]-2-(dimethylamino)propyl]benzamide ("Compound 37"):

[0426] [ka]

[0427] Compound 37 (39.9 mg, 79%) was synthesized from intermediate 16 and intermediate 27 as described in Example B9. MS (m / z): 531.2 (M+H).

[0428] Example B38: Preparation of 3-chloro-4-[(2S)-2-(dimethylamino)-3-[3-(pyridin-3-yl)-3-[1-(trifluoromethyl)cyclopropyl]propanamido]propyl]benzamide ("Compound 38"):

[0429] [ka]

[0430] Compound 38 (90 mg, 90%) was synthesized from intermediate 16 and intermediate 28 as described in Example B9. MS (m / z): 497.2 (M+H).

[0431] Example B39: Preparation of 3-chloro-4-[(2S)-2-(dimethylamino)-3-[(3R)-3-phenyl-3-[1-(trifluoromethyl)cyclopropyl]propanamido]propyl]benzamide ("Compound 39"):

[0432] [ka]

[0433] Compound 39 (36.3 mg, 70%) was synthesized from intermediate 16 and intermediate 3 as described in Example B17. MS (m / z): 496.2 (M+H).

[0434] Example B40: Preparation of 3-chloro-4-((S)-2-(dimethylamino)-3-((R)-4-methyl-3-phenylpentanamido)propyl)benzamide ("Compound 40"):

[0435] [ka]

[0436] Compound 40 (10 mg, 15%) was synthesized from intermediate 16 and intermediate 66 as described in Example B17. MS (m / z): 430.2 (M+H).

[0437] Example B41: Preparation of 3-chloro-4-((S)-2-(dimethylamino)-3-((S)-3-(pyridin-3-yl)-3-(1-(trifluoromethyl)cyclopropyl)propanamido)propyl)benzamide ("Compound 41"):

[0438] [ka]

[0439] Compound 41 (220 mg, 56%) was synthesized from intermediate 16 and intermediate 29 as described in Example B9. MS (m / z): 497.2 (M+H).

[0440] Example B42: Preparation of 4-((S)-3-((S)-3-cyclopropyl-3-(2-methylpyrimidin-5-yl)propanamido)-2-(dimethylamino)propyl)-2-fluoro-3-methylbenzamide ("Compound 42"):

[0441] [ka]

[0442] Compound 42 (10 mg, 28%) was synthesized from intermediate 30 and intermediate 18 as described in Example B1. MS (m / z): 442.2 (M+H).

[0443] Example B43: Preparation of 4-((S)-2-(dimethylamino)-3-((S)-3-(2-methylthiazol-5-yl)-3-(1-(trifluoromethyl)cyclopropyl)propanamido)propyl)-2-fluoro-3-methylbenzamide ("Compound 43")

[0444] [ka]

[0445] Compound 43 (38 mg, 59%) was synthesized from intermediate 30 and intermediate 6 as described in Example B1. MS (m / z): 515.2 (M+H).

[0446] Example B44: Preparation of 4-((S)-2-(dimethylamino)-3-((R)-3-(2-methylpyrimidin-5-yl)-3-(1-(trifluoromethyl)cyclopropyl)propanamido)propyl)-2-fluoro-3-methylbenzamide ("Compound 44")

[0447] [ka]

[0448] Compound 44 (18 mg, 49%) was synthesized from intermediate 30 and intermediate 9 as described in Example B1. MS (m / z): 510.2 (M+H).

[0449] Example B45: Preparation of 4-((S)-2-(dimethylamino)-3-((R)-3-(5-fluoropyridin-3-yl)-4,4-dimethylpentanamido)propyl)-2-fluoro-3-methylbenzamide ("Compound 45"):

[0450] [ka]

[0451] Compound 45 (18 mg, 36%) was synthesized from intermediate 30 and intermediate 34 as described in Example B17. MS (m / z): 461.2 (M+H).

[0452] Example B46: Preparation of 4-((S)-2-(dimethylamino)-3-((R)-3-(6-methylpyridin-3-yl)-3-(1-(trifluoromethyl)cyclopropyl)propanamido)propyl)-2-fluoro-3-methylbenzamide ("Compound 46"):

[0453] [ka]

[0454] Compound 46 (33 mg, 71%) was synthesized from intermediate 30 and intermediate 10 as described in Example B17. MS (m / z): 509.3 (M+H).

[0455] Example B47: Preparation of 4-((S)-2-(dimethylamino)-3-((R)-3-(6-methylpyridin-3-yl)-3-(1-(trifluoromethyl)cyclopropyl)propanamido)propyl)-2,6-difluorobenzamide ("Compound 47")

[0456] [ka]

[0457] Compound 47 (5 mg, 10%) was synthesized from intermediate 35 and intermediate 10 as described in Example B9. MS (m / z): 513.2 (M+H).

[0458] Example B48: Preparation of 4-((S)-2-(dimethylamino)-3-((R)-3-(2-methylpyrimidin-5-yl)-3-(1-(trifluoromethyl)cyclopropyl)propanamido)propyl)-2,6-difluorobenzamide ("Compound 48"):

[0459] [ka]

[0460] Compound 48 (12 mg, 20%) was synthesized from intermediate 35 and intermediate 9 as described in Example B9. MS (m / z): 514.2 (M+H).

[0461] Example B49: Preparation of 4-[(2S)-2-(dimethylamino)-3-[3-(6-methoxypyridin-3-yl)-3-[1-(trifluoromethyl)cyclopropyl]propanamido]propyl]-2,6-difluorobenzamide ("Compound 49")

[0462] [ka]

[0463] Compound 49 (15 mg, 45%) was synthesized from intermediate 35 and intermediate 25 as described in Example B9. MS (m / z): 529.3 (M+H).

[0464] Example B50: Preparation of 4-[(2S)-2-(dimethylamino)-3-[3-(pyridin-3-yl)-3-[1-(trifluoromethyl)cyclopropyl]propanamido]propyl]-2,6-difluorobenzamide ("Compound 50"):

[0465] [ka]

[0466] Compound 50 (30 mg, 51%) was synthesized from intermediate 35 and intermediate 28 as described in Example B9. MS (m / z): 499.2 (M+H).

[0467] Example B51: Preparation of 4-((S)-2-(dimethylamino)-3-((R)-3-(furan-3-yl)-3-(1-(trifluoromethyl)cyclopropyl)propanamido)propyl)-2-fluorobenzamide ("Compound 51"):

[0468] [ka]

[0469] Compound 51 (155 mg, 69%) was synthesized from Intermediate 2 and Intermediate 36 as described in Example B1. MS (m / z): 470.2 (M+H).

[0470] Example B52: Preparation of 4-((S)-2-(dimethylamino)-3-((S)-3-(5-methylthiophen-3-yl)-3-(1-(trifluoromethyl)cyclopropyl)propanamido)propyl)-2-fluorobenzamide ("Compound 52")

[0471] [ka]

[0472] Compound 52 (155 mg, 69%) was synthesized from Intermediate 2 and Intermediate 37 as described in Example B9. MS (m / z): 500.2 (M+H).

[0473] Example B53: Preparation of 4-((S)-2-(dimethylamino)-3-((S)-3-(5-methylthiophen-2-yl)-3-(1-(trifluoromethyl)cyclopropyl)propanamido)propyl)-2-fluorobenzamide ("Compound 53")

[0474] [ka]

[0475] Compound 53 (15 mg, 34%) was synthesized from Intermediate 2 and Intermediate 38 as described in Example B9. MS (m / z): 500.2 (M+H).

[0476] Example B54: Preparation of 4-((S)-2-(dimethylamino)-3-((S)-3-(thiophen-3-yl)-3-(1-(trifluoromethyl)cyclopropyl)propanamido)propyl)-2-fluorobenzamide ("Compound 54")

[0477] [ka]

[0478] Compound 54 (40 mg, 79%) was synthesized from Intermediate 2 and Intermediate 39 as described in Example B9. MS (m / z): 486.1 (M+H).

[0479] Example B55: Preparation of 4-((S)-2-(dimethylamino)-3-((S)-3-(thiazol-5-yl)-3-(1-(trifluoromethyl)cyclopropyl)propanamido)propyl)-2-fluorobenzamide ("Compound 55")

[0480] [ka]

[0481] Compound 55 (34 mg, 74%) was synthesized from Intermediate 2 and Intermediate 40 as described in Example B1. MS (m / z): 487.2 (M+H).

[0482] Example B56: Preparation of 4-((S)-2-(dimethylamino)-3-((S)-3-(5-methylthiazol-2-yl)-3-(1-(trifluoromethyl)cyclopropyl)propanamido)propyl)-2-fluorobenzamide ("Compound 56")

[0483] [ka]

[0484] Compound 56 (72 mg, 81%) was synthesized from Intermediate 2 and Intermediate 43 as described in Example B1. MS (m / z): 501.1 (M+H).

[0485] Example B57: Preparation of 4-((S)-2-(dimethylamino)-3-((S)-3-(5-methylpyrimidin-2-yl)-3-(1-(trifluoromethyl)cyclopropyl)propanamido)propyl)-2-fluorobenzamide ("Compound 57")

[0486] [ka]

[0487] A mixture of intermediate 2 (94.8 mg, 2 equiv., 396 μmol) and methyl (3S)-3-(5-methylpyrimidin-2-yl)-3-[1-(trifluoromethyl)cyclopropyl]propanoate (57.1 mg, 198 μmol) was heated neat at 150 °C for 4 h by microwave. The mixture was cooled to room temperature, dissolved in DCM, and purified by flash chromatography (0–15% MeOH / DCM) to give 4-[(2S)-2-(dimethylamino)-3-[(3R)-3-(5-methylpyrimidin-2-yl)-3-[1-(trifluoromethyl)cyclopropyl]propanamido]propyl]-2-fluorobenzamide (9.8 mg, 10%). MS (m / z): 496.2 (M+H).

[0488] Example B58: Preparation of 4-((S)-2-(dimethylamino)-3-((R)-3-(2-methylthiazol-5-yl)-3-(1-(trifluoromethyl)cyclopropyl)propanamido)propyl)-2-fluorobenzamide ("Compound 58")

[0489] [ka]

[0490] Compound 58 (59 mg, 68%) was synthesized from Intermediate 2 and Intermediate 42 as described in Example B1. MS (m / z): 501.2 (M+H).

[0491] Example B59: Preparation of 4-((S)-2-(dimethylamino)-3-((S)-3-(2-methylthiazol-5-yl)-3-(1-(trifluoromethyl)cyclopropyl)propanamido)propyl)-2-fluorobenzamide ("Compound 59")

[0492] [ka]

[0493] Compound 59 (72 mg, 81%) was synthesized from Intermediate 2 and Intermediate 43 as described in Example B1. MS (m / z): 501.2 (M+H).

[0494] Example B60: Preparation of 4-((S)-2-(dimethylamino)-3-((R)-5-methyl-3-(pyridin-3-yl)hexanamido)propyl)-2-fluorobenzamide ("Compound 60"):

[0495] [ka]

[0496] Compound 60 (31 mg, 68%) was synthesized from Intermediate 2 and Intermediate 45 as described in Example B9. MS (m / z): 429.2 (M+H).

[0497] Example B61: Preparation of 4-((S)-2-(dimethylamino)-3-((R)-3-(3-fluoropyridin-4-yl)-3-(1-(trifluoromethyl)cyclopropyl)propanamido)propyl)-2-fluorobenzamide ("Compound 61"):

[0498] [ka]

[0499] Compound 61 (31 mg, 68%) was synthesized from Intermediate 2 and Intermediate 47 as described in Example B9. MS (m / z): 499.2 (M+H).

[0500] Example B62: Preparation of 4-((S)-3-((S)-4-cyclopropyl-3-(pyridin-4-yl)butanamido)-2-(dimethylamino)propyl)-2-fluorobenzamide ("Compound 62"):

[0501] [ka]

[0502] Compound 62 (28 mg, 63%) was synthesized from Intermediate 2 and Intermediate 46 as described in Example B9. MS (m / z): 427.2 (M+H).

[0503] Example B63: Preparation of 4-((S)-2-(dimethylamino)-3-((R)-3-(5-fluoropyridin-3-yl)-4,4-dimethylpentanamido)propyl)-2-fluorobenzamide ("Compound 63"):

[0504] [ka]

[0505] Compound 63 (30 mg, 80%) was synthesized from Intermediate 2 and Intermediate 34 as described in Example B17. MS (m / z): 447.2 (M+H).

[0506] Example B64: Preparation of 4-((S)-3-((R)-4-cyclopropyl-3-(pyrimidin-5-yl)butanamido)-2-(dimethylamino)propyl)-2-fluorobenzamide ("Compound 64"):

[0507] [ka]

[0508] Compound 64 (24 mg, 54%) was synthesized from Intermediate 2 and Intermediate 48 as described in Example B9. MS (m / z): 427.2 (M+H).

[0509] Example B65: Preparation of 2-fluoro-4-((S)-3-((R)-3-(2-methylpyrimidin-5-yl)-3-(1-(trifluoromethyl)cyclopropyl)propanamido)-2-(pyrrolidin-1-yl)propyl)benzamide ("Compound 65"):

[0510] [ka]

[0511] Compound 65 (41 mg, 71%) was synthesized from Intermediate 2 and Intermediate 23G as described in Example B23. MS (m / z): 522.2 (M+H).

[0512] Example B66: Preparation of 4-((S)-3-((R)-4-cyclopropyl-3-(pyridin-3-yl)butanamido)-2-(dimethylamino)propyl)-2-fluorobenzamide ("Compound 66"):

[0513] [ka]

[0514] Compound 66 (14 mg, 43%) was synthesized from Intermediate 2 and Intermediate 49 as described in Example B9. MS (m / z): 427.3 (M+H).

[0515] Example B67: Preparation of 4-((S)-3-((S)-3-cyclopropyl-3-(2-methylpyrimidin-5-yl)propanamido)-2-(dimethylamino)propyl)-2-fluorobenzamide ("Compound 67"):

[0516] [ka]

[0517] Compound 67 (14 mg, 43%) was synthesized from Intermediate 2 and Intermediate 18 as described in Example B9. MS (m / z): 428.0 (M+H).

[0518] Example B68: Preparation of 4-((S)-2-(dimethylamino)-3-((R)-3-(2-methylpyrimidin-5-yl)-3-(1-(trifluoromethyl)cyclopropyl)propanamido)propyl)-2-fluorobenzamide ("Compound 68"):

[0519] [ka]

[0520] Compound 68 (14 mg, 43%) was synthesized from Intermediate 2 and Intermediate 9 as described in Example B9. MS (m / z): 496.3 (M+H).

[0521] Example B69: Preparation of 4-((2S)-3-(3-(5-chloropyridin-2-yl)-3-(1-(trifluoromethyl)cyclopropyl)propanamido)-2-(dimethylamino)propyl)-2-fluorobenzamide ("Compound 69"):

[0522] [ka]

[0523] Compound 69 (28 mg, 72%) was synthesized from Intermediate 2 and Intermediate 109 as described in Example B9. MS (m / z): 515.2 (M+H).

[0524] Example B70: Preparation of 4-[(2S)-2-(dimethylamino)-3-[3-(pyridin-4-yl)-3-[1-(trifluoromethyl)cyclopropyl]propanamido]propyl]-2-fluorobenzamide ("Compound 70"):

[0525] [ka]

[0526] Compound 70 (31 mg, 61%) was synthesized from Intermediate 2 and Intermediate 12 as described in Example B9. MS (m / z): 481.2 (M+H).

[0527] Example B71: Preparation of 4-[(2S)-2-(dimethylamino)-3-[3-(pyrimidin-2-yl)-3-[1-(trifluoromethyl)cyclopropyl]propanamido]propyl]-2-fluorobenzamide ("Compound 71"):

[0528] [ka]

[0529] Compound 71 (25 mg, 67%) was synthesized from Intermediate 2 and Intermediate 19 as described in Example B9. MS (m / z): 482.3 (M+H).

[0530] Example B72: Preparation of 4-[(2S)-2-(dimethylamino)-3-[3-(pyrimidin-5-yl)-3-[1-(trifluoromethyl)cyclopropyl]propanamido]propyl]-2-fluorobenzamide ("Compound 72"):

[0531] [ka]

[0532] Compound 72 (17.2 mg, 43%) was synthesized from Intermediate 2 and Intermediate 21 as described in Example B9. MS (m / z): 482.2 (M+H).

[0533] Example B73: Preparation of 4-[(2S)-3-[3-(5-chloropyrimidin-2-yl)-3-[1-(trifluoromethyl)cyclopropyl]propanamido]-2-(dimethylamino)propyl]-2-fluorobenzamide ("Compound 73")

[0534] [ka]

[0535] Compound 73 (10.2 mg, 17%) was synthesized from Intermediate 2 and Intermediate 101 as described in Example B9. MS (m / z): 516.2 (M+H).

[0536] Example B74: Preparation of 4-[(2S)-2-(dimethylamino)-3-[3-(pyridin-3-yl)-3-[1-(trifluoromethyl)cyclopropyl]propanamido]propyl]-2-fluorobenzamide ("Compound 74"):

[0537] [ka]

[0538] Compound 74 (34 mg, 70%) was synthesized from Intermediate 2 and Intermediate 15 as described in Example B9. MS (m / z): 481.2 (M+H).

[0539] Example B75: Preparation of 4-[(2S)-2-(dimethylamino)-3-[(3R)-3-(6-methylpyridin-3-yl)-3-[1-(trifluoromethyl)cyclopropyl]propanamido]propyl]-2-fluorobenzamide ("Compound 75"):

[0540] [ka]

[0541] Compound 75 (34 mg, 70%) was synthesized from Intermediate 2 and Intermediate 10 as described in Example B17. MS (m / z): 495.2 (M+H).

[0542] Example B76: Preparation of 4-[(2S)-2-(dimethylamino)-3-[3-(5-fluoropyridin-3-yl)-3-[1-(trifluoromethyl)cyclopropyl]propanamido]propyl]-2-fluorobenzamide ("Compound 76"):

[0543] [ka]

[0544] Compound 76 (36.4 mg, 67%) was synthesized from Intermediate 2 and Intermediate 26 as described in Example B9. MS (m / z): 499.2 (M+H).

[0545] Example B77: Preparation of 4-((S)-2-(dimethylamino)-3-((R)-3-phenyl-3-(1-(trifluoromethyl)cyclopropyl)propanamido)propyl)-2-fluorobenzamide ("Compound 77"):

[0546] [ka]

[0547] Compound 77 (27 mg, 58%) was synthesized from Intermediate 2 and Intermediate 3 as described in Example B17. MS (m / z): 480.3 (M+H).

[0548] Example B78: Preparation of 4-[(2S)-2-(dimethylamino)-3-[(3S)-4-methyl-3-(pyridin-3-yl)pentanamido]propyl]-2-fluorobenzamide ("Compound 78"):

[0549] [ka]

[0550] Compound 78 (20 mg, 32%) was synthesized from Intermediate 2 and Intermediate 50 as described in Example B17. MS (m / z): 415.2 (M+H).

[0551] Example B79: Preparation of 4-((S)-2-(dimethylamino)-3-((R)-3-(2-methylpyrimidin-5-yl)-3-(1-(trifluoromethyl)cyclopropyl)propanamido)propyl)benzamide ("Compound 79"):

[0552] [ka]

[0553] Compound 79 (20 mg, 32%) was synthesized from intermediate 73 and intermediate 9 as described in Example B9. MS (m / z): 478.2 (M+H).

[0554] Example B80: Preparation of 4-((S)-3-((R)-3-(3,4-dichlorophenyl)-3-(1-(trifluoromethyl)cyclopropyl)propanamido)-2-(dimethylamino)propyl)benzamide ("Compound 80"):

[0555] [ka]

[0556] Compound 80 (23.1 mg, 46%) was synthesized from intermediate 73 and intermediate 51 as described in Example B9. MS (m / z): 530.1 (M+H).

[0557] Example B81: Preparation of 4-((S)-2-(dimethylamino)-3-((S)-3-(pyridin-2-yl)-3-(1-(trifluoromethyl)cyclopropyl)propanamido)propyl)benzamide ("Compound 81"):

[0558] [ka]

[0559] Compound 81 (20 mg, 32%) was synthesized from intermediate 73 and intermediate 52 as described in Example B9. MS (m / z): 463.2 (M+H).

[0560] Example B82: Preparation of 4-((S)-2-(methylamino)-3-((S)-3-phenyl-3-(1-(trifluoromethyl)cyclopropyl)propanamido)propyl)benzamide ("Compound 82"):

[0561] [ka]

[0562] Step 1: Preparation of 4-((S)-2-(benzyl(methyl)amino)-3-((S)-3-phenyl-3-(1-(trifluoromethyl)cyclopropyl)propanamido)propyl)benzamide. To a solution of (3S)-3-phenyl-3-[1-(trifluoromethyl)cyclopropyl]propanoic acid (Intermediate 56, 31.0 mg, 0.120 mmol) and DIEA (31.4 uL, 0.180 mmol) in DMF (0.45 mL) was added TSTU (36.1 mg, 0.120 mmol) in one portion. The mixture was stirred at room temperature for 1 hour. To the reaction mixture was added 4-[(2S)-3-amino-2-[benzyl(methyl)amino]propyl]benzamide (Intermediate 53, 35.4 mg, 0.120 mmol), and stirring was continued for an additional 1 hour. The reaction mixture was diluted with ethyl acetate and saturated NaHCO3, water, and brine. The organic layer was dried over MgSO4, filtered, and concentrated. The crude material was purified by silica gel column (0-10% MeOH / DCM with 1% NH4OH) to give the title compound (49 mg, 77%). MS (m / z): 538.2 (M+H).

[0563] Step 2: Preparation of 4-((S)-2-(methylamino)-3-((S)-3-phenyl-3-(1-(trifluoromethyl)cyclopropyl)propanamido)propyl)benzamide. Compound 82A (44 mg, 0.0818 mmol) and 20% palladium hydroxide on carbon (Pd(OH) on carbon) (44 mg) in EtOH (10 mL) were treated with H at 55 psi for 6 hours. The catalyst was removed by filtration, rinsed with EtOH, and concentrated. The crude product was purified by reverse-phase preparative HPLC (on a C-18 column, 0-100% ACN with 0.1% TFA / water with 0.1% TFA). Pure fractions were combined, adjusted to pH 9 by adding saturated NaHCO (aqueous), extracted with DCM (3x), dried over MgSO, filtered, and concentrated to give the title compound (9 mg, 24%). MS(m / z):448.2(M+H).

[0564] Example B83: Preparation of 4-((S)-3-((R)-3-(4-chlorophenyl)-3-(1-(trifluoromethyl)cyclopropyl)propanamido)-2-(dimethylamino)propyl)benzamide ("Compound 83"):

[0565] [ka]

[0566] Compound 83 (51 mg, 84%) was synthesized from intermediate 73 and intermediate 54 as described in Example B17. MS (m / z): 496.2 (M+H).

[0567] Example B84: Preparation of 4-[(2S)-2-(dimethylamino)-3-[(3R)-3-(pyridin-2-yl)-3-[1-(trifluoromethyl)cyclopropyl]propanamido]propyl]benzamide ("Compound 84"):

[0568] [ka]

[0569] Compound 84 (151 mg, 54%) was synthesized from intermediate 73 and intermediate 55 as described in Example B9. MS (m / z): 463.2 (M+H).

[0570] Example B85: Preparation of 4-[(2S)-2-(methylamino)-3-[(3R)-3-phenyl-3-[1-(trifluoromethyl)cyclopropyl]propanamido]propyl]benzamide ("Compound 85"):

[0571] [ka]

[0572] Compound 85 (9 mg, 24%) was synthesized as described in Example B82. MS (m / z): 448.2 (M+H).

[0573] Example B86: Preparation of 4-[(2S)-2-[benzyl(methyl)amino]-3-[(3R)-3-phenyl-3-[1-(trifluoromethyl)cyclopropyl]propanamido]propyl]benzamide ("Compound 86"):

[0574] [ka]

[0575] Compound 86 (49 mg, 77%) was synthesized as described in Example B82. MS (m / z): 538.2 (M+H).

[0576] Example B87: Preparation of 4-[(2S)-2-amino-3-[(3R)-3-phenyl-3-[1-(trifluoromethyl)cyclopropyl]propanamido]propyl]benzamide ("Compound 87"):

[0577] [ka]

[0578] Step 1: Preparation of tert-butyl N-[(2S)-1-(4-carbamoylphenyl)-3-[(3R)-3-phenyl-3-[1-(trifluoromethyl)cyclopropyl]propanamido]propan-2-yl]carbamate (87A). To a solution of the acid (Intermediate 3, 31.0 mg, 0.120 mmol) and DIEA (31.4 uL, 0.180 mmol) in DMF (0.45 mL) was added TSTU (36.1 mg, 0.120 mmol) in one portion. The mixture was stirred at room temperature for 1 hour. To the reaction mixture was added an amine (35.2 mg, 0.120 mmol), and stirring was continued for an additional 1 hour. The reaction mixture was diluted with ethyl acetate (15 mL) and saturated NaHCO3, water, and brine. The organic layer was dried over MgSO4, filtered, and concentrated. The crude material was purified by silica gel column (0-10% MeOH / DCM with 1% NH4OH) to give the title compound (52 mg, 81%). MS (m / z): 556.3 (M+H).

[0579] Step 2: Preparation of 4-[(2S)-2-amino-3-[(3R)-3-phenyl-3-[1-(trifluoromethyl)cyclopropyl]propanamido]propyl]benzamide (Compound 87). Compound 87A (50 mg, 0.0937 mmol) in MeOH (0.5 mL) was treated with 4 N HCl in dioxane (0.5 mL) at room temperature for 2 hours. The solvent was removed by rotary evaporation and triturated with ethyl ether. The precipitated solid was filtered, washed with ether, and dried under vacuum to give the title compound as the HCl salt (48 mg, 100%). MS (m / z): 434.2 (M+H).

[0580] Example B88: Preparation of 4-[(2S)-2-(dimethylamino)-3-[(3S)-3-phenyl-3-[1-(trifluoromethyl)cyclopropyl]propanamido]propyl]benzamide ("Compound 88"):

[0581] [ka]

[0582] Compound 88 (77.2 mg, 41%) was synthesized from intermediate 73 and intermediate 56 as described in Example B9. MS (m / z): 462.2 (M+H).

[0583] Example B89: Preparation of 4-[(2S)-2-(dimethylamino)-3-[(3R)-3-phenyl-3-[1-(trifluoromethyl)cyclopropyl]propanamido]propyl]benzamide ("Compound 89"):

[0584] [ka]

[0585] Compound 89 (377 mg, 86%) was synthesized from Intermediate 73 and Intermediate 3 as described in Example B9. MS (m / z): 462.2 (M+H).

[0586] Example B90: Preparation of 4-[(2S)-3-[(3S)-4-cyclobutyl-3-phenylbutanamido]-2-(dimethylamino)propyl]benzamide ("Compound 90"):

[0587] [ka]

[0588] Compound 90 (89.9 mg, 27%) was synthesized from intermediate 73 and intermediate 57 as described in Example B9. MS (m / z): 422.2 (M+H).

[0589] Example B91: Preparation of 4-[(2S)-2-(dimethylamino)-3-[(3S)-5-methyl-3-phenylhexanamido]propyl]benzamide ("Compound 91"):

[0590] [ka]

[0591] Compound 91 (620 mg, 60%) was synthesized from intermediate 73 and intermediate 68 as described in Example B9. MS (m / z): 410.3 (M+H).

[0592] Example B92: Preparation of 4-((S)-2-(dimethylamino)-3-((R)-4-methyl-3-phenylpentanamido)propyl)benzamide ("Compound 92"):

[0593] [ka]

[0594] Compound 92 (26 mg, 58%) was synthesized from intermediate 73 and intermediate 66 as described in Example B9. MS (m / z): 396.3 (M+H).

[0595] Example B93: Preparation of 4-[(2S)-3-[(3R)-4,4-dimethyl-3-phenylpentanamido]-2-(dimethylamino)propyl]benzamide ("Compound 93"):

[0596] [ka]

[0597] Compound 93 (49 mg, 66%) was synthesized from intermediate 73 and intermediate 69 as described in Example B9. MS (m / z): 410.2 (M+H).

[0598] Example B94: Preparation of 4-[(2S)-2-(dimethylamino)-3-[(3S)-4-methyl-3-phenylpentanamido]propyl]benzamide ("Compound 94"):

[0599] [ka]

[0600] Compound 94 (45 mg, 72%) was synthesized from intermediate 73 and intermediate 94 as described in Example B9. MS (m / z): 396.5 (M+H).

[0601] Example B95: Preparation of 4-((S)-3-((R)-4,4-dimethyl-3-phenylpentanamido)-2-(dimethylamino)propyl)benzamide ("Compound 95"):

[0602] [ka]

[0603] Compound 95 (51 mg, 69%) was synthesized from intermediate 73 and intermediate 69 as described in Example B9. MS (m / z): 410.3 (M+H).

[0604] Example B96: Preparation of 4-((S)-2-(dimethylamino)-3-((R)-5-methyl-3-phenylhexanamido)propyl)benzamide ("Compound 96"):

[0605] [ka]

[0606] Compound 96 (48 mg, 74%) was synthesized from intermediate 73 and intermediate 67 as described in Example B9. MS (m / z): 410.3 (M+H).

[0607] Example B97: Preparation of 4-((S)-3-((R)-3-cyclopropyl-3-phenylpropanamido)-2-(dimethylamino)propyl)benzamide ("Compound 97"):

[0608] [ka]

[0609] Compound 97 (10 mg, 21%) was synthesized from intermediate 73 and intermediate 64 as described in Example B9. MS (m / z): 394.3 (M+H).

[0610] Example B98: Preparation of 4-((S)-2-(dimethylamino)-3-((R)-3-phenylbutanamido)propyl)benzamide ("Compound 98"):

[0611] [ka]

[0612] Compound 98 (152 mg, 55%) was synthesized from intermediate 73 and intermediate 61 as described in Example B9. MS (m / z): 368.2 (M+H).

[0613] Example B99: Preparation of 4-((S)-2-(dimethylamino)-3-((S)-3-phenylbutanamido)propyl)benzamide ("Compound 99"):

[0614] [ka]

[0615] Compound 99 (118 mg, 65%) was synthesized from intermediate 73 and intermediate 62 as described in Example B9. MS (m / z): 368.2 (M+H).

[0616] Example B100: Preparation of 4-((S)-2-(dimethylamino)-3-((S)-3-phenylbutanamido)propyl)-3,5-dimethylbenzamide ("Compound 100"):

[0617] [ka]

[0618] Compound 100 (190 mg, 52%) was synthesized from intermediate 74 and intermediate 62 as described in Example B9. MS (m / z): 396.3 (M+H).

[0619] Example B101: Preparation of 4-((S)-3-((S)-4,4-dimethyl-3-phenylpentanamido)-2-(dimethylamino)propyl)-2-fluoro-N-(2,2,2-trifluoroethyl)benzamide ("Compound 101"):

[0620] [ka]

[0621] Compound 101 (59 mg, 45%) was synthesized as described in Example B17. MS (m / z): 510.3 (M+H).

[0622] Example B102: Preparation of (R)—N-((S)-2-(dimethylamino)-3-(2-oxo-1,2-dihydroquinolin-6-yl)propyl)-3-(pyridin-3-yl)-3-(1-(trifluoromethyl)cyclopropyl)propanamide (“Compound 102”)

[0623] [ka]

[0624] Step 1: Preparation of (R)-N-((S)-2-(dimethylamino)-3-(2-methoxyquinolin-6-yl)propyl)-3-(pyridin-3-yl)-3-(1-(trifluoromethyl)cyclopropyl)propanamide (102A). To a stirred mixture of [(2S)-1-amino-3-(2-methoxyquinolin-6-yl)propan-2-yl]dimethylamine) (29.3 mg, 113 μmol), (3S)-3-(pyridin-3-yl)-3-[1-(trifluoromethyl)cyclopropyl]propanoic acid (30.8 mg, 1.1 equivalents, 119 μmol), and DIEA (30.0 μL, 1.5 equivalents, 169 μmol) in DMF (1 mL) at room temperature was added HATU (51.5 mg, 1.2 equivalents, 136 μmol). The reaction mixture was stirred at room temperature for 1 hour. HO was added and extracted with EtOAc (3x). The combined extracts were dried over MgSO, concentrated, and purified by flash chromatography (0-10% MeOH / DCM) to give (3S)-N-[(2S)-2-(dimethylamino)-3-(2-methoxyquinolin-6-yl)propyl]-3-(pyridin-3-yl)-3-[1-(trifluoromethyl)cyclopropyl]propanamide (56.0 mg, 99%). MS (m / z). 501.1 (M+H).

[0625] Step 2: Preparation of (R)—N-((S)-2-(dimethylamino)-3-(2-oxo-1,2-dihydroquinolin-6-yl)propyl)-3-(pyridin-3-yl)-3-(1-(trifluoromethyl)cyclopropyl)propanamide (Compound 102): To a stirred solution of (3S)—N-[(2S)-2-(dimethylamino)-3-(2-methoxyquinolin-6-yl)propyl]-3-(pyridin-3-yl)-3-[1-(trifluoromethyl)cyclopropyl]propanamide (56.0 mg, 112 μmol) in p-dioxane (2 mL) was added hydrogen chloride (186 μL, 10 equiv., 1.12 mmol). The reaction mixture was stirred at 60° C. for 16 hours and then ramped to 100° C. for 4 hours. LC / MS showed no SM remained. The mixture was cooled, concentrated to dryness, diluted with HO, basified with 10 N NaOH to pH = 5-6, and extracted with DCM (3x). The combined extracts were dried over MgSO, concentrated, and purified by flash chromatography (0-15% MeOH / DCM) to give compound 102 (18.9 mg, 35%). MS (m / z): 487.2 (M+H).

[0626] Example B103: Preparation of (R)—N-((S)-2-(dimethylamino)-3-(2-oxo-1,2-dihydroquinolin-6-yl)propyl)-3-(pyridin-4-yl)-3-(1-(trifluoromethyl)cyclopropyl)propanamide (“Compound 103”)

[0627] [ka]

[0628] Compound 103 (23.7 mg, 32%) was synthesized as described in Example B102. MS (m / z): 487.2 (M+H).

[0629] Example B104: Preparation of 4-((S)-3-((S)-4,4-dimethyl-3-phenylpentanamido)-2-(dimethylamino)propyl)-2,5-difluoro-N-methylbenzamide ("Compound 104"):

[0630] [ka]

[0631] Compound 104 (226 mg, 60%) was synthesized from Intermediate 94 and Intermediate 70 as described in Example B9. MS (m / z): 460.2 (M+H).

[0632] Example B105: Preparation of 4-((S)-2-(dimethylamino)-3-((R)-3-(2-methylpyrimidin-5-yl)-3-(1-(trifluoromethyl)cyclopropyl)propanamido)propyl)-3,5-difluoro-N-methylbenzamide ("Compound 105")

[0633] [ka]

[0634] Compound 105 (226 mg, 60%) was synthesized from Intermediate 95 and Intermediate 9 as described in Example B9. MS (m / z): 528.2 (M+H).

[0635] Example B106: Preparation of 4-((S)-3-((R)-3-(4-chlorophenyl)-3-(1-(trifluoromethyl)cyclopropyl)propanamido)-2-(dimethylamino)propyl)-N,3,5-trimethylbenzamide ("Compound 106"):

[0636] [ka]

[0637] Compound 106 (36 mg, 78%) was synthesized from intermediate 96 and intermediate 54 as described in Example B9. MS (m / z): 539.2 (M+H).

[0638] Example B107: Preparation of 4-((S)-3-((R)-3-(4-chlorophenyl)-3-(1-(trifluoromethyl)cyclopropyl)propanamido)-2-(dimethylamino)propyl)-2-fluoro-N-methylbenzamide ("Compound 107")

[0639] [ka]

[0640] Compound 107 (33 mg, 75%) was synthesized from intermediate 97 and intermediate 54 as described in Example B9. MS (m / z): 529.2 (M+H).

[0641] Example B108: Preparation of 4-((S)-2-(dimethylamino)-3-((R)-5-methyl-3-(pyridin-2-yl)hexanamido)propyl)-N,3,5-trimethylbenzamide ("Compound 108"):

[0642] [ka]

[0643] Compound 108 (9 mg, 18%) was synthesized from intermediate 96 and intermediate 98 as described in Example B9. MS (m / z): 453.2 (M+H).

[0644] Example B109: Preparation of 3-chloro-4-((S)-2-(dimethylamino)-3-((S)-3-(pyridin-3-yl)-3-(1-(trifluoromethyl)cyclopropyl)propanamido)propyl)-2-fluoro-N-methylbenzamide ("Compound 109"):

[0645] [ka]

[0646] Compound 109 (15 mg, 45%) was synthesized from intermediate 99 and intermediate 15 as described in Example B9. MS (m / z): 529.2 (M+H).

[0647] Example B110: Preparation of 3-chloro-4-((S)-2-(dimethylamino)-3-((S)-3-(pyridin-4-yl)-3-(1-(trifluoromethyl)cyclopropyl)propanamido)propyl)-2-fluoro-N-methylbenzamide ("Compound 110"):

[0648] [ka]

[0649] Compound 110 (15 mg, 63%) was synthesized from intermediate 99 and intermediate 100 as described in Example B9. MS (m / z): 529.2 (M+H).

[0650] Example B111: Preparation of 3-chloro-4-((S)-2-(dimethylamino)-3-((R)-3-(pyridin-4-yl)-3-(1-(trifluoromethyl)cyclopropyl)propanamido)propyl)-2-fluoro-N-methylbenzamide ("Compound 111"):

[0651] [ka]

[0652] Compound 111 (46 mg, 82%) was synthesized from intermediate 99 and intermediate 59 as described in Example B9. MS (m / z): 529.2 (M+H).

[0653] Example B112: Preparation of 3-chloro-4-((2S)-3-(3-(5-chloropyrimidin-2-yl)-3-(1-(trifluoromethyl)cyclopropyl)propanamido)-2-(dimethylamino)propyl)-2-fluoro-N-methylbenzamide ("Compound 112"):

[0654] [ka]

[0655] Compound 112 (33 mg, 78%) was synthesized from intermediate 99 and intermediate 101 as described in Example B9. MS (m / z): 564.2 (M+H).

[0656] Example B113: Preparation of 3-chloro-4-((S)-2-(dimethylamino)-3-((R)-3-(6-methylpyridin-3-yl)-3-(1-(trifluoromethyl)cyclopropyl)propanamido)propyl)-N-methylbenzamide ("Compound 113"):

[0657] [ka]

[0658] Compound 113 (42 mg, 74%) was synthesized from intermediate 102 and intermediate 10 as described in Example B9. MS (m / z): 525.2 (M+H).

[0659] Example B114: Preparation of 3-chloro-4-((S)-3-((R)-3-(5-chloropyridin-3-yl)-3-(1-(trifluoromethyl)cyclopropyl)propanamido)-2-(dimethylamino)propyl)-N-methylbenzamide ("Compound 114")

[0660] [ka]

[0661] Compound 114 (47 mg, 54%) was synthesized from intermediate 102 and intermediate 103 as described in Example B9. MS (m / z): 545.2 (M+H).

[0662] Example B115: Preparation of 3-chloro-4-((2S)-2-(dimethylamino)-3-(3-(6-methoxypyridin-3-yl)-3-(1-(trifluoromethyl)cyclopropyl)propanamido)propyl)-N-methylbenzamide ("Compound 115")

[0663] [ka]

[0664] Compound 115 (50 mg, 65%) was synthesized from intermediate 102 and intermediate 25 as described in Example B9. MS (m / z): 541.2 (M+H).

[0665] Example B116: Preparation of 3-chloro-4-((2S)-2-(dimethylamino)-3-(3-(6-methoxypyridin-3-yl)-3-(1-(trifluoromethyl)cyclopropyl)propanamido)propyl)-N-methylbenzamide ("Compound 116"):

[0666] [ka]

[0667] Compound 116 (45 mg, 65%) was synthesized from intermediate 102 and intermediate 26 as described in Example B9. MS (m / z): 529.3 (M+H).

[0668] Example B117: Preparation of 3-chloro-4-((2S)-2-(dimethylamino)-3-(3-(5-methoxypyridin-3-yl)-3-(1-(trifluoromethyl)cyclopropyl)propanamido)propyl)-N-methylbenzamide ("Compound 117")

[0669] [ka]

[0670] Compound 117 (25 mg, 42%) was synthesized from intermediate 102 and intermediate 104 as described in Example B9. MS (m / z): 541.3 (M+H).

[0671] Example B118: Preparation of 3-chloro-4-((2S)-2-(dimethylamino)-3-(3-(4-methylpyridin-2-yl)-3-(1-(trifluoromethyl)cyclopropyl)propanamido)propyl)-N-methylbenzamide ("Compound 118"):

[0672] [ka]

[0673] Compound 118 (25 mg, 42%) was synthesized from intermediate 102 and intermediate 105 as described in Example B9. MS (m / z): 525.2 (M+H).

[0674] Example B119: Preparation of 3-chloro-4-((2S)-2-(dimethylamino)-3-(3-(pyridin-3-yl)-3-(1-(trifluoromethyl)cyclopropyl)propanamido)propyl)-N-methylbenzamide ("Compound 119"):

[0675] [ka]

[0676] Compound 119 (36 mg, 74%) was synthesized from intermediate 102 and intermediate 106 as described in Example B9. MS (m / z): 511.2 (M+H).

[0677] Example B120: Preparation of 3-chloro-4-((2S)-2-(dimethylamino)-3-(3-(3-fluoropyridin-2-yl)-3-(1-(trifluoromethyl)cyclopropyl)propanamido)propyl)-N-methylbenzamide ("Compound 120")

[0678] [ka]

[0679] Compound 120 (36 mg, 74%) was synthesized from intermediate 102 and intermediate 107 as described in Example B9. MS (m / z): 529.2 (M+H).

[0680] Example B121: Preparation of 3-chloro-4-((2S)-2-(dimethylamino)-3-(3-(5-fluoropyridin-2-yl)-3-(1-(trifluoromethyl)cyclopropyl)propanamido)propyl)-N-methylbenzamide ("Compound 121"):

[0681] [ka]

[0682] Compound 121 (16 mg, 33%) was synthesized from intermediate 102 and intermediate 108 as described in Example B9. MS (m / z): 529.3 (M+H).

[0683] Example B122: Preparation of 3-chloro-4-((2S)-3-(3-(5-chloropyridin-2-yl)-3-(1-(trifluoromethyl)cyclopropyl)propanamido)-2-(dimethylamino)propyl)-N-methylbenzamide ("Compound 122"):

[0684] [ka]

[0685] Compound 122 (16 mg, 35%) was synthesized from intermediate 102 and intermediate 109 as described in Example B9. MS (m / z): 545.2 (M+H).

[0686] Example B123: Preparation of 4-((S)-2-(dimethylamino)-3-((S)-3-(2-methylthiazol-5-yl)-3-(1-(trifluoromethyl)cyclopropyl)propanamido)propyl)-3-fluoro-N-methylbenzamide ("Compound 123"):

[0687] [ka]

[0688] Compound 123 (33 mg, 63%) was synthesized from intermediate 110 and intermediate 6 as described in Example B9. MS (m / z): 515.2 (M+H).

[0689] Example B124: Preparation of 4-((S)-2-(dimethylamino)-3-((S)-3-(pyridin-3-yl)-3-(1-(trifluoromethyl)cyclopropyl)propanamido)propyl)-2-fluoro-N,3-dimethylbenzamide ("Compound 124")

[0690] [ka]

[0691] Compound 124 (35 mg, 71%) was synthesized from intermediate 111 and intermediate 15 as described in Example B9. MS (m / z): 509.2 (M+H).

[0692] Example B125: Preparation of 4-((S)-2-(dimethylamino)-3-((R)-3-(6-methylpyridin-3-yl)-3-(1-(trifluoromethyl)cyclopropyl)propanamido)propyl)-2-fluoro-N,3-dimethylbenzamide ("Compound 125")

[0693] [ka]

[0694] Compound 125 (26 mg, 56%) was synthesized from intermediate 111 and intermediate 10 as described in Example B9. MS (m / z): 523.2 (M+H).

[0695] Example B126: Preparation of 4-((S)-2-(dimethylamino)-3-((R)-5-methyl-3-(pyridin-3-yl)hexanamido)propyl)-N,3-dimethylbenzamide ("Compound 126"):

[0696] [ka]

[0697] Compound 126 (30 mg, 59%) was synthesized from intermediate 112 and intermediate 113 as described in Example B9. MS (m / z): 439.3 (M+H).

[0698] Example B127: Preparation of 4-((S)-2-(dimethylamino)-3-((R)-3-(3-fluoropyridin-4-yl)-3-(1-(trifluoromethyl)cyclopropyl)propanamido)propyl)-N,3-dimethylbenzamide ("Compound 127"):

[0699] [ka]

[0700] Compound 127 (10 mg, 39%) was synthesized from intermediate 112 and intermediate 114 as described in Example B9. MS (m / z): 509.2 (M+H).

[0701] Example B128: Preparation of 4-((S)-2-(dimethylamino)-3-((R)-3-(4-fluorophenyl)-3-(1-(trifluoromethyl)cyclopropyl)propanamido)propyl)-N,3-dimethylbenzamide ("Compound 128"):

[0702] [ka]

[0703] Compound 128 (32 mg, 78%) was synthesized from intermediate 112 and intermediate 115 as described in Example B9. MS (m / z): 508.3 (M+H).

[0704] Example B129: Preparation of 4-((S)-3-((S)-4,4-dimethyl-3-(pyridin-3-yl)pentanamido)-2-(dimethylamino)propyl)-N,3-dimethylbenzamide ("Compound 129"):

[0705] [ka]

[0706] Compound 129 (14 mg, 63%) was synthesized from intermediate 112 and intermediate 116 as described in Example B9. MS (m / z): 439.3 (M+H).

[0707] Example B130: Preparation of 4-((S)-2-(dimethylamino)-3-((S)-3-(pyridin-4-yl)-3-(1-(trifluoromethyl)cyclopropyl)propanamido)propyl)-N,3-dimethylbenzamide ("Compound 130")

[0708] [ka]

[0709] Compound 130 (32 mg, 78%) was synthesized from intermediate 112 and intermediate 59 as described in Example B9. MS (m / z): 491.3 (M+H).

[0710] Example B131: Preparation of 4-((S)-2-(dimethylamino)-3-((R)-3-(pyridin-3-yl)-3-(1-(trifluoromethyl)cyclopropyl)propanamido)propyl)-N,3-dimethylbenzamide ("Compound 131"):

[0711] [ka]

[0712] Compound 131 (32 mg, 78%) was synthesized from intermediate 112 and intermediate 15 as described in Example B9. MS (m / z): 491.3 (M+H).

[0713] Example B132: Preparation of 4-((S)-2-(dimethylamino)-3-((R)-3-(6-methylpyridin-3-yl)-3-(1-(trifluoromethyl)cyclopropyl)propanamido)propyl)-N,3-dimethylbenzamide ("Compound 132"):

[0714] [ka]

[0715] Compound 132 (32 mg, 78%) was synthesized from intermediate 112 and intermediate 10 as described in Example B9. MS (m / z): 505.3 (M+H).

[0716] Example B133: Preparation of 4-((S)-3-((R)-4-cyclopropyl-3-(pyridin-3-yl)butanamido)-2-(dimethylamino)propyl)-N,3-dimethylbenzamide ("Compound 133"):

[0717] [ka]

[0718] Compound 133 (32 mg, 78%) was synthesized from intermediate 112 and intermediate 49 as described in Example B9. MS (m / z): 437.3 (M+H).

[0719] Example B134: Preparation of 4-((2S)-2-(dimethylamino)-3-(3-(pyridin-4-yl)-3-(1-(trifluoromethyl)cyclopropyl)propanamido)propyl)-N,3-dimethylbenzamide ("Compound 134")

[0720] [ka]

[0721] Compound 134 (28 mg, 70%) was synthesized from intermediate 112 and intermediate 12 as described in Example B9. MS (m / z): 491.2 (M+H).

[0722] Example B135: Preparation of 4-((S)-2-(dimethylamino)-3-((R)-3-(2-methylpyrimidin-5-yl)-3-(1-(trifluoromethyl)cyclopropyl)propanamido)propyl)-N,3-dimethylbenzamide ("Compound 135"):

[0723] [ka]

[0724] Compound 135 (28 mg, 70%) was synthesized from intermediate 112 and intermediate 9 as described in Example B9. MS (m / z): 506.3 (M+H).

[0725] Example B136: Preparation of 4-((S)-3-((R)-3-(3,5-difluorophenyl)-3-(1-(trifluoromethyl)cyclopropyl)propanamido)-2-(dimethylamino)propyl)-N,3-dimethylbenzamide ("Compound 136"):

[0726] [ka]

[0727] Compound 136 (18 mg, 64%) was synthesized from intermediate 112 and intermediate 117 as described in Example B9. MS (m / z): 526.2 (M+H).

[0728] Example B137: Preparation of 4-((S)-3-((R)-3-(5-chloropyridin-2-yl)-3-(1-(trifluoromethyl)cyclopropyl)propanamido)-2-(dimethylamino)propyl)-N,3-dimethylbenzamide ("Compound 137"):

[0729] [ka]

[0730] Compound 137 (18 mg, 64%) was synthesized from intermediate 112 and intermediate 118 as described in Example B9. MS (m / z): 525.2 (M+H).

[0731] Example B138: Preparation of 4-((S)-3-((S)-3-(5-chloropyridin-2-yl)-3-(1-(trifluoromethyl)cyclopropyl)propanamido)-2-(dimethylamino)propyl)-N,3-dimethylbenzamide ("Compound 138"):

[0732] [ka]

[0733] Compound 138 (27 mg, 74%) was synthesized from intermediate 112 and intermediate 119 as described in Example B9. MS (m / z): 525.2 (M+H).

[0734] Example B139: Preparation of 4-((S)-3-((S)-4-cyclopropyl-3-(pyridin-2-yl)butanamido)-2-(dimethylamino)propyl)-N,3-dimethylbenzamide ("Compound 139"):

[0735] [ka]

[0736] Compound 139 (10 mg, 67%) was synthesized from intermediate 112 and intermediate 120 as described in Example B9. MS (m / z): 437.2 (M+H).

[0737] Example B140: Preparation of 4-((S)-2-(dimethylamino)-3-((R)-5-methyl-3-(pyridin-2-yl)hexanamido)propyl)-N,3-dimethylbenzamide ("Compound 140"):

[0738] [ka]

[0739] Compound 140 (32 mg, 83%) was synthesized from intermediate 112 and intermediate 98 as described in Example B9. MS (m / z): 439.3 (M+H).

[0740] Example B141: Preparation of 4-((2S)-2-(dimethylamino)-3-(3-(pyridin-2-yl)-3-(1-(trifluoromethyl)cyclopropyl)propanamido)propyl)-N,3-dimethylbenzamide ("Compound 141"):

[0741] [ka]

[0742] Compound 141 was synthesized from intermediate 112 and intermediate 121 as described in Example B9. MS (m / z): 491.3 (M+H).

[0743] Example B142: Preparation of 4-((S)-3-((R)-3-(4-chlorophenyl)-3-(1-(trifluoromethyl)cyclopropyl)propanamido)-2-(dimethylamino)propyl)-N,3-dimethylbenzamide ("Compound 142"):

[0744] [ka]

[0745] Compound 142 was synthesized from intermediate 112 and intermediate 54 as described in Example B9. MS (m / z): 524.2 (M+H).

[0746] Example B143: Preparation of 4-((S)-2-(dimethylamino)-3-((R)-3-phenyl-3-(1-(trifluoromethyl)cyclopropyl)propanamido)propyl)-N,3-dimethylbenzamide ("Compound 143"):

[0747] [ka]

[0748] Compound 143 was synthesized from intermediate 112 and intermediate 3 as described in Example B9. MS (m / z): 490.3 (M+H).

[0749] Example B144: Preparation of 4-((S)-2-(dimethylamino)-3-((R)-3-phenyl-3-(1-(trifluoromethyl)cyclopropyl)propanamido)propyl)-2-fluoro-N,5-dimethylbenzamide ("Compound 144"):

[0750] [ka]

[0751] Compound 144 (25 mg, 79%) was synthesized from intermediate 122 and intermediate 3 as described in Example B9. MS (m / z): 508.2 (M+H).

[0752] Example B145: Preparation of 4-((S)-2-(dimethylamino)-3-((R)-3-phenyl-3-(1-(trifluoromethyl)cyclopropyl)propanamido)propyl)-2-fluoro-N,5-dimethylbenzamide ("Compound 145"):

[0753] [ka]

[0754] Compound 145 (43 mg, 71%) was synthesized from intermediate 112 and intermediate 61 as described in Example B9. MS (m / z): 396.3 (M+H).

[0755] Example B146: Preparation of 4-((S)-3-((R)-4,4-dimethyl-3-phenylpentanamido)-2-(dimethylamino)propyl)-2-fluoro-N,5-dimethylbenzamide ("Compound 146"):

[0756] [ka]

[0757] Compound 146 (52 mg, 76%) was synthesized from intermediate 122 and intermediate 69 as described in Example B9. MS (m / z): 456.3 (M+H).

[0758] Example B147: Preparation of 2-chloro-4-((S)-2-(dimethylamino)-3-((R)-5-methyl-3-phenylhexanamido)propyl)-N-methylbenzamide ("Compound 147"):

[0759] [ka]

[0760] Compound 147 (35 mg, 63%) was synthesized from intermediate 123 and intermediate 67 as described in Example B9. MS (m / z): 458.3 (M+H).

[0761] Example B148: Preparation of 2-chloro-4-((S)-2-(dimethylamino)-3-((S)-4-methyl-3-phenylpentanamido)propyl)-N-methylbenzamide ("Compound 148"):

[0762] [ka]

[0763] Compound 148 (35 mg, 67%) was synthesized from intermediate 123 and intermediate 65 as described in Example B9. MS (m / z): 444.3 (M+H).

[0764] Example B149: Preparation of 2-chloro-4-((S)-2-(dimethylamino)-3-((R)-3-phenylbutanamido)propyl)-N-methylbenzamide ("Compound 149"):

[0765] [ka]

[0766] Compound 149 (22 mg, 81%) was synthesized from intermediate 123 and intermediate 61 as described in Example B9. MS (m / z): 416.2 (M+H).

[0767] Example B150: Preparation of 2-chloro-4-((S)-3-((S)-4,4-dimethyl-3-phenylpentanamido)-2-(dimethylamino)propyl)-N-methylbenzamide ("Compound 150"):

[0768] [ka]

[0769] Compound 150 (22 mg, 81%) was synthesized from intermediate 123 and intermediate 70 as described in Example B9. MS (m / z): 458.3 (M+H).

[0770] Example B151: Preparation of 4-((S)-2-(dimethylamino)-3-((R)-3-(5-fluoropyridin-3-yl)-4,4-dimethylpentanamido)propyl)-2-fluoro-N-methylbenzamide ("Compound 151"):

[0771] [ka]

[0772] Compound 151 (22 mg, 81%) was synthesized from intermediate 97 and intermediate 34 as described in Example B9. MS (m / z): 461.3 (M+H).

[0773] Example B152: Preparation of 4-((S)-2-(dimethylamino)-3-((R)-3-(2-methylpyrimidin-5-yl)-3-(1-(trifluoromethyl)cyclopropyl)propanamido)propyl)-2-fluoro-N-methylbenzamide ("Compound 152"):

[0774] [ka]

[0775] Compound 152 (40 mg, 74%) was synthesized from Intermediate 97 and Intermediate 9 as described in Example B9. MS (m / z): 510.3 (M+H).

[0776] Example B153: Preparation of 4-((S)-2-(dimethylamino)-3-((R)-3-(pyridin-2-yl)-3-(1-(trifluoromethyl)cyclopropyl)propanamido)propyl)-2-fluoro-N-methylbenzamide ("Compound 153"):

[0777] [ka]

[0778] Compound 153 (19 mg, 54%) was synthesized from intermediate 97 and intermediate 55 as described in Example B9. MS (m / z): 495.2 (M+H).

[0779] Example B154: Preparation of 4-((S)-2-(dimethylamino)-3-((S)-3-phenyl-3-(1-(trifluoromethyl)cyclopropyl)propanamido)propyl)-2-fluoro-N-methylbenzamide ("Compound 154"):

[0780] [ka]

[0781] Compound 154 (25 mg, 77%) was synthesized from intermediate 97 and intermediate 56 as described in Example B9. MS (m / z): 494.3 (M+H).

[0782] Example B155: Preparation of 4-((S)-3-((R)-3-(4-chlorophenyl)butanamido)-2-(dimethylamino)propyl)-2-fluoro-N-methylbenzamide ("Compound 155"):

[0783] [ka]

[0784] Compound 155 (71 mg, 83%) was synthesized from intermediate 97 and intermediate 124 as described in Example B9. MS (m / z): 434.2 (M+H).

[0785] Example B156: Preparation of 4-((S)-3-((S)-3-(4-chlorophenyl)butanamido)-2-(dimethylamino)propyl)-2-fluoro-N-methylbenzamide ("Compound 156"):

[0786] [ka]

[0787] Compound 156 (41 mg, 63%) was synthesized from intermediate 97 and intermediate 125 as described in Example B9. MS (m / z): 434.2 (M+H).

[0788] Example B157: Preparation of 4-((S)-3-((S)-4,4-dimethyl-3-phenylpentanamido)-2-(pyrrolidin-1-yl)propyl)-2-fluoro-N-methylbenzamide ("Compound 157"):

[0789] [ka]

[0790] Compound 157 (41 mg, 63%) was synthesized from intermediate 131 and intermediate 70 as described in Example B9. MS (m / z): 468.3 (M+H).

[0791] Example B158: Preparation of 4-((S)-3-((S)-4,4-dimethyl-3-phenylpentanamido)-2-(dimethylamino)propyl)-2-fluoro-N-methylbenzamide ("Compound 158"):

[0792] [ka]

[0793] Compound 158 (42 mg, 77%) was synthesized from intermediate 97 and intermediate 70 as described in Example B9. MS (m / z): 442.3 (M+H).

[0794] Example B159: Preparation of 4-((S)-3-((R)-4,4-dimethyl-3-phenylpentanamido)-2-(dimethylamino)propyl)-2-fluoro-N-methylbenzamide ("Compound 159"):

[0795] [ka]

[0796] Compound 159 (600 mg, 83%) was synthesized from intermediate 97 and intermediate 69 as described in Example B9. MS (m / z): 442.3 (M+H).

[0797] Example B160: Preparation of 4-((S)-2-(dimethylamino)-3-((R)-5-methyl-3-phenylhexanamido)propyl)-2-fluoro-N-methylbenzamide ("Compound 160"):

[0798] [ka]

[0799] Compound 160 (9 mg, 43%) was synthesized from intermediate 97 and intermediate 67 as described in Example B9. MS (m / z): 442.3 (M+H).

[0800] Example B161: Preparation of 44-((S)-2-(1H-imidazol-1-yl)-3-((S)-3-phenylbutanamido)propyl)-2-fluoro-N-methylbenzamide ("Compound 161"):

[0801] [ka]

[0802] Compound 161 (15 mg, 56%) was synthesized as described in Example B9. MS (m / z): 423.2 (M+H).

[0803] Example B162: Preparation of 4-((S)-2-(dimethylamino)-3-((R)-4-methyl-3-phenylpentanamido)propyl)-2-fluoro-N-methylbenzamide ("Compound 162"):

[0804] [ka]

[0805] Compound 162 (44 mg, 69%) was synthesized from intermediate 97 and intermediate 66 as described in Example B9. MS (m / z): 428.3 (M+H).

[0806] Example B163: Preparation of 4-((S)-2-(dimethylamino)-3-((S)-3-(pyridin-2-yl)butanamido)propyl)-2-fluoro-N-methylbenzamide ("Compound 163"):

[0807] [ka]

[0808] Compound 163 (44 mg, 69%) was synthesized from intermediate 97 and intermediate 132 as described in Example B9. MS (m / z): 401.2 (M+H).

[0809] Example B164: Preparation of 4-((S)-2-(dimethylamino)-3-((S)-3-phenylbutanamido)propyl)-2-fluoro-N-methylbenzamide ("Compound 164"):

[0810] [ka]

[0811] Compound 164 (45 mg, 82%) was synthesized from intermediate 131 and intermediate 62 as described in Example B9. MS (m / z): 426.3 (M+H).

[0812] Example B165: Preparation of 4-((S)-2-(dimethylamino)-3-((S)-3-phenylbutanamido)propyl)-2-fluoro-N-methylbenzamide ("Compound 165"):

[0813] [ka]

[0814] Compound 165 (35 mg, 72%) was synthesized from intermediate 97 and intermediate 127 as described in Example B9. MS (m / z): 440.3 (M+H).

[0815] Example B166: Preparation of 4-((S)-2-(diethylamino)-3-((R)-4,4-dimethyl-3-phenylpentanamido)propyl)-2-fluoro-N-methylbenzamide ("Compound 166"):

[0816] [ka]

[0817] Compound 166 (47 mg, 62%) was synthesized from intermediate 128 and intermediate 69 as described in Example B9. MS (m / z): 470.3 (M+H).

[0818] Example B167: Preparation of 4-((S)-2-(dimethylamino)-3-((S)-3-phenylbutanamido)propyl)-2-fluoro-N-methylbenzamide ("Compound 167"):

[0819] [ka]

[0820] Compound 167 (35 mg, 62%) was synthesized from intermediate 97 and intermediate 62 as described in Example B9. MS (m / z): 400.3 (M+H).

[0821] Example B168: Preparation of (S)-3-(((S)-4,4-dimethyl-3-phenylpentanamido)methyl)-N,2-dimethyl-1,2,3,4-tetrahydroisoquinoline-7-carboxamide ("Compound 168"):

[0822] [ka]

[0823] Compound 168 (40 mg, 75%) was synthesized from intermediate 129 and intermediate 70 as described in Example B9. MS (m / z): 422.2 (M+H).

[0824] Example B169: Preparation of (R)—N-((S)-2-(dimethylamino)-3-(7-methyl-2-oxo-2,3-dihydrobenzo[d]oxazol-6-yl)propyl)-3-(2-methylpyrimidin-5-yl)-3-(1-(trifluoromethyl)cyclopropyl)propanamide (“Compound 169”)

[0825] [ka]

[0826] Compound 169 (9 mg, 10%) was synthesized from Intermediate 76 and Intermediate 9 as described in Example B9. MS (m / z): 506.2 (M+H).

[0827] Example B170: Preparation of (R)—N-((S)-2-(dimethylamino)-3-(7-methyl-2-oxo-2,3-dihydrobenzo[d]oxazol-6-yl)propyl)-3-(pyridin-4-yl)-3-(1-(trifluoromethyl)cyclopropyl)propanamide (“Compound 170”)

[0828] [ka]

[0829] Compound 170 (27.4 mg, 41%) was synthesized from intermediate 76 and intermediate 59 as described in Example B9. MS (m / z): 491.2 (M+H).

[0830] Example B171: Preparation of (3S)—N-[(2S)-2-(dimethylamino)-3-(7-methyl-2-oxo-2,3-dihydro-1,3-benzoxazol-6-yl)propyl]-3-phenylbutanamide (“Compound 171”):

[0831] [ka]

[0832] Compound 171 (14.5 mg, 18%) was synthesized from intermediate 76 and intermediate 62 as described in Example B9. MS (m / z): 396.2 (M+H).

[0833] Example B172: Preparation of (3S)—N-[(2S)-2-(dimethylamino)-3-(2-oxo-2,3-dihydro-1,3-benzoxazol-6-yl)propyl]-5-methyl-3-phenylhexanamide (“Compound 172”):

[0834] [ka]

[0835] Step 1: Compound 172A was synthesized from intermediate 75 and intermediate 68 as described in Example B9.

[0836] Step 2: A solution of (1S,2S)—N-[(2S)-2-(dimethylamino)-3-(2-oxo-3-{[2-(trimethylsilyl)ethoxy]methyl}-2,3-dihydro-1,3-benzoxazol-6-yl)propyl]-2-phenylcyclopropane-1-carboxamide (172A, 950 mg, 1.86 mmol) in TFA (10 mL) was stirred at room temperature for 1 h. LC / MS showed conversion to product 172-A. The mixture was concentrated to dryness, dissolved in MeOH (3 mL), potassium carbonate (99.9 mg, 0.723 mmol) was added, and stirring was continued at room temperature for 16 h. The mixture was concentrated to dryness, taken up in water, acidified with 2 N HCl until pH = 6-7, and extracted with DCM (3x). The combined extracts were dried over MgSO, concentrated, and purified by flash chromatography (0–10% MeOH / DCM) to give (3S)-N-[(2S)-2-(dimethylamino)-3-(2-oxo-2,3-dihydro-1,3-benzoxazol-6-yl)propyl]-5-methyl-3-phenylhexanamide (40 mg, 63.7%). MS (m / z): 424.3 (M+H).

[0837] Example B173: Preparation of (R)—N-((S)-2-(dimethylamino)-3-(2-oxo-2,3-dihydrobenzo[d]oxazol-6-yl)propyl)-4-methyl-3-phenylpentanamide (“Compound 173”):

[0838] [ka]

[0839] Compound 173 (23 mg, 33%) was synthesized as described in Example B172. MS (m / z): 410.2 (M+H).

[0840] Example B174: Preparation of (S)—N-((S)-2-(dimethylamino)-3-(2-oxo-2,3-dihydrobenzo[d]oxazol-6-yl)propyl)-3-phenylheptanamide (“Compound 174”):

[0841] [ka]

[0842] Compound 174 was synthesized as described in Example B175. MS (m / z): 424.3 (M+H).

[0843] Example B175: Preparation of (S)—N-((S)-2-(dimethylamino)-3-(2-oxo-2,3-dihydrobenzo[d]oxazol-6-yl)propyl)-3-phenylbutanamide (“Compound 175”):

[0844] [ka]

[0845] Step 1: Preparation of 2-(benzyloxy)-4-bromo-1-nitrobenzene (175A): A mixture of 5-bromo-2-nitrophenol (5 g, 22.9 mmol), benzyl bromide (3.0 mL, 25.2 mmol), and potassium carbonate (10 g, 72.3 mmol) was taken up in DMF (36 mL) and stirred at room temperature overnight. After cooling to ambient temperature, the reaction mixture was diluted with water and ethyl acetate. The layers were separated, and the aqueous layer was extracted with ethyl acetate. The combined organic layers were washed with water and brine, dried over sodium sulfate, and concentrated in vacuo. The crude material was purified by flash column chromatography (9:1 hexane / ethyl acetate) to give 2-(benzyloxy)-4-bromo-1-nitrobenzene (8.25 g, 97%) as a pale yellow solid. LC-MS 332.0 (M+Na).

[0846] Step 2: Preparation of methyl (S)-3-(3-(benzyloxy)-4-nitrophenyl)-2-((tert-butoxycarbonyl)amino)propanoate (175B): Zinc dust (1.6 g, 24.5 mmol) was added to a flame-dried round-bottom flask (100 mL) and then purged with nitrogen. Dry DMF (10 mL) was added via syringe, followed by a solution of iodine (150 mg) in dry DMF (1 mL). A color change of the DMF from colorless to yellow and back to colorless was observed. After 5 minutes, a solution of iodoalanine (2.47 g, 7.49 mmol) in dry DMF (5 mL) was added, followed immediately by a solution of iodine (150 mg) in dry DMF (1 mL). The solution was stirred at room temperature, producing a noticeable exotherm. When the solution had cooled (approximately 20 min), a mixture of Pd2(dba)3 (312 mg, 0.34 mmol), SPhos (279 mg, 0.68 mmol), and 2-(benzyloxy)-4-bromo-1-nitrobenzene (175A, 2.1 g, 6.81 mmol) in dry DMF (9 mL) was added to the flask via syringe. The reaction mixture was heated at 55 °C overnight under a positive nitrogen pressure. After cooling to room temperature, ethyl acetate (100 mL) and water (30 mL) were added. After stirring for 30 min at room temperature, the mixture was filtered through Celite (80 g) and washed with ethyl acetate (100 mL). The yellow filtrate was then washed with water (4 × 100 mL). After drying over anhydrous MgSO4 and concentrating under vacuum, the crude reaction mixture was purified by flash chromatography eluting with ethyl acetate-hexane (0–35%) to give the product (2.1 g, 71%) as a white solid. MS(m / z):453.2(M+Na).

[0847] Step 3: To a solution of methyl (S)-3-(3-(benzyloxy)-4-nitrophenyl)-2-((tert-butoxycarbonyl)amino)propanoate (175B, 6 g, 13.9 mmol) in dry THF (60 mL), LiBH (789 mg, 36.2 mmol) was added slowly over 15 minutes at 0 °C, and the mixture was stirred for 1 hour at 0 °C. The reaction mixture was then stirred overnight at room temperature (the progress of the reaction was monitored by TLC or LC-MS). It was then cooled to 0 °C, and water (5 mL) was added, followed by saturated aqueous NH Cl (10 mL) (slow addition is required). Water (30 mL) and ethyl acetate (200 mL) were then added, and the aqueous layer was separated and further extracted with ethyl acetate (100 mL). The combined organic layers were washed with water (40 mL) and dried over anhydrous Na SO . After filtration and concentration, the crude product was lyophilized overnight and used in the next step without further purification (5.3 g). MS (m / z): 425.2 (M+Na).

[0848] Step 4: Preparation of tert-butyl (S)-(1-(3-(benzyloxy)-4-nitrophenyl)-3-(1,3-dioxoisoindolin-2-yl)propan-2-yl)carbamate (175D): To a mixture of tert-butyl (S)-(1-(3-(benzyloxy)-4-nitrophenyl)-3-hydroxypropan-2-yl)carbamate (175C, crude, 5.3 g), triphenylphosphine (4.4 g, 16.7 mmol), and phthalimide (2.45 g, 16.7 mmol) in anhydrous THF (60 mL) at 0° C. under nitrogen was added DIAD (3.3 mL, 16.7 mmol) dropwise over 20 min. The reaction mixture was then stirred from 0° C. to room temperature overnight. The crude reaction mixture was mixed with silica gel (20 g), concentrated to dryness on a rotary evaporator, and purified on a 120 g silica gel column eluted with EtOAc / hexanes (0–50%) to give the desired product as a yellow solid (6.0 g, 81% over two steps). MS (m / z): 554.2 (M+Na).

[0849] Step 5: Preparation of (S)-2-(3-(3-(benzyloxy)-4-nitrophenyl)-2-(dimethylamino)propyl)isoindoline-1,3-dione (175E): To a solution of tert-butyl (S)-(1-(3-(benzyloxy)-4-nitrophenyl)-3-(1,3-dioxoisoindolin-2-yl)propan-2-yl)carbamate (175D, 4.5 g, 8.4 mmol) in dry MeOH (60 mL) was added 4 M HCl in dioxane solution (19 mL). The mixture was stirred at room temperature overnight. Then the solvent was evaporated. The solid residue was used in the next step without further purification. To a suspension of the above solid in CH3CN (60 mL) and water (3 mL) was added 37% formaldehyde (3.8 mL, 50.7 mmol) and sodium cyanoborohydride (2.1 g, 33.8 mmol). After stirring for 10 minutes at room temperature, acetic acid (1.45 mL, 25.3 mmol) was added. The mixture was stirred for 2 hours at room temperature. The reaction mixture was partitioned between ethyl acetate (200 mL) and saturated sodium bicarbonate (40 mL). The layers were separated, and the aqueous layer was extracted with more ethyl acetate (3 × 100 mL). The combined organic layers were dried over anhydrous Na2SO4, filtered, and concentrated. The crude material was purified on an 80 g silica gel column (eluted with 10% MeOH in DCM:DCM (0–100%)) to give the desired product (3.2 g), which was impure (by H-NMR and TLC) and was not used in the next step. MS (m / z) = 460.2 (M+H).

[0850] Step 6: Preparation of (S)-3-(3-(benzyloxy)-4-nitrophenyl)-N,N-dimethylpropane-1,2-diamine (175F): To a solution of (S)-2-(3-(3-(benzyloxy)-4-nitrophenyl)-2-(dimethylamino)propyl)isoindoline-1,3-dione (175E, 3.2 g, 6.9 mmol) in 95% ethanol (50 mL) was added hydrazine hydrate (2.3 mL, 41.8 mmol). The mixture was heated at 70° C. for 3 h. The crude reaction mixture was diluted with MeOH (50 mL), mixed with silica gel (approximately 10 g), concentrated to dryness on a rotary evaporator, and purified on a 40 g silica gel column eluted with 10% MeOH (with 1% NH4OH) in DCM:DCM (0-100 / 100) to give the desired product as a white solid (1.25 g, 45% over the last three steps). MS (m / z): 330.2 M+H).

[0851] Step 7: Preparation of (S)—N-((S)-3-(3-(benzyloxy)-4-nitrophenyl)-2-(dimethylamino)propyl)-3-phenylbutanamide (175G): (S)-3-(3-(benzyloxy)-4-nitrophenyl)-N,N-dimethylpropane-1,2-diamine (175F, 200 mg, 0.6 mmol) and acid (0.67 mmol) were dissolved in dry DMF (5 mL), followed by the addition of EDCI (140 mg, 0.73 mmol), HOBT (98 mg, 0.73 mmol), and DIPEA (0.123 mL, 0.73 mmol). The reaction mixture was stirred overnight at room temperature and worked up with ethyl acetate and water. The organic layer was dried over anhydrous MgSO4 and concentrated in vacuo, and the crude reaction mixture was purified by flash chromatography eluting with 10% MeOH (containing 1% NH4OH) in DCM:DCM (0-40 / 100) to give the corresponding product as a yellow solid (249 mg, 86%). MS (m / z): 476.2 (M+H).

[0852] Step 8: Preparation of (S)—N-((S)-3-(4-amino-3-hydroxyphenyl)-2-(dimethylamino)propyl)-3-phenylbutanamide (175H): (S)—N-((S)-3-(3-(benzyloxy)-4-nitrophenyl)-2-(dimethylamino)propyl)-3-phenylbutanamide (175G, 240 mg, 0.5 mmol) and 10% palladium on carbon (55 mg, Aldrich) in MeOH (12 mL) were stirred under an H atmosphere for 16 hours. The mixture was filtered through Celite®, and the filtrate was evaporated under reduced pressure to give the title compound (185 mg, 100%). MS (m / z): 356.3 (M+H).

[0853] Step 9: Preparation of (S)—N—((S)-2-(dimethylamino)-3-(2-oxo-2,3-dihydrobenzo[d]oxazol-6-yl)propyl)-3-phenylbutanamide (Compound 175): 1,1′-Carbonyldiimidazole (230 mg, 1.68 mmol) was added to a solution of (S)—N—((S)-3-(4-amino-3-hydroxyphenyl)-2-(dimethylamino)propyl)-3-phenylbutanamide (175, 300 mg, 0.84 mmol) in 7 mL of THF, and the solution was heated at 60° C. for 2 hours. After cooling to room temperature, the reaction mixture was poured into 100 mL of water and then extracted twice with 100 mL of ethyl acetate. After removing water with sodium sulfate, the solvent was removed using a rotary flash evaporator, and the residual material was purified by silica gel column chromatography using 10% MeOH (containing 1% NH4OH) in DCM:DCM (0-60 / 100) to give the desired product (94 mg, 52% over the last three steps) as a white solid. MS (m / z): 382.2 (M+H).

[0854] Example B176: Preparation of (S)—N—((S)-2-(dimethylamino)-3-(2-oxo-2,3-dihydrobenzo[d]oxazol-6-yl)propyl)-3-(pyridin-3-yl)-3-(1-(trifluoromethyl)cyclopropyl)propanamide (“Compound 176”)

[0855] [ka]

[0856] Compound 176 (20 mg, 45%) was synthesized from (S)-6-(3-amino-2-(dimethylamino)propyl)benzo[d]oxazol-2(3H)-one (175F) and (S)-3-(pyridin-3-yl)-3-(1-(trifluoromethyl)cyclopropyl)propanoic acid) as described in Example B175. MS (m / z): 477.2 (M+H).

[0857] Example B177: Preparation of (S)-3-cyclopropyl-N-((S)-2-(dimethylamino)-3-(2-oxo-2,3-dihydrobenzo[d]oxazol-6-yl)propyl)-3-phenylpropanamide ("Compound 177"):

[0858] [ka]

[0859] Compound 177 (74 mg, 70%) was synthesized as described in Example B175. MS (m / z): 408.3 (M+H).

[0860] Example B178: Preparation of (R)-3-cyclopropyl-N-((S)-2-(dimethylamino)-3-(2-oxo-2,3-dihydrobenzo[d]oxazol-6-yl)propyl)-3-phenylpropanamide ("Compound 178"):

[0861] [ka]

[0862] Compound 178 (40 mg, 65%) was synthesized as described in Example B175. MS (m / z): 408.2 (M+H).

[0863] Example B179: Preparation of (R)-4-cyclopropyl-N-((S)-2-(dimethylamino)-3-(4-methyl-2-oxoindolin-5-yl)propyl)-3-(pyridin-3-yl)butanamide ("Compound 179"):

[0864] [ka]

[0865] DIPEA (19.3 mg, 150 mmL) was added to a solution of 5-[(2S)-3-amino-2-(dimethylamino)propyl]-4-methyl-2,3-dihydro-1H-indol-2-one (14.8 mg, 59.8 mmol), (3R)-3-(pyridin-3-yl)-3-[1-(trifluoromethyl)cyclopropyl]propanoic acid (12.3 mg, 59.8 mmol), EDC (13.8 mg, 71.8 mmol), and HOBt (4.04 mg, 29.9 mmol) in 1 mL of dry DMF. The reaction was stirred for 16 hours at room temperature. After completion of the reaction, the mixture was diluted with water and extracted with ethyl acetate (3x). The combined organic layers were washed with water and brine, then dried over MgSO4, filtered, and concentrated. The crude material was purified by SiO chromatography (0-10% MeOH in DCM) to give the title compound (13.6 mg, 52%). MS (m / z): 435.3 (M+H).

[0866] Example B180: Preparation of (R)—N-((S)-2-(dimethylamino)-3-(4-methyl-2-oxoindolin-5-yl)propyl)-3-(pyridin-3-yl)-3-(1-(trifluoromethyl)cyclopropyl)propanamide (“Compound 180”)

[0867] [ka]

[0868] Compound 180 (20 mg, 68%) was synthesized from intermediate 78 and intermediate 15 as described in Example B179. MS (m / z): 489.2 (M+H).

[0869] Example B181: Preparation of (3S)—N-[(2S)-2-(dimethylamino)-3-(4-methyl-2-oxo-2,3-dihydro-1H-indol-5-yl)propyl]-3-phenylbutanamide (“Compound 181”):

[0870] [ka]

[0871] Compound 181 (35 mg, 73%) was synthesized from intermediate 78 and intermediate 62 as described in Example B179. MS (m / z): 394.2 (M+H).

[0872] Example B182: Preparation of (R)—N-((S)-2-(dimethylamino)-3-(2-oxoindolin-5-yl)propyl)-4-methyl-3-phenylpentanamide (“Compound 182”):

[0873] [ka]

[0874] Compound 182 (28 mg, 60%) was synthesized from intermediate 79 and intermediate 66 as described in Example B179. MS (m / z): 408.3 (M+H).

[0875] Example B183: Preparation of (S)—N-((S)-2-(dimethylamino)-3-(2-oxoindolin-5-yl)propyl)-5-methyl-3-phenylhexanamide (“Compound 183”):

[0876] [ka]

[0877] Compound 183 (22 mg, 63%) was synthesized from intermediate 79 and intermediate 68 as described in Example B179. MS (m / z): 422.2 (M+H).

[0878] Example B184: Preparation of (3S)—N-[(2S)-2-(dimethylamino)-3-(2-oxo-2,3-dihydro-1H-indol-5-yl)propyl]-3-phenylbutanamide (“Compound 184”):

[0879] [ka]

[0880] Compound 184 (706 mg, 67%) was synthesized from intermediate 79 and intermediate 62 as described in Example B179. MS (m / z): 380.2 (M+H).

[0881] Example B185: Preparation of (3R)—N-[(2S)-2-(dimethylamino)-3-(2-oxo-2,3-dihydro-1H-indol-5-yl)propyl]-3-phenylbutanamide (“Compound 185”):

[0882] [ka]

[0883] Compound 185 (31 mg, 62%) was synthesized from intermediate 79 and intermediate 61 as described in Example B179. MS (m / z): 380.2 (M+H).

[0884] Example B186: Preparation of (R)-3-cyclopropyl-N-((S)-2-(dimethylamino)-3-(2-oxoindolin-5-yl)propyl)-3-phenylpropanamide ("Compound 186"):

[0885] [ka]

[0886] Compound 186 (31.6 mg, 45%) was synthesized from intermediate 79 and intermediate 64 as described in Example B179. MS (m / z): 406.3 (M+H).

[0887] Example B187: Preparation of (S)—N—((S)-2-(dimethylamino)-3-(3-oxo-3,4-dihydro-2H-benzo[b][1,4]oxazin-7-yl)propyl)-3-phenylbutanamide (“Compound 187”):

[0888] [ka]

[0889] A solution of chloroacetyl chloride (142 mg, 1.26 mmol) in THF (2.5 mL) was added dropwise over approximately 15 minutes under nitrogen to a stirred suspension of sodium bicarbonate (189 mg, 2.25 mmol) and (S)—N-((S)-3-(4-amino-3-hydroxyphenyl)-2-(dimethylamino)propyl)-3-phenylbutanamide (175H) (320 mg, 0.9 mmol) in THF (3 mL) at 0° C. Vigorous effervescence was observed with an exotherm to approximately 25° C. The resulting yellow suspension was stirred at room temperature for 1.5 hours. Potassium carbonate (311 mg, 2.25 mmol) was added, and the mixture was heated to reflux and stirred for 2 hours. The mixture was cooled to 40° C., diluted with ethyl acetate and water, the layers were separated, and the aqueous was extracted twice with ethyl acetate. The combined organic layers were washed with water and brine, dried over sodium sulfate, and concentrated in vacuo. The crude material was purified by flash column chromatography using 10% MeOH in DCM:DCM (0-50%) as the eluent to give the product (140 mg, 39%) as a white solid. MS (m / z): 396.2.

[0890] Example B188: Preparation of N-((S)-2-(dimethylamino)-3-(2-oxoindolin-5-yl)propyl)-3-(pyrimidin-2-yl)-3-(1-(trifluoromethyl)cyclopropyl)propenamide ("Compound 188"):

[0891] [ka]

[0892] Compound 188 (13.1 mg, 25%) was synthesized from intermediate 79 and intermediate 72 as described in Example B179. MS (m / z): 476.2 (M+H).

[0893] Example B189: Preparation of (R)—N-((S)-2-(dimethylamino)-3-(2-oxoindolin-5-yl)propyl)-3-phenyl-3-(1-(trifluoromethyl)cyclopropyl)propanamide (“Compound 189”):

[0894] [ka]

[0895] To a solution of the acid (Intermediate 72, 20.7 mg, 0.0802 mmol) and DIEA (20.9 uL, 0.120 mmol) in DMF (0.3 mL) was added TSTU (24.1 mg, 0.0802 mmol) in one portion. The mixture was stirred at room temperature for 1 hour. To the reaction mixture was added the amine (Intermediate 79, 18.7 mg, 0.0802 mmol), and stirring was continued for another 1 hour. The reaction mixture was diluted with ethyl acetate (15 mL), saturated NaHCO3, water, and brine. The organic layer was dried over MgSO4, filtered, and concentrated on a rotary evaporator. The crude material was purified by silica gel column (0-10% MeOH / DCM with 1% NH4OH) to give the title compound (21.5 mg, 57). MS (m / z): 474.3.

[0896] Example B190: Preparation of (S)—N-((S)-2-(dimethylamino)-3-(1H-indazol-5-yl)propyl)-3-phenyl-3-(1-(trifluoromethyl)cyclopropyl)propanamide (“Compound 190”)

[0897] [ka]

[0898] Step 1: Preparation of (S)—N-((S)-2-(dimethylamino)-3-(1-tosyl-1H-indazol-5-yl)propyl)-3-phenyl-3-(1-(trifluoromethyl)cyclopropyl)propenamide (190A). To a solution of the acid (Intermediate 4D, 49.0 mg, 0.190 mmol) and DIEA (49.7 uL, 0.286 mmol) in DMF (0.3 mL) at room temperature was added TSTU (57.2 mg, 0.190 mmol). The mixture was stirred for 40 minutes at room temperature. The resulting solution was poured into a suspension of (Intermediate 84, 70.7 mg, 0.190 mmol) and stirred for 1 hour. The reaction mixture was diluted with ethyl acetate and washed with saturated NaHCO3, water, and brine. The organic layer was dried over MgSO4, filtered, and concentrated on a rotary evaporator. The crude material was purified by 12 g silica gel column (0-10% MeOH / DCM with 1% NH4OH) to give the title compound (38 mg, 33%). MS (m / z): 612.2 (M+H).

[0899] Step 2: Preparation of (S)—N-((S)-2-(dimethylamino)-3-(1H-indazol-5-yl)propyl)-3-phenyl-3-(1-(trifluoromethyl)cyclopropyl)propenamide (Compound 190): Compound 190A (36.0 mg, 0.0588 mmol) in MeOH (2 mL) was treated with KCO (mg, mmol) for 40 minutes at 70 °C. LCMS showed the reaction was complete. The reaction mixture was cooled to room temperature and concentrated to dryness. The crude material was dissolved in DMF (1 mL) / HO with 0.1% TFA (0.5 mL) / ACN with 0.1% TFA (0.5 mL), filtered, and purified on a C18 column (0-100% ACN with 0.1% TFA / water with 0.1% TFA). The pure fractions were combined, concentrated, the pH adjusted to approximately 9 with saturated NaHCO3 (aqueous), and extracted with DCM (3x). The combined extracts were dried and concentrated to give the title compound (16 mg, 59%). MS (m / z): 459.2 (M+H).

[0900] Example B191: Preparation of (R)—N-((S)-3-(4-chloro-1H-indazol-5-yl)-2-(dimethylamino)propyl)-3-(pyridin-4-yl)-3-(1-(trifluoromethyl)cyclopropyl)propanamide (“Compound 191”)

[0901] [ka]

[0902] Compound 191 was synthesized from intermediate 82 and intermediate 69 as described in Example B190. MS (m / z): 494.2 (M+H).

[0903] Example B192: Preparation of (R)—N-((S)-3-(4-chloro-1H-indazol-5-yl)-2-(dimethylamino)propyl)-3-(pyridin-3-yl)-3-(1-(trifluoromethyl)cyclopropyl)propanamide (“Compound 192”):

[0904] [ka]

[0905] Compound 192 (25.8 mg, 39%) was synthesized from 192A, which was synthesized from intermediate 82 and intermediate 15 (59.7 mg, 68%) as described in Example B190. MS (m / z): 494.2 (M+H).

[0906] Example B193: Preparation of (R)-N-((S)-3-(4-chloro-1H-indazol-5-yl)-2-(dimethylamino)propyl)-3-phenylbutanamide ("Compound 193"):

[0907] [ka]

[0908] Compound 193 (29.5 mg, 43%) was synthesized from intermediate 82 and intermediate 61 as described in Example B190. MS (m / z): 399.2 (M+H).

[0909] Example B194: Preparation of (S)—N-((S)-3-(4-chloro-1H-indazol-5-yl)-2-(dimethylamino)propyl)-3-phenylbutanamide (“Compound 194”):

[0910] [ka]

[0911] Compound 194 (23.5 mg, 34%) was synthesized from Intermediate 82 and Intermediate 62 as described in Example B190. MS (m / z): 399.2 (M+H).

[0912] Example B195: Preparation of (R)—N-((S)-2-(dimethylamino)-3-(4-fluoro-1H-indazol-5-yl)propyl)-3-(pyridin-3-yl)-3-(1-(trifluoromethyl)cyclopropyl)propanamide (“Compound 195”)

[0913] [ka]

[0914] Compound 195 was synthesized from intermediate 92 and intermediate 15 as described in Example B190. MS (m / z): 478.2 (M+H).

[0915] Example B196: Preparation of (R)—N-((S)-2-(dimethylamino)-3-(4-methyl-1H-indazol-5-yl)propyl)-3-(pyridin-4-yl)-3-(1-(trifluoromethyl)cyclopropyl)propanamide (“Compound 196”):

[0916] [ka]

[0917] Compound 196 was synthesized from intermediate 81 and intermediate 59 as described in Example B190. MS (m / z): 474.3 (M+H).

[0918] Example B197: Preparation of (R)—N-((S)-2-(dimethylamino)-3-(4-methyl-1H-indazol-5-yl)propyl)-3-(pyridin-3-yl)-3-(1-(trifluoromethyl)cyclopropyl)propanamide (“Compound 197”)

[0919] [ka]

[0920] Compound 197 was synthesized from intermediate 81 and intermediate 15 as described in Example B190. MS (m / z): 474.3 (M+H).

[0921] Example B198: Preparation of (S)—N-((S)-2-(dimethylamino)-3-(4-methyl-1H-indazol-5-yl)propyl)-3-phenylbutanamide (“Compound 198”):

[0922] [ka]

[0923] Compound 198 was synthesized from intermediate 81 and intermediate 62 as described in Example B190. MS (m / z): 379.3 (M+H).

[0924] Example B199: Preparation of (S)—N—((S)-2-(dimethylamino)-3-(4-methyl-1H-indazol-5-yl)propyl)-3-(1-methylcyclopropyl)-3-(pyridin-3-yl)propanamide (“Compound 199”):

[0925] [ka]

[0926] Compound 199 was synthesized from intermediate 81 and intermediate 77 as described in Example B190. MS (m / z): 420.3 (M+H).

[0927] Example B200: Preparation of (R)—N-((S)-3-(-1H-indazol-5-yl)-2-(methylamino)propyl)-3-(pyridin-3-yl)-3-(1-(trifluoromethyl)cyclopropyl)propanamide (“Compound 200”)

[0928] [ka]

[0929] (R)-N-((S)-2-(benzyl(methyl)amino)-3-(1H-indazol-5-yl)propyl)-3-(pyridin-3-yl)-3-(1-(trifluoromethyl)cyclopropyl)propanamide (200A, 120 mg, 0.224 mmol) was taken up with palladium(II) hydroxide (100 mg) followed by the addition of ethanol (5 ml). The flask was evacuated and filled with hydrogen (balloon). The reaction was stirred under a hydrogen balloon for the next 18 hours. TLC and LCMS indicated product formation. The solution was filtered through packed Celite to remove the palladium, and the filtrate was concentrated. The residue was purified by flash chromatography (0-15% MeOH / DCM in 1% ammonium hydroxide) to give the title compound (55 mg, 53%). MS (m / z): 446.2 (M+H).

[0930] Example B201: Preparation of (R)-N-((S)-2-amino-3-(1H-indazol-5-yl)propyl)-3-(pyridin-3-yl)-3-(1-(trifluoromethyl)cyclopropyl)propenamide dihydrochloride salt ("Compound 201"):

[0931] [ka]

[0932] tert-Butyl ((S)-1-(1H-indazol-5-yl)-3-((R)-3-(pyridin-3-yl)-3-(1-(trifluoromethyl)cyclopropyl)propanamido)propan-2-yl)carbamate (201A, 125 mg, 0.23 mmol) was taken up in 1,4-dioxane (3 ml), and then a solution of hydrogen chloride in 1,4-dioxane (2 ml, 4 M solution) was added dropwise to it. The suspension was stirred for 18 hours at room temperature. TLC and LCMS showed that the reaction was complete. The solution was partially concentrated, and MTBE was added. The precipitated solid was collected by filtration. The solid was then dried under vacuum to give the title compound (110 mg, 75%) as the dihydrochloride salt. MS (m / z): 432.2 (M+H).

[0933] Example B202: Preparation of (R)—N-((S)-2-(dimethylamino)-3-(1H-indazol-5-yl)propyl)-3-(2-methylpyridin-4-yl)-3-(1-(trifluoromethyl)cyclopropyl)propanamide (“Compound 202”)

[0934] [ka]

[0935] Compound 202 was synthesized from intermediate 84 and intermediate 89 as described in Example B190. MS (m / z): 474.2 (M+H).

[0936] Example B203: Preparation of (S)—N-((S)-2-(dimethylamino)-3-(1H-indazol-5-yl)propyl)-3-(5-methylpyridin-3-yl)-3-(1-(trifluoromethyl)cyclopropyl)propanamide (“Compound 203”)

[0937] [ka]

[0938] Compound 203 was synthesized from intermediate 84 and intermediate 90 as described in Example B190. MS (m / z): 474.3 (M+H).

[0939] Example B204: Preparation of (S)—N-((S)-2-(dimethylamino)-3-(1H-indazol-5-yl)propyl)-3-(1-methylcyclopropyl)-3-(pyridin-3-yl)propanamide (“Compound 204”):

[0940] [ka]

[0941] Compound 204 was synthesized from intermediate 84 and intermediate 77 as described in Example B190. MS (m / z): 406.3 (M+H).

[0942] Example B205: Preparation of (R)-3-(5-chloropyridin-3-yl)-N-((S)-2-(dimethylamino)-3-(1H-indazol-5-yl)propyl)-3-(1-(trifluoromethyl)cyclopropyl)propanamide ("Compound 205")

[0943] [ka]

[0944] Compound 205 was synthesized from intermediate 84 and intermediate 103 as described in Example B190. MS (m / z): 494.2 (M+H).

[0945] Example B206: Preparation of (S)—N—((S)-2-(dimethylamino)-3-(1H-indazol-5-yl)propyl)-4-methyl-3-(pyridin-3-yl)pentanamide (“Compound 206”):

[0946] [ka]

[0947] Compound 206 was synthesized from intermediate 84 and intermediate 50 as described in Example B190. MS (m / z): 394.2 (M+H).

[0948] Example B207: Preparation of (S)-3-cyclopropyl-N-((S)-2-(dimethylamino)-3-(1H-indazol-5-yl)propyl)-3-(pyridin-3-yl)propanamide ("Compound 207"):

[0949] [ka]

[0950] Compound 207 was synthesized from intermediate 84 and intermediate 91 as described in Example B190. MS (m / z): 392.1 (M+H).

[0951] Example B208: Preparation of (S)—N-((S)-2-(dimethylamino)-3-(1H-indazol-5-yl)propyl)-3-(pyridin-4-yl)-3-(1-(trifluoromethyl)cyclopropyl)propanamide (“Compound 208”)

[0952] [ka]

[0953] Compound 208 was synthesized from intermediate 84 and intermediate 93 as described in Example B190. MS (m / z): 460.2 (M+H).

[0954] Example B209: Preparation of (R)—N-((S)-2-(dimethylamino)-3-(1H-indazol-5-yl)propyl)-3-(pyridin-4-yl)-3-(1-(trifluoromethyl)cyclopropyl)propanamide (“Compound 209”)

[0955] [ka]

[0956] Compound 209 was synthesized from intermediate 84 and intermediate 59 as described in Example B190. MS (m / z): 460.2 (M+H).

[0957] Example B210: Preparation of (3S)—N-[(2S)-2-(dimethylamino)-3-(1H-indazol-5-yl)propyl]-3-(pyridin-4-yl)-3-[1-(trifluoromethyl)cyclopropyl]propenamide (“Compound 210”)

[0958] [ka]

[0959] Compound 210 was synthesized from intermediate 84 and intermediate 12 as described in Example B190. MS (m / z): 460.2 (M+H).

[0960] Example B211: Preparation of (R)—N-((S)-2-(dimethylamino)-3-(1H-indazol-5-yl)propyl)-3-(6-methylpyridin-3-yl)-3-(1-(trifluoromethyl)cyclopropyl)propanamide (“Compound 211”):

[0961] [ka]

[0962] Compound 211 was synthesized from intermediate 84 and intermediate 10 as described in Example B190. MS (m / z): 474.3 (M+H).

[0963] Example B212: Preparation of (R)-4-cyclopropyl-N-((S)-2-(dimethylamino)-3-(1H-indazol-5-yl)propyl)-3-(pyridin-3-yl)butanamide ("Compound 212"):

[0964] [ka]

[0965] Compound 212 was synthesized from intermediate 84 and intermediate 49 as described in Example B190. MS (m / z): 406.2 (M+H).

[0966] Example B213: Preparation of (R)—N-((S)-2-(dimethylamino)-3-(1H-indazol-5-yl)propyl)-3-(pyridin-3-yl)-3-(1-(trifluoromethyl)cyclopropyl)propanamide (“Compound 213”)

[0967] [ka]

[0968] Compound 213 was synthesized from intermediate 84 and intermediate 15 as described in Example B190. MS (m / z): 460.2 (M+H).

[0969] Example B214: Preparation of (S)—N-((S)-2-(dimethylamino)-3-(1H-indazol-5-yl)propyl)-5-methyl-3-phenylhexanamide (“Compound 214”):

[0970] [ka]

[0971] Compound 214 was synthesized from intermediate 84 and intermediate 68 as described in Example B190. MS (m / z): 407.3 (M+H).

[0972] Example B215: Preparation of (R)-N-((S)-2-(dimethylamino)-3-(1H-indazol-5-yl)propyl)-3-(3-fluorophenyl)butanamide ("Compound 215"):

[0973] [ka]

[0974] Compound 215 was synthesized from intermediate 84 and intermediate 71 as described in Example B190. MS (m / z): 383.2 (M+H).

[0975] Example B216: Preparation of (S)—N-((S)-2-(dimethylamino)-3-(1H-indazol-5-yl)propyl)-3-(pyridin-2-yl)butanamide (“Compound 216”):

[0976] [ka]

[0977] Compound 216 was synthesized from intermediate 84 and intermediate 132 as described in Example B190. MS (m / z): 366.3 (M+H).

[0978] Example B217: Preparation of (S)—N-((S)-2-(dimethylamino)-3-(1H-indazol-5-yl)propyl)-3-(p-tolyl)butanamide (“Compound 217”):

[0979] [ka]

[0980] Compound 217 was synthesized from intermediate 84 as described in Example B190. MS (m / z): 379.2 (M+H).

[0981] Example B218: Preparation of (S)—N-((S)-2-(dimethylamino)-3-(1H-indazol-5-yl)propyl)-3-(4-fluorophenyl)butanamide (“Compound 218”):

[0982] [ka]

[0983] Compound 218 was synthesized from intermediate 84 as described in Example B190. MS (m / z): 383.2 (M+H).

[0984] Example B219: Preparation of (R)-N-((S)-2-(dimethylamino)-3-(1H-indazol-5-yl)propyl)-4-methyl-3-phenylpentanamide ("Compound 219"):

[0985] [ka]

[0986] Compound 219 was synthesized from intermediate 84 and intermediate 66 as described in Example B190. MS (m / z): 393.3 (M+H).

[0987] Example B220: Preparation of (S)-3-(4-chlorophenyl)-N-((S)-2-(dimethylamino)-3-(1H-indazol-5-yl)propyl)butanamide ("Compound 220"):

[0988] [ka]

[0989] Compound 220 was synthesized from intermediate 84 and intermediate 125 as described in Example B190. MS (m / z): 399.2 (M+H).

[0990] Example B221: Preparation of (S)—N-(2-(dimethylamino)-3-(1H-indazol-5-yl)propyl)-3-methyl-3-phenylbutanamide (“Compound 221”):

[0991] [ka]

[0992] Compound 221 was synthesized from intermediate 84 as described in Example B190. MS (m / z): 379.4 (M+H).

[0993] Example B222: Preparation of (S)—N-((S)-3-(1H-indazol-5-yl)-2-(pyrrolidin-1-yl)propyl)-3-phenylbutanamide (“Compound 222”):

[0994] [ka]

[0995] Compound 222 was synthesized from intermediate 85 and intermediate 62 as described in Example B190. MS (m / z): 391.2 (M+H).

[0996] Example B223: Preparation of (S)—N-((S)-2-(dimethylamino)-3-(1H-indazol-5-yl)propyl)-3-phenylhex-5-enamide (“Compound 223”):

[0997] [ka]

[0998] Compound 223 was synthesized from intermediate 84 and intermediate 127 as described in Example B190. MS (m / z): 405.3 (M+H).

[0999] Example B224: Preparation of (S)—N—((S)-3-(1H-indazol-5-yl)-2-(piperidin-1-yl)propyl)-3-phenylbutanamide (“Compound 224”):

[1000] [ka]

[1001] Compound 224 was synthesized from intermediate 86 and intermediate 62 as described in Example B190. MS (m / z): 405.2 (M+H).

[1002] Example B225: Preparation of (S)—N—((S)-3-(1H-indazol-5-yl)-2-(isopropyl(methyl)amino)propyl)-3-phenylbutanamide (“Compound 225”):

[1003] [ka]

[1004] Compound 225 was synthesized from intermediate 87 and intermediate 62 as described in Example B190. MS (m / z): 393.2 (M+H).

[1005] Example B226: Preparation of (3R)-3-cyclopropyl-N-[(2S)-2-(dimethylamino)-3-(1H-indazol-5-yl)propyl]-3-phenylpropanamide ("Compound 226"):

[1006] [ka]

[1007] Compound 226 was synthesized from intermediate 84 and intermediate 64 as described in Example B190. MS (m / z): 391.3 (M+H).

[1008] Example B227: Preparation of (3S)-3-cyclopropyl-N-[(2S)-2-(dimethylamino)-3-(1H-indazol-5-yl)propyl]-3-phenylpropanamide ("Compound 227"):

[1009] [ka]

[1010] Compound 227 was synthesized from intermediate 84 and intermediate 63 as described in Example B190. MS (m / z): 391.3 (M+H).

[1011] Example B228: Preparation of (3R)—N-[(2S)-2-(dimethylamino)-3-(1H-indazol-5-yl)propyl]-3-phenylbutanamide (“Compound 228”):

[1012] [ka]

[1013] Compound 228 was synthesized from intermediate 84 and intermediate 61 as described in Example B190. MS (m / z): 365.2 (M+H).

[1014] Example B229: Preparation of (3R)—N-((2S)-2-(dimethylamino)-3-(1H-indazol-5-yl)butyl)-3-(2-methylpyrimidin-5-yl)-3-(1-(trifluoromethyl)cyclopropyl)propanamide (“Compound 229”):

[1015] [ka]

[1016] Compound 229 was synthesized from intermediate 84 and intermediate 18 as described in Example B190. MS (m / z): 489.3 (M+H).

[1017] Example B230: Preparation of (R)—N-((S)-2-(dimethylamino)-3-(7-fluoro-1H-indazol-5-yl)propyl)-3-(pyridin-3-yl)-3-(1-(trifluoromethyl)cyclopropyl)propanamide (“Compound 230”)

[1018] [ka]

[1019] Compound 230 was synthesized from intermediate 84 and intermediate 18 as described in Example B190. MS (m / z): 478.2 (M+H).

[1020] Example B231: Preparation of (R)—N-((S)-2-(dimethylamino)-3-(7-methyl-1H-indazol-5-yl)propyl)-3-(pyridin-3-yl)-3-(1-(trifluoromethyl)cyclopropyl)propanamide; bis(trifluoroacetic acid) (“Compound 231”)

[1021] [ka]

[1022] To a solution of (R)-N-((S)-2-amino-3-(7-methyl-1H-indazol-5-yl)propyl)-3-(pyridin-3-yl)-3-(1-(trifluoromethyl)cyclopropyl)propanamide hydrochloride (78.0 mg, 146 μmol) in 8:2 CH3CN:water (1 mL) was added NaBH3(CN) (27.5 mg, 3 equiv., 437 μmol), followed by formaldehyde 37% w / w (47.3 mg, 4 equiv., 583 μmol). LCMS showed complete conversion. Saturated NaHCO3 was added (2 mL). Acetonitrile was removed under vacuum. To the residue, more saturated NaHCO3 (another 10 mL) was added to bring the pH to 6-7 and extracted with EtOAc (3x). The combined extracts were washed with brine, dried over Na2SO4, concentrated, and purified by flash chromatography (0-15% MeOH + 1% NH4OH in DCM), then purified again by reverse-phase preparative HPLC. Pure fractions were concentrated to dryness to give the title compound (27.5 mg, 25%) as the di-trifluoroacetic acid (di-TFA) salt. MS (m / z): 474.2 (M+H).

[1023] Example B232: Preparation of (R)—N-((S)-2-(dimethylamino)-3-(1H-indazol-6-yl)propyl)-3-(pyridin-3-yl)-3-(1-(trifluoromethyl)cyclopropyl)propanamide (“Compound 232”)

[1024] [ka]

[1025] Compound 232 was synthesized from intermediate 80 and intermediate 15 as described in Example B190. MS (m / z): 460.2 (M+H).

[1026] Example B233: Preparation of (R)—N-((S)-3-(6-chloro-1H-indazol-5-yl)-2-(dimethylamino)propyl)-3-(2-methylpyrimidin-5-yl)-3-(1-(trifluoromethyl)cyclopropyl)propanamide (“Compound 233”)

[1027] [ka]

[1028] Compound 233 was synthesized from intermediate 83 and intermediate 9 as described in Example B190. MS (m / z): 509.2 (M+H).

[1029] Example B234: Preparation of (R)—N-((S)-3-(6-chloro-1H-indazol-5-yl)-2-(dimethylamino)propyl)-3-(pyridin-4-yl)-3-(1-(trifluoromethyl)cyclopropyl)propanamide (“Compound 234”)

[1030] [ka]

[1031] Compound 234 was synthesized from intermediate 83 and intermediate 59 as described in Example B190. MS (m / z): 494.2 (M+H).

[1032] Example B235: Preparation of (R)—N-((S)-3-(6-chloro-1H-indazol-5-yl)-2-(dimethylamino)propyl)-3-(pyridin-3-yl)-3-(1-(trifluoromethyl)cyclopropyl)propanamide (“Compound 235”):

[1033] [ka]

[1034] Compound 235 was synthesized from intermediate 83 and intermediate 15 as described in Example B190. MS (m / z): 494.2 (M+H).

[1035] Example B236: Preparation of (S)—N-((S)-3-(6-chloro-1H-indazol-5-yl)-2-(dimethylamino)propyl)-3-phenylbutanamide (“Compound 236”):

[1036] [ka]

[1037] Compound 236 was synthesized from intermediate 83 and intermediate 62 as described in Example B190. MS (m / z): 399.2 (M+H).

[1038] Example B237: Prepa...

Claims

1. A compound having the structure of formula (I), or a pharmaceutically acceptable salt or solvate thereof: 【Chemistry 1】 During the ceremony, R １ is C ６－１０ Aryl and C １－９ heteroaryl, wherein C ６－１０ Aryl and C １－９ Heteroaryl can be one, two, three, four, or five R ７ is optionally replaced by R ２ is C ６－１０ Aryl and C １－９ heteroaryl, wherein C ６－１０ Aryl and C １－９ Heteroaryl can be one, two, three, four, or five R ８ is optionally replaced by R ３ is —X—R3a, X is a bond; R ３ａ is one, two, or three R ９ C substituted with ３－８ is cycloalkyl, R ４ is hydrogen, C １ -C ６ Alkyl, or C １ -C ６ is haloalkyl, R ５ and R ６ are each independently hydrogen, C １ -C ６ Alkyl, and C １ -C ６ haloalkyl; or R ５ and R ６ are combined to form an azetidinyl, pyrrolidinyl, piperidinyl, or piperazinyl ring; R ７ are each independently a halogen, —CN, or C １－６ Alkyl, C １－６ Haloalkyl, C ２－６ Alkenyl, C ２－６ Alkynyl, C ３－６ Cycloalkyl, C ２－９ Heterocycloalkyl, C ６－１０ Aryl, C １－９ Heteroaryl, —OR １０ , -SR １０ , -C(O)OR １０ , -OC(O)N(R １０ ) (R １１ ), -N(R １２ )C(O)N(R １０ ) (R １１ ), -N(R １２ ) C(O)R １３ , -N(R １２ )C(O)OR １３ , -N(R １２ ) S (O) ２ R １３ , -C(O)R １３ , -OC(O)R １３ , -C(O)N(R １０ ) (R １１ ), -C(O)C(O)N(R １０ ) (R １１ ), -S(O)R １３ , -S(O) ２ R １３ , and -S(O) ２ N (R １０ ) (R １１ ) wherein C １－６ Alkyl, C ２－６ Alkenyl, C ２－６ Alkynyl, C ３－６ Cycloalkyl, C ２－９ Heterocycloalkyl, C ６－１０ Aryl, and C １－９ Heteroaryl is a group containing halogen, —CN, C １－６ Alkyl, C １－６ Haloalkyl, C ２－６ Alkenyl, C ２－６ Alkynyl, C ３－６ Cycloalkyl, C ２－９ Heterocycloalkyl, C ６－１０ Aryl, C １－９ Heteroaryl, —OR １４ , -SR １４ , -C(O)OR １４ , -OC(O)N(R １４ ) (R １５ ), -N(R １６ )C(O)N(R １４ ) (R １５ ), -N(R １６ ) C(O)R １７ , -N(R １６ )C(O)OR １７ , -N(R １６ ) S (O) ２ R １７ , -C(O)R １７ , -OC(O)R １７ , -C(O)N(R １４ ) (R １５ ), -C(O)C(O)N(R １４ ) (R １５ ), -S(O)R １７ , -S(O) ２ R １７ , and -S(O) ２ N (R １４ ) (R １５ Optionally substituted with one, two, or three groups selected from two R ７ are combined to form a heterocycloalkyl ring optionally substituted with oxo, or R ７ and R ６ are combined to form a heterocycloalkyl ring; Each R ８ and each R ９ are each independently a halogen, —CN, or C １－６ Alkyl, C １－６ Haloalkyl, C ２－６ Alkenyl, C ２－６ Alkynyl, C ３－６ Cycloalkyl, C ２－９ Heterocycloalkyl, C ６－１０ Aryl, C １－９ Heteroaryl, —OR １０ , -SR １０ , -C(O)OR １０ , -OC(O)N(R １０ ) (R １１ ), -N(R １２ )C(O)N(R １０ ) (R １１ ), -N(R １２ ) C(O)R １３ , -N(R １２ )C(O)OR １３ , -N(R １２ ) S (O) ２ R １３ , -C(O)R １３ , -OC(O)R １３ , -C(O)N(R １０ ) (R １１ ), -C(O)C(O)N(R １０ ) (R １１ ), -S(O)R １３ , -S(O) ２ R １３ , and -S(O) ２ N (R １０ ) (R １１ ) wherein C １－６ Alkyl, C ２－６ Alkenyl, C ２－６ Alkynyl, C ３－６ Cycloalkyl, C ２－９ Heterocycloalkyl, C ６－１０ Aryl, and C １－９ Heteroaryl is a group containing halogen, —CN, C １－６ Alkyl, C １－６ Haloalkyl, C ２－６ Alkenyl, C ２－６ Alkynyl, C ３－６ Cycloalkyl, C ２－９ Heterocycloalkyl, C ６－１０ Aryl, C １－９ Heteroaryl, —OR １４ , -SR １４ , -C(O)OR １４ , -OC(O)N(R １４ ) (R １５ ), -N(R １６ )C(O)N(R １４ ) (R １５ ), -N(R １６ ) C(O)R １７ , -N(R １６ )C(O)OR １７ , -N(R １６ ) S (O) ２ R １７ , -C(O)R １７ , -OC(O)R １７ , -C(O)N(R １４ ) (R １５ ), -C(O)C(O)N(R １４ ) (R １５ ), -S(O)R １７ , -S(O) ２ R １７ , and -S(O) ２ N (R １４ ) (R １５ Optionally substituted with one, two, or three groups selected from R １０ are each independently hydrogen, C １－６ Alkyl, C １－６ Haloalkyl, C ２－６ Alkenyl, C ２－６ Alkynyl, C ３－６ Cycloalkyl, C ２－９ Heterocycloalkyl, C ６－１０ Aryl, and C １－９ heteroaryl, wherein C １－６ Alkyl, C ２－６ Alkenyl, C ２－６ Alkynyl, C ３－６ Cycloalkyl, C ２－９ Heterocycloalkyl, C ６－１０ Aryl, and C １－９ Heteroaryl is a group containing halogen, C １－６ Alkyl, C １－６ Haloalkyl, C １－６ Alkoxy, C ３－６ Cycloalkyl, C ２－９ Heterocycloalkyl, C ６－１０ Aryl, and C １－９ optionally substituted with one, two, or three groups selected from heteroaryl; R １１ are each independently hydrogen, C １－６ Alkyl, and C １－６ haloalkyl; R １２ are each independently hydrogen, C １－６ Alkyl, and C １－６ haloalkyl; R １３ are each independently １－６ Alkyl, C ２－６ Alkenyl, C ２－６ Alkynyl, C ３－６ Cycloalkyl, C ２－９ Heterocycloalkyl, C ６－１０ Aryl, and C １－９ heteroaryl, wherein C １－６ Alkyl, C ２－６ Alkenyl, C ２－６ Alkynyl, C ３－６ Cycloalkyl, C ２－９ Heterocycloalkyl, C ６－１０ Aryl, and C １－９ Heteroaryl is a group containing halogen, C １－６ Alkyl, C １－６ Haloalkyl, C １－６ Alkoxy, C ３－６ Cycloalkyl, C ２－９ Heterocycloalkyl, C ６－１０ Aryl, and C １－９ optionally substituted with one, two, or three groups selected from heteroaryl; R １４ are each independently hydrogen, C １－６ Alkyl, C １－６ Haloalkyl, C ２－６ Alkenyl, C ２－６ Alkynyl, C ３－６ Cycloalkyl, C ２－９ Heterocycloalkyl, C ６－１０ Aryl, and C １－９ heteroaryl, wherein C １－６ Alkyl, C ２－６ Alkenyl, C ２－６ Alkynyl, C ３－６ Cycloalkyl, C ２－９ Heterocycloalkyl, C ６－１０ Aryl, and C １－９ Heteroaryl is a group containing halogen, C １－６ Alkyl, C １－６ Haloalkyl, C １－６ Alkoxy, C ３－６ Cycloalkyl, C ２－９ Heterocycloalkyl, C ６－１０ Aryl, and C １－９ optionally substituted with one, two, or three groups selected from heteroaryl; R １５ are each independently hydrogen, C １－６ Alkyl, and C １－６ haloalkyl; R １６ are each independently hydrogen, C １－６ Alkyl, and C １－６ haloalkyl, and R １７ are each independently １－６ Alkyl, C ２－６ Alkenyl, C ２－６ Alkynyl, C ３－６ Cycloalkyl, C ２－９ Heterocycloalkyl, C ６－１０ Aryl, and C １－９ heteroaryl, wherein C １－６ Alkyl, C ２－６ Alkenyl, C ２－６ Alkynyl, C ３－６ Cycloalkyl, C ２－９ Heterocycloalkyl, C ６－１０ Aryl, and C １－９ Heteroaryl is a group containing halogen, C １－６ Alkyl, C １－６ Haloalkyl, C １－６ Alkoxy, C ３－６ Cycloalkyl, C ２－９ Heterocycloalkyl, C ６－１０ Aryl, and C １－９ A compound, or a pharmaceutically acceptable salt or solvate thereof, optionally substituted with one, two, or three groups selected from heteroaryl.

2. having the structure of formula (Ia): 【Chemistry 2】 2. The compound of claim 1, or a pharmaceutically acceptable salt or solvate thereof, wherein n is 0, 1, 2, 3, or 4.

3. The compound of claim 2, or a pharmaceutically acceptable salt or solvate thereof, wherein R 10 is independently selected from hydrogen and C 1-6 alkyl; R 11 is hydrogen; and n is 0, 1, or 2.

4. The compound of claim 1, or a pharmaceutically acceptable salt or solvate thereof, wherein each R 7 is independently selected from halogen and C 1-6 alkyl.

5. The compound of claim 1, or a pharmaceutically acceptable salt or solvate thereof, wherein each R 9 is independently selected from halogen, —CN, C 1-6 alkyl, and C 1-6 haloalkyl.

6. The compound of claim 5, or a pharmaceutically acceptable salt or solvate thereof, wherein R 3a is cyclopropyl substituted with one R 9 .

7. The compound of claim 6, or a pharmaceutically acceptable salt or solvate thereof, wherein R 3a is cyclopropyl substituted with —CF 3 .

8. The compound of claim 1, or a pharmaceutically acceptable salt or solvate thereof, wherein R 2 is phenyl optionally substituted with one, two, three, four, or five R 8 .

9. The compound of claim 1, or a pharmaceutically acceptable salt or solvate thereof, wherein R 2 is pyridinyl, pyrimidinyl, or thiazolyl, and the pyridinyl, pyrimidinyl, and thiazolyl are substituted with one, two, or three R 8 .

10. The compound of claim 1, or a pharmaceutically acceptable salt or solvate thereof, wherein each R 8 is independently selected from halogen, C 1-6 alkyl, C 1-6 haloalkyl, and —OR 10 .

11. The compound of claim 1, or a pharmaceutically acceptable salt or solvate thereof, wherein R 2 is unsubstituted phenyl.

12. The compound of claim 1, or a pharmaceutically acceptable salt or solvate thereof, wherein R 5 and R 6 are C 1 -C 6 alkyl.

13. The compound of claim 1, or a pharmaceutically acceptable salt or solvate thereof, wherein R 4 is hydrogen. 【Request Item 14】 【Chemistry 3-1】 【Chemistry 3-2】 【Chemistry 3-3】 [Chemistry 3-4] [Transformation 3-5] 【Chemistry 3-6】 【Chemistry 3-7】 【Transformation 3-8】 【Chemistry 3-9】 【Chemistry 3-10】 【Chemistry 3-11】 【Chemistry 3-12】 【Chemistry 3-13】 【Chemistry 3-14】 【Chemistry 3-15】 【Chemistry 3-16】 【Chemistry 3-17】 2. The compound of claim 1 selected from: or a pharmaceutically acceptable salt or solvate thereof.

15. A pharmaceutical composition comprising a compound according to any one of claims 1 to 14, or a pharmaceutically acceptable salt or solvate thereof, and at least one pharmaceutically acceptable excipient.

16. Use of a compound according to any one of claims 1 to 14, or a pharmaceutically acceptable salt or solvate thereof, in the manufacture of a medicament for treating a disease or illness selected from neuropsychiatric disorders, depression, obsessive-compulsive disorder, alcoholism, gambling addiction, pain, opioid overdose, opioid use disorder and addiction in a subject in need thereof.

Images